Xxxxxxxx Xxxxxx 2000/32/ES
ze xxx 19. xxxxxx 2000,
xxxxxx xx xx xxxxxxx xxxxx přizpůsobuje xxxxxxxxxxx pokroku xxxxxxxx Xxxx 67/548/XXX x xxxxxxxxxx xxxxxxxx a xxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx, xxxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx [1]
(Xxxx s xxxxxxxx xxx EHP)
KOMISE XXXXXXXXXX SPOLEČENSTVÍ,
s ohledem xx Smlouvu x xxxxxxxx Xxxxxxxxxx xxxxxxxxxxxx,
x xxxxxxx na směrnici Xxxx 67/548/EHS ze xxx 27. června 1967 x xxxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx týkajících se xxxxxxxxxxx, balení x xxxxxxxxxx xxxxxxxxxxxx látek [2], naposledy pozměněnou xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 1999/33/XX [3], x xxxxxxx xx článek 28 xxxxxxx xxxxxxxx,
xxxxxxxx x xxxxx xxxxxxx:
(1) Příloha X směrnice 67/548/XXX xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxx xxxxx x xxxxxxxxxxx x označování xxxxx látky. Xxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxx, že xx xxx xxx xxxxxx xxxxxxxxxxxx látek x uvedené příloze xxxxxxxxxxx. Některé jazykové xxxxx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxx oddílů xxxxxxxxx x xxxxxxx X x příloze X.
(2) Příloha XXX xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxx xxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx s xxxxxxxxxxxx xxxxxxx x přípravky. Xxxxxxx IV xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxx x xxxxxxxxxxxxxx xxxxxx týkajícími xx xxxxxxxxxxxx xxxxx x xxxxxxxxx. Xxxxxxx XX xxxxxxxx 67/548/EHS obsahuje xxxxx xx xxxxxxxxxxx x k označování xxxxxxxxxxxx látek x xxxxxxxxx. Některé xxxxxxxx xxxxx xxxxxxxx vyžadují xxxxxx xxxxxxxx xxxxxx xxxxxx XXX, XX x XX.
(3) X xxxxxxx X směrnice 67/548/XXX se stanoví xxxxxx xxx xxxxxxxxx xxxxxxxxx-xxxxxxxxxx xxxxxxxxxx, xxxxxxxx x xxxxxxxxxxx xxxxx x přípravků. Xx xxxxxxxx xxxxxxxxxxx xxxx xxxxxxx technickému xxxxxxx.
(4) Xxxxxxx IX xxxxxxxx 67/548/XXX xxxxxxxx předpisy xxxxxxxx xx xxxxxxx xxxxxxxx xxxxx otevření xxxxx. Xxxx xxxxxxxx xx xxxx xxx xxxxxxxxxxxx x xxxxxxxxxxxxx. Xx xxxxxxxx xxxxxxxx xxxxxx, xxx se xxxxxxx xxxxxx proti xxxxxxxx xxxxx xxxxxxxxx.
(5) Xxxxxxxx této xxxxxxxx xxxx v xxxxxxx xx xxxxxxxxxxx Xxxxxx xxx přizpůsobení technickému xxxxxxx xxxxxxx xxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xx úseku xxxxxxxxxxxx xxxxx x xxxxxxxxx,
XXXXXXX TUTO XXXXXXXX:
Xxxxxx 1
Xxxxxxxx 67/548/EHS xx xxxx xxxxx:
1. Xxxxxxx X xx xxxx xxxxx:
x) odpovídající xxxxxxxx x předmluvě xx xxxxxxxxx xxxxxxxxx X x příloze 1X xxxx směrnice;
b) xxxxxxxxxxxx řádky x xxxxxxx X xx xxxxxxxxx xxxxx x xxxxxxx 1B xxxx xxxxxxxx;
x) xxxxxxxxxxxx položky xx xxxxxxxxx položkami x xxxxxxx 1X xxxx xxxxxxxx;
x) xxxxxxxx xx xxxxxxx v xxxxxxx 1X xxxx xxxxxxxx.
2. Xxxxxxxxxxxx věta x příloze XXX xx xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxx 2 této xxxxxxxx.
3. Xxxxxxx XX xx xxxx xxxxx:
x) xxxxxxxxxxxx xxxxxx x xxxxxxx XX se nahrazují xxxxxxxxxxxx xxxxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxx 3A této xxxxxxxx;
x) xxxxxxxxxxxx pokyny x xxxxxxx XX xx xxxxxxxxx kombinovanými xxxxxxxxxxxx xxxxxx xxx xxxxxxxx zacházení x xxxxxxx 3B této xxxxxxxx.
4. Xxxx X xxxxxxx V xx xxxx xxxxx:
x) xxxxxxxx X.10 xx nahrazuje xxxxxx x xxxxxxx 4X xxxx xxxxxxxx;
x) xxxxxxxx B.11 xx xxxxxxxxx xxxxxx v xxxxxxx 4B této xxxxxxxx;
x) kapitola X.12 xx xxxxxxxxx textem x xxxxxxx 4C xxxx směrnice;
d) xxxxxxxx X.13 x B.14 xx nahrazují xxxxxx x xxxxxxx 4X xxxx směrnice;
e) xxxxxxxx X.17 xx xxxxxxxxx xxxxxx v xxxxxxx 4X xxxx směrnice;
f) xxxxxxxx X.23 xx xxxxxxxxx xxxxxx x xxxxxxx 4X xxxx xxxxxxxx. Název kapitoly X.23 xx vysvětlivce xx xxxx xxxxxxxxxxxxx xxxxxxxx;
x) xxxxxx se xxxx v xxxxxxx 4X této směrnice.
5. Xxxxxxx se xxxxxx xxxxxxx xxxxxxxx úvodu x xxxxx X xxxxxxx X.
6. Xxxxxxxxxxxx xxxxx v příloze XX xx nahrazují xxxxx x xxxxxxx 5 této směrnice.
7. Xxxxxxx XX xx xxxx xxxxxxxx xxxxxxxx x xxxxxxx 6 xxxx směrnice.
Článek 2
1. Xxxxxxx xxxxx uvedou x xxxxxxxx xxxxxx x xxxxxxx xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xx 1. xxxxxx 2001. Xxxxxxxxxx x xxxx xxxxxxx Xxxxxx.
Xxxx předpisy xxxxxxx xxxxxxxxx státy xxxx xxxxxxxxx xxxxx na xxxx xxxxxxxx xxxx xxxx takový xxxxx xxx xxxxxx xxx xxxxxx úředním xxxxxxxxx. Xxxxxx xxxxxx si xxxxxxx xxxxxxx státy.
2. Xxxxxxx státy xxxxx Xxxxxx xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxx, které xxxxxxx x xxxxxxx xxxxxxxxxx xxxx xxxxxxxx, x xxxxxxxxxx xxxxxxx xxxx xxxxxxxx a xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxx.
Článek 3
Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxxxx dnem xx xxxxxxxxx v Xxxxxxx xxxxxxxx Xxxxxxxxxx společenství.
Xxxxxx 4
Xxxx xxxxxxxx xx určena xxxxxxxx xxxxxx.
X Xxxxxxx dne 19. xxxxxx 2000.
Xx Xxxxxx
Xxxxxx Xxxxxxxöx
xxxxxx Xxxxxx
[1] Xxxxxxx po xxxxxxxxxxxx po dvacáté xxxxx.
[2] Xx. věst. 196, 16.8.1967, s. 1.
[3] Xx. xxxx. X 199, 30.7.1999, x. 57.
XXXXXXX 1X
XXXXXXXXX X XXXXXXX X
Xxxxxxxxxx poznámek xxxxxxxxxx xx identifikace, xxxxxxxxxxx x xxxxxxxxxx xxxxx
(Xxxxxx xx xxxxxxx xxxxx)
PŘÍLOHA 1B
"TABULKA X
|
X |
Xxxxxx |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
|
18 |
Xx |
Xxxxx |
Xxxxx |
Xxxxx |
Αργό |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
|
64 |
Xx |
Xxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxxx |
Γαδολίνιο |
Xxxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxx |
Xxxxxxxxxx" |
XXXXXXX 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx x látkám |
Číslo XX |
Xxxxx CAS |
Klasifikace |
Označení |
Koncentrační xxxxxx |
Xxxxxxxx x přípravkům |
|
006–011–00–7 |
karbaryl (XXX) 1-xxxxxx-X-xxxxxxxxxxxxxx |
200–555–0 |
63–25–2 |
Xxxx. kat. 3; X40 Xx; X22 X; R50 |
Xn; X X: 22–40–50 X: (2-)22–24–36/37–46–61 |
|||
|
006–013–00–8 |
xxxxxx-xxxxxxx (ISO) xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx |
205–293–0 |
137–42–8 |
Xx; X22 X31 X; X34 R43 N; X50–53 |
X; X X: 22–31–34–43–50/53 X: (1/2-)26–36/37/39–45–60–61 |
|||
|
006–015–00–9 |
xxxxxx (XXX) 3-(3,4-dichlorfenyl)-1,1-dimethylmočovina |
206–354–4 |
330–54–1 |
Karc. kat. 3; R40 Xxxx. xxx. 3; R40 Xx; X22–48/22 X; X50–53 |
Xx; N X: 22–40–48/22–50/53 S: (2-)13–22–23–37–46–60–61 |
|||
|
006–016–00–4 |
xxxxxxxx (XXX) 2- isopropoxyfenyl-N-methylkarbamát |
204–043–8 |
114–26–1 |
T; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–017–00-X |
xxxxxxxx (XXX) 2-xxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxxx-X-(X-xxxxxxxxxxxxxxx)xxxx |
204–123–2 |
116–06–3 |
X+; X26/28 T; X24 X; R50–53 |
T+; X X: 24–26/28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–018–00–5 |
xxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
217–990–7 |
2032–59–9 |
X; X24/25 X; X50–53 |
X; X R: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–019–00–0 |
xx-xxxxx (XXX) X-(2,3-xxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–961–1 |
2303–16–4 |
Xxxx. xxx. 3; X40 Xx; X22 N; X50–53 |
Xx; X X: 22–40–50/53 X: (2-)25–36/37–60–61 |
|||
|
006–020–00–6 |
barban (XXX) 4-xxxxxxxx-2-xx-1-xx-X -(3-chlorfenyl)karbamát |
202–930–4 |
101–27–9 |
Xn; X22 X43 N; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–36/37–60–61 |
|||
|
006–023–00–2 |
xxxxxxxxxxxxxxxx (XXX) xxxxxxxxxx 3,5-xxxxxxxx-4-(xxxxxxxxxxxxxx)xxxxx-X -methylkarbamát |
217–991–2 |
2032–65–7 |
T; X25 X; R50–53 |
T; X X: 25–50/53 X: (1/2-)22–37–45–60–61 |
|||
|
006–024–00–8 |
xxxxxx-xxxxxxx (ISO) xxxxxxx-X-xxxxxxxxx-xxxxxxxxxxxxxx |
205–443–5 |
140–93–2 |
Xx; R22 Xx; X38 N; X51–53 |
Xx; X R: 22–38–51/53 X: (2-)13-61 |
|||
|
006–026–00–9 |
xxxxxxxxxx (ISO) 2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx-X-xxxxxxxxxxxxxx |
216–353–0 |
1563–66–2 |
X+; R26/28 X; X50–53 |
X+; N X: 26/28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–028–00-X |
xxxxxxxxx (XXX) 2-(1-xxxxxxxxxxxx)-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx 2-sek-butyl-4,6-dinitrofenyl-isopropyl-karbonát |
213–546–1 |
973–21–7 |
T; X25 X; R50–53 |
T; X R: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–029–00–5 |
xxxxxxxxx (XXX) 2-(1,3-xxxxxxxx-2-xx)xxxxx-X-xxxxxxxxxxxxxx |
230–253–4 |
6988–21–2 |
X; R25 X; X51–53 |
X; N X: 25–51/53 S: (1/2-)37–45–61 |
|||
|
006–033–00–7 |
xxxxxxxxx (XXX) 3-(3-xxxxx-4-xxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
243–433–2 |
19937–59–8 |
X; X50–53 |
X X: 5 0/ 5 3 X: 60-61 |
|||
|
006–034–00–2 |
xxxxxxx (XXX) X-xxxxxx-X-xxxxx-X-xxxxxxxxxxxxxxxxx |
214–215–4 |
1114–71–2 |
Xx; X22 N; R51–53 |
Xn; X R: 22–51/53 X: (2-)23-61 |
|||
|
006–035–00–8 |
pirimikarb (XXX) 2-(xxxxxxxxxxxxx)- 5,6-xxxxxxxx xxxxxxxxx-4-xx-X,X-xxxxxxxxxxxxxxxx |
245–430–1 |
23103–98–2 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2)22–37–45–60–61 |
|||
|
006–037–00–9 |
xxxxxxxxx (XXX) 3-xxxxxxxxx-5-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–113–0 |
2631–37–0 |
X; R25 X; X50–53 |
X; N X: 25–50/53 S: (1/2-)24–37–45–60–61 |
|||
|
006–038–00–4 |
xxxxxxxxx (XXX) 2-xxxxxxxxxx-X,X-xxxxxxxxxxxxxxxxxxxxxx |
X |
202–388–9 |
95–06–7 |
Xxxx. xxx. 2; X45 Xx; X22 X; R50–53 |
T; X X: 45–22–50/53 X: 53–45–60–61 |
||
|
006–039–00-X |
xxx-xxxxx (XXX) X-(2,3,3-xxxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–962–7 |
2303–17–5 |
Xx; X22–48/22 X43 X; X50–53 |
Xx; N X: 22–43–48/22–50/53 X: (2-)24–37–60–61 |
|||
|
006–042–00–6 |
xxxxxxx (ISO) 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
205–766–1 |
150–68–5 |
Xxxx. xxx. 3; R40 Xx; R22 X; X50–53 |
Xx; N X: 22–40–50/53 X: (2-)36/37–60–61 |
|||
|
006–043–00–1 |
xxxxxxx-XXX 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
140–41–0 |
Xx; X36/38 Karc. xxx. 3; X40 X; X50–53 |
Xx; N X: 36/38–40–50/53 S: (2-)36/37–60–61 |
|||
|
006–045–00–2 |
xxxxxxxx (XXX) xxxxxx-X-[(X-xxxxxxxxxxxxxxx)xxx]xxxxxxxxxxxxxx |
240–815–0 |
16752–77–5 |
X+; X28 X; X50–53 |
X+; X X: 28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–046–00–8 |
bendiokarb (XXX) 2,2-xxxxxxxx-1,3-xxxxxxxxxxx-4-xx-X-xxxxxxxxxxxxxx |
245–216–8 |
22781–23–3 |
X; X23/25 Xn; X21 X; X50–53 |
X; X R: 21–23/25–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–047–00–3 |
xxxxxxxxx (ISO) xxxx: 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx x 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx |
— |
8065–36–9 |
X; R24/25 X; X50–53 |
X; N R: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–048–00–9 |
ethiofenkarb (XXX) 2-[(xxxxxxxxxxxxx)xxxxxx]xxxxx-X-xxxxxxxxxxxxxx |
249–981–9 |
29973–13–5 |
Xx; X22 X; X50–53 |
Xx; N X: 22–50/53 X: (2-)60-61 |
|||
|
006–050–00–X |
xxxxxxx-XXX 3-xxxxx-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
4482–55–7 |
Xx; X38 X; R50–53 |
Xi; X X: 38–50/53 S: (2-)60-61 |
|||
|
006–053–00–6 |
xxxxxxxxxx (XXX) 2-xxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–114–6 |
2631–40–5 |
Xx; X22 N; R50–53 |
Xn; X R: 22–50/53 X: (2-)60-61 |
|||
|
006–054–00–1 |
xxxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3,5-xxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
206–249–3 |
315–18–4 |
X+; R28 Xx; X21 N; R50–53 |
T+; X X: 21–28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–057–00–8 |
xxxxxxxxxx (XXX) 2-xxxxx-6-(xxxxxxxxxxxxxx)xxxxxxx |
217–682–2 |
1929–82–4 |
Xx; X22 X; X51–53 |
Xx; X X: 22–51/53 S: (2-)24-61 |
|||
|
006–060–00–4 |
xxxxxxxxxxx (XXX) 2-xxxxxx-4,4-xxxxx-5,6-xxxxxxx-4λ4-1,4-xxxxxxxx-3-xxxxxxxxxxxx |
226–066–2 |
5259–88–1 |
Xx; X22 X52–53 |
Xx X:22–52/53 X: (2-)61 |
|||
|
006–069–00–3 |
xxxxxxxxx-xxxxxx (XXX) 1,2-xx[3-(xxxxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx |
245–740–7 |
23564–05–8 |
Xxxx. xxx. 3; R40 X; X50–53 |
Xx; X X: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–070–00–9 |
xxxxxxxxxxx X-xxxxxxxxxx-X-xxxxxxx-2,5-xxxxxxxx-3-xxxxxxx |
262–302–0 |
60568–05–0 |
Xxxx. xxx. 3; X40 N; X50–53 |
Xx; X X: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–088–00–7 |
xxxxxxxxxxx (XXX) ethyl-N -[({[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy]karbonyl}methylamino)sulfanyl]-N-isopropyl-β-alaninát(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-N-({[2-(ethoxykarbonyl)ethyl]isopropylamino}sulfanyl)-N-methylkarbamát |
— |
82560–54–1 |
T; X23/25 X; X50–53 |
X; X X: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
007–012–00–5 |
N,N-dimethylhydrazin 1,1-dimethylhydrazin |
E |
200–316–0 |
57–14–7 |
F; X11 Xxxx. xxx. 2; R45 T; X23/25 C; X34 X; X51–53 |
X; X; X X: 45–11–23/25–34–51/53 X: 53–45–61 |
||
|
007–013–00–0 |
N,N-dimethylhydrazin 1,2-dimethylhydrazin |
E |
— |
540–73–8 |
Karc. xxx. 2; R45 X; X23/24/25 X; X51–53 |
X; N X: 45–23/24/25–51/53 S: 53–45–61 |
X ≥ 25 %: X; R45–23/24/25 3 % < X &xx; 25 %: X; X45–20/21/22 0,01 % &xx; C &xx; 3 %: X; X45 |
|
|
009–003–00–1 |
xxxxxxxx xxxxxxxxxxxxxx … % |
X |
231–634–8 |
7664–39–3 |
X+; R26/27/28 X; X35 |
X+; X X: 26/27/28–35 X: (1/2-)7/9–26–36/37–45 |
X ≥ 7 %: T+; X; X26/27/28–35 1 % ≤ X &xx; 7 %: X; X23/24/25–34 0,1 % ≤ X < 1 %: Xx; X20/21/22–36/37/38 |
|
|
015–039–00–9 |
xxxxxxx-xxxxxx (XXX) O,O-dimethyl-S -[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
201–676–1 |
86–50–0 |
X+; R26/28 X; X24 R43 X; X50–53 |
X+; N X: 24–26/28–43–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
015–048–00–8 |
xxxxxxxx (XXX) X,X-xxxxxxxx-X-[3-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxx]-xxxxxxxxxxxxx |
200–231–9 |
55–38–9 |
Xxxx. xxx. 3; X40 X; X23–48/25 Xn; X21/22 X; X50–53 |
X; X X: 21/22–23–40–48/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
015–056–00–1 |
azinfos-ethyl (XXX) X,X-xxxxxxx-X-[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
220–147–6 |
2642–71–9 |
X+; X28 X; R24 N; X50–53 |
X+; N X: 24–28–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
015–140–00–8 |
triazofos (XXX) X,X-xxxxxxx-X-(1-xxxxx-1 X- 1,2,4-xxxxxxx-3-xx)-xxxxxxxxxxxxx |
245–986–5 |
24017–47–8 |
X; X23/25 Xx; X21 X; X50–53 |
X; X X: 21–23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
016–013–00-X |
xxxxxxx sirnatý |
234–129–0 |
10545–99–0 |
R14 X; X34 X; X50 |
X; N R: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
C ≥ 10 %: X; X34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
|
016–014–00–5 |
xxxxxxx xxxxxxxx |
— |
13451–08–6 |
X14 X; R34 N; X50 |
X; X R: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
C ≥ 10 %: X; R34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
|
016–023–00–4 |
xxxxxxxx-xxxxxx |
X |
201–058–1 |
77–78–1 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 3; X40 X+; R26 T; X25 X; X34 X43 |
X+ X: 45–25–26–34–43 X: 53-4 5 |
C ≥ 25 %: X+; X45–25–26–34–43 10 % ≤ X &xx; 25 %: X+; X45–22–26–34–43 7 % ≤ X &xx; 10 %: X+; R45–22–26–36/ 37/38–43 5 % ≤ X < 7 %: X; R45–22–23–36/37/38–43 3 % ≤ X &xx; 5 %: T; R45–22–23–43 1 % ≤ X < 3 %: T; X45–23–43 0,1 % ≤ X &xx; 1 %: T; X45–20 0,01 % ≤ X < 0,1 %:X; X45 |
|
|
016–024–00-X |
xxxxxxxx (XXX) xxx(xxxxxxxxxxxxxxxxxxx)xxxxxxxx |
X,X′-xxxxxxxx-xxxxxxxxxxx(xxxxxxxxxxx)215–993–8 |
1468–37–7 |
Xx; R22 X; X50–53 |
Xx; N R: 22–50/53 X: (2-)60-61 |
|||
|
016–071–00–6 |
3-xxxxx-6,13-xxxxxxx-10-[(3-{[4-xxxxx-6-(2-xxxxxxxxxxxxxxxx)- 1,3,5-xxxxxxx-2-xx]xxxxx}xxxxxx)xxxxx][1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx xxxxxxxx |
410–130–3 |
136248–03–8 |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
022–001–00–5 |
xxxxxxx xxxxxxxxxx |
231–441–9 |
7550–45–0 |
X14 C; R34 |
C X: 14-34 S: (1/2-)7/8–26–36/37/39–45 |
X ≥ 10 %: X; X34 5 % ≤ X < 10 %: Xx; X36/37/38 |
||
|
030–004–00–8 |
xxxxxxxxxxxxx [1] xxxxxxxxxxxx [2] |
208–884–1 [1] 209–161–3 [2] |
544–97–8 [1] 557–20–0 [2] |
X14 X; R17 X; X34 X; R50–53 |
F; X; X R: 14–17–34–50/53 X: (1/2-)16–43–45–60–61 |
|||
|
050–002–00–0 |
xxxxxxxxx (XXX) tricyklohexyl(hydroxy)stannan xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx |
236–049–1 |
13121–70–5 |
Xx; X20/21/22 X; R50–53 |
Xn; X X: 20/21/22–50/53 X: (2-)13–60–61 |
|||
|
050–012–00–5 |
xxxxxxxxxxxxxxxxxxxxxx [1] xxxxx(xxxxxxxxxxxxx)xxxxxxx [2] xxxxx(xxxxxxxxxxxxx)xxxxxxx [3] |
215–910–5 [1] 221–437–5 [2] 230–358–5 [3] |
1449–55–4 [1] 3091–32–5 [2] 7067–44–9 [3] |
Xn; X20/21/22 X; X50–53 |
Xx; X X: 20/21/22–50/53 S: (2-)26–28–60–61 |
X ≥ 1 %: Xx; X20/21/22 |
1 |
|
|
050–017–00–2 |
xxxxxxxxxxxxxx (XXX) 1,1,1,3,3,3-xxxxxxx(2-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxx |
236–407–7 |
13356–08–6 |
X+; X26 Xx; X36/38 X; X50/53 |
X+; X X: 26–36/38–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
082–009–00–X |
žluť (xxxxxxxxxxxx xxxxxxxx) XX Xxxxxxx Xxxxxx 34 (XX 77603) CI xxxxxxxxxx žluť 34 (XX 77603) |
215–693–7 |
1344–37–2 |
Xxxx. kat. 3; R40 Repr. xxx. 1; X61 Xxxx. kat. 3; X62 X33 X; X50–53 |
X; X X: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
|
082–010–00–5 |
červeň (xxxxxxx-xxxxxxxxxx-xxxxx olovnatý) CI Xxxxxxx Xxx 104 (XX 77605) XX xxxxxxxxxx xxxxxx 104 (XX 77605) |
235–759–9 |
12656–85–8 |
Xxxx. xxx. 3; R40 Xxxx. xxx. 1; R61 Xxxx. kat. 3; X62 R33 N; X50–53 |
X; N X: 61–33–40–50/53–62 S: 53–45–60–61 |
1 |
||
|
601–024–00-X |
xxxxx [1] xxxxxxxxxxxx [2] |
202–704–5 [1] 203–132–9 [2] |
98–82–8 [1] 103–65–1 [2] |
X10 Xx; X65 Xx; X37 X; X51–53 |
Xx; X X: 10–37–51/53–65 X: (2-)24–37–61–62 |
4 |
||
|
601–032–00–3 |
benzo[a]pyren xxxxx[xxx]xxxxxxx |
200–028–5 |
50–32–8 |
Xxxx. xxx.2; X45 Xxxx. xxx. 2; R46 Xxxx. kat. 2; X60–61 X; X50–53 |
X; X X: 45–46–60–61–50/53 X: 53–45–60–61 |
|||
|
601–034–00–4 |
xxxxx[x]xxxxxxxxxxxxxxx |
205–911–9 |
205–99–2 |
Xxxx. xxx.2; X45 X; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
602–035–00–2 |
1,4-dichlorbenzen x-xxxxxxxxxxxxx |
203–400–5 |
106–46–7 |
Xx; X36 X; X50–53 |
Xx; X R: 36–50/53 X: (2-)24/25–46–60–61 |
|||
|
602–054–00–6 |
3-xxxxxxx-1-xx xxxxxxxxxx |
209–130–4 |
556–56–9 |
X10 X; X34 |
X X: 10-34 S: (1/2-)7–26–45 |
|||
|
603–076–00–9 |
but-2-yn-1,4-diol |
203–788–6 |
110–65–6 |
T; X23/25 Xx; X21–48/22 X; X34 |
X R: 21–23/25–34–48/22 X: (1/2-)26–36/37/39–45 |
X ≥ 50 %: X; X21–23/25–34–48/22 25 % ≤ X &xx; 50 %: X; R21–23/25–36/38–48/22 10 % ≤ X &xx; 25 %: Xx; X20/22–48/22 3 % ≤ C &xx; 10 %: Xx; X20/22 |
||
|
603–091–00–0 |
xxx-4-xxxxxxxxx-1-xxxxxx-7-xxxxxxxxxx[2.2.1]xxxxxx-2-xx |
402–470–6 |
87172–89–2 |
X; X8 Xx; X22 Xx; X36 |
X; Xx R: 8–22–36 X: (2-)26 |
|||
|
603–093–00–1 |
xxx-(±)-4-xxxxxxxxx-1-xxxxxx-2-[(2-xxxxxxxxxxxx)xxx]-7-xxxxxxxxxx[2.2.1]xxxxxx |
402–410–9 |
87818–31–3 |
Xx; X20 X; X51–53 |
Xx; X X: 20–51/53 X: (2-)23-61 |
|||
|
603–097–00–3 |
1,1', 1′′-xxxxxxxxxxxxxxxx-2-xx xxxxxxxxxxxxxxxxxx |
204–528–4 |
122–20–3 |
Xx; X36 R52–53 |
Xi X:36–52/53 X: (2-)26-61 |
|||
|
603–117–00–0 |
xxxxxx-2-xx xxxxxxxxxxxxxxxx xxxxxxxxxxx |
200–661–7 |
67–63–0 |
X; X11 Xx; X36 X67 |
X; Xx R: 11–36–67 X: (2-)7–16–24/25–26 |
|||
|
604–020–00–6 |
bifenyl-2-ol 2-xxxxxxxxxxxxxx 2-xxxxxxxxxx (XXX) |
201–993–5 |
90–43–7 |
Xx; X36/37/38 X; X50 |
Xx; N X: 36/37/38–50 X: (2-)22-61 |
|||
|
604–021–00–1 |
2-xxxxxxxxxx, xxxxx xxx xxxxxxx-2-xxxxxxxxxxxx 2-xxxxxxxxx xxxxx xxxxxxx-xxxxxxx-2-xxxx |
205–055–6 |
132–27–4 |
Xx; X22 Xx; X37/38–41 N; R50 |
Xn; X X: 37/38–41–50 X: (2-)22–26–61 |
|||
|
604–024–00–8 |
4,4'-(4-xxxxxxxxxxxx-2,2-xxxx)xxxxxxx 2,2-xxx(4-xxxxxxxxxxxx)-4-xxxxxxxxxxxx |
401–720–1 |
6807–17–6 |
Xxxx. xxx. 2; X60 Xx; X36 X; X50–53 |
X; X X: 60–36–50/53 X: 53–45–60–61 |
|||
|
604–041–00–0 |
xxxxxxxxxxx [1] xxxxxxxxxxx-xxxxxxx [2] 5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxxx kyselina [1] xxxxxxx-5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxx [2] |
256–634–5 [1] 263–560–7 [2] |
50594–66–6 [1] 62476–59–9 [2] |
Xx; X22 Xx; X38–41 X; X50–53 |
Xx; X X: 22–38–41–50/53 S: (2-)24–39–60–61 |
|||
|
604–043–00–1 |
xxxxxxxxxxxxxxxx (4-xxxxxxxxxxxx)xxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx 4-(benzyloxy)fenol |
203–083–3 |
103–16–2 |
Xi; X36 X43 |
Xx X: 36-43 X: (2-)24/25–26–37 |
|||
|
604–044–00–7 |
xxxxxxxx 4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx |
205–769–8 |
150–76–5 |
Xx; X22 Xx; X36 R43 |
Xn X: 22–36–43 S: (2-)24/25–26–37/39–46 |
|||
|
605–016–00–7 |
xxxxxxx… % ethandial… % |
X |
203–474–9 |
107–22–2 |
Xxxx. kat. 3; X40 Xx; X20 Xx; R36/38 X43 |
Xx X: 20–36/38–40–43 S: (2-)36/37 |
X ≥ 10 %: Xn; X20–36/38–40–43 1 % ≤ X &xx; 10 %: Xn; X40–43 |
|
|
606–016–00-X |
xxxxxx (XXX) 2-(xxxxxxxxxxxxxxx)xxxxx-1,3-xxxx |
201–462–8 |
83–26–1 |
X; X25–48/25 X; X50–53 |
X; X X: 25–48/25–50/53 X: (1/2-)37–45–60–61 |
|||
|
606–018–00–0 |
xxxxxxx (ISO) 2,3-xxxxxxx-1,4-xxxxxxxxxxx |
204–210–5 |
117–80–6 |
Xx; X22 Xx; R36/38 X; X50–53 |
Xx; X X: 22–36/38–50/53 X: (2-)26–60–61 |
|||
|
606–019–00–6 |
xxxxxxxxxx (XXX) xxxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx xxxxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx 1,2,4,5,6,7,8,8,9,10-xxxxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx |
205–601–3 |
143–50–0 |
Xxxx. xxx. 3; R40 X; X24/25 X; X50–53 |
X; X X: 24/25–40–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
606–034–00–8 |
xxxxxxxxxx (XXX) 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-1,2,4-xxxxxxx-5(4 X)-xx 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-4,5-xxxxxxx-1,2,4-xxxxxxx-5-xx |
244–209–7 |
21087–64–9 |
Xx; X22 X; X50–53 |
Xx; X R: 22–50/53 X: (2-)60-61 |
|||
|
606–035–00–3 |
xxxxxxxxxxx (XXX) 5-xxxxx-4-xxxxx-2-xxxxxxxxxxxxxx-3(2X)-xx pyrazon |
216–920–2 |
1698–60–8 |
R43 N; X50–53 |
Xx; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
606–036–00–9 |
chinomethionát (XXX) 6-xxxxxx-2 X-[1,3]xxxxxxxx[4,5-x]xxxxxxxxxx-2-xx |
219–455–3 |
2439–01–2 |
Xxxx. xxx. 3; X62 Xx; X20/21/22–48/22 Xi; X36 X43 X; X50–53 |
Xx; N X: 20/21/22–36–43–48/22–50/53–62 X: (2-)24–37–60–61 |
|||
|
606–037–00–4 |
xxxxxxxxxxx (XXX) 1-(4-chlorfenoxy)- 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-on |
256–103–8 |
43121–43–3 |
Xn; X22 X; X51–53 |
Xx; X R: 22–51/53 X: (2-)61 |
|||
|
606–044–00–2 |
2,4,6-xxxxxxxxxxxxxxxxxxx xxxxx(2,4,6-xxxxxxxxxxxxxx)xxxxxxxx |
403–150–9 |
954–16–5 |
Xx; X22 Xx; X36 X; X50–53 |
Xx; X X: 22–36–50/53 X: (2-)26–60–61 |
|||
|
607–043–00-X |
xxxxxxx (ISO) 3,6-dichlor-2-methoxybenzoová xxxxxxxx |
217–635–6 |
1918–00–9 |
Xx; X22 Xi; X41 X52–53 |
Xx; X X: 22–41–52/53 X: (2-)26-61 |
|||
|
607–057–00–6 |
xxxxxxxxx (ISO) 3-[1-(4-xxxxxxxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx3-[1-(4-xxxxxxxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 X-xxxxxxx-2-xx |
201–378–1 |
81–82–3 |
Xx; X48/22 X52–53 |
Xx X:48/22–52/53 X: (2-)37-61 |
|||
|
607–058–00–1 |
xxxxxxxxx (XXX) fumarin (RS)-3-[1-(2-furyl)-3-oxobutyl)]-4-hydroxykumarin (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxx-2 X -xxxxxxx-2-xx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 X -xxxxxxx-2-xx |
204–195–5 |
117–52–2 |
X; R25–48/25 X52–53 |
X X:25–48/25–52/53 S: (1/2-)37–45–61 |
|||
|
607–079–00–6 |
xxxxxxx (XXX) xxxxx-4-xxx-5-(xxxxxxxx-5-xxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx)xxxxxxxxx ethyl-5-(1,2,3,5,6,7,8,9,10,10-dekachlor-4-hydroxypentacyklo[5.2.1.02,6.03,9.05,8]dekan-4-yl)-4-oxopentanoát xxxxx-5-(1,2,4,5,6,7,8,8,9,10-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx)-4-xxxxxxxxxxxx |
— |
4234–79–1 |
X; R24 Xn; X22 X; R51–53 |
T; X R: 22–24–51/53 X: (1/2-)36/37–45–61 |
|||
|
607–097–00–4 |
xxxxxx-1,2,4-xxxxxxxxx-1,2-xxxxxxxx 1,2-xxxxxxxx xxxxxx-1,2,4-xxxxxxxxxxxxxx kyseliny xxxxxxxxxxxxxxxxx |
209–008–0 |
552–30–7 |
Xx; X37–41 X42/43 |
Xx X: 37–41–42/43 X: (2-)22–26–36/37/39 |
|||
|
607–143–00–3 |
xxxxxxxxx xxxxxxxx xxxxxxxx kyselina |
203–677–2 |
109–52–4 |
C; X34 X52–53 |
X R:34–52/53 X: (1/2-)26–36–45–61 |
|||
|
607–152–00–2 |
2,3,6-XXX (ISO) 2,3,6-xxxxxxxxxxxxxxxx kyselina |
200–026–4 |
50–31–7 |
Xn; R22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)61 |
|||
|
607–153–00–8 |
xxxxxxxxx (XXX) (4-xxxxx-2-xxx-2,3-xxxxxxx-1,3-xxxxxxxxxxxx-3-xx)xxxxxx xxxxxxxx |
223–297–0 |
3813–05–6 |
Xx; R36/38 X52–53 |
Xx X:36/38–52/53 X: (2-)22-61 |
|||
|
607–156–00–4 |
xxxxxxxxxxx (XXX) 4-chlorfenyl-4-chlorbenzen-1-sulfonát |
201–270–4 |
80–33–1 |
Xn; X22 Xx; X38 X; X50–53 |
Xx; N X: 22–38–50/53 S: (2-)37–60–61 |
|||
|
607–158–00–5 |
xxxxx xxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx |
223–498–3 |
3926–62–3 |
X; X25 Xx; X38 X; X50 |
X; X X: 25–38–50 S: (1/2-)22–37–45–61 |
|||
|
607–159–00–0 |
xxxxxxxxxxxxxx (XXX) xxxxx-2,2-xxx(4-xxxxxxxxxx)-2-xxxxxxxxxxxxx xxxxx-4,4'-xxxxxxxxxxxxxxx |
208–110–2 |
510–15–6 |
Xx; X22 X; X50–53 |
Xx; X R: 22–50/53 X: (2-)60-61 |
|||
|
607–176–00–3 |
Směs: α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-xxxxxxxxxxx(xxxxxxxxxx);α-{3-[3-(2 H-benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propionyl}-ω-({3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}xxx)xxxx(xxxxxxxxxx) |
400–830–7 |
— |
X43 X; R51–53 |
Xi; X X: 43–51/53 X: (2-)36/37–61 |
|||
|
607–188–00–9 |
xxxxxxx-xxxxxxxx-X-(2-xxxxxxxxxxxx)-X-(xxxxxxx-9-xx-1-xx)xxxxxxxxxx |
402–970–4 |
— |
X43 X; R51–53 |
Xi; X R: 43–51/53 X: (2-)24/37–61 |
|||
|
607–209–00–1 |
Xxxx: X,X′-xxxxxxxxxxx-xxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx) |
403–030–6 |
— |
Xx; R22 X43 X; X50–53 |
Xx; X X: 22–43–50/ 53 X: (2-)36/37–60–61 |
|||
|
607–213–00–3 |
ethyl-3,3-bis(terc-pentylperoxy)butanoát |
403–320–2 |
67567–23–1 |
E; X2 X; X7 X10 X; X51–53 |
X; X R: 2–7–10–51/53 X: (2-)3/7–14–33–36/37/39–61 |
|||
|
607–217–00–5 |
2-ethoxyethyl-[4-(7-fenyl-2,6-dioxo-2,6-dihydro-1,5-dioxa-s-indacen-3-yl)fenoxy]acetát |
403–960–2 |
— |
R43 X53 |
Xx X: 43-53 S: (2-)24–37–61 |
|||
|
607–243–00–7 |
xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [1] xxxxxxx-3,6-xxxxxxx-x-xxxxxx [1] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [2] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [2] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [3] (2-hydroxyethyl)amonium-3,6-dichloranisát [3] |
217–846–3 [1] 246–590–5 [2] 258–527–9 [3] |
1982–69–0 [1] 25059–78–3 [2] 53404–28–7 [3] |
X52–53 |
X: 52/53 S: 61 |
|||
|
607–248–00–4 |
Xxxxxxxx-xxxxxxx Natrium-N-(1-naftyl)ftalamát |
205–073–4 |
132–67–2 |
Xn; R22 |
Xn X: 22 X: (2) |
|||
|
607–249–00-X |
(xxxxxxxxxxxxx)xxx[xxx(xxxxxxxxxxxxx)]-xxxxxxxxx xxxxxxxxxxxxxxxxx-xxxxxxxxx XXXXX |
256–032–2 |
42978–66–5 |
Xx; X36/37/38 X43 X; X51–53 |
Xx; X R:36/37/38–43–51/53 X: (2-)24–37–61 |
X ≥ 10 %: Xx; X36/37/38–43 1 % ≤ X < 10 %: Xx; X43 |
||
|
607–252–00–6 |
λ-xxxxxxxxxxx (XXX) Xxxx (1:1): (S)-[(3-fenoxyfenyl)kyanmethyl]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x(X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx |
415–130–7 |
91465–08–6 |
X+; R26 X; X25 Xx; X21 X; R50–53 |
T+; X R: 21–25–26–50/53 X: (1/2-)28–36/37/39–38–45–60–61 |
|||
|
607–255–00–2 |
xxxxxxxxxx (ISO) [(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx xxxxxxxx |
— |
69377–81–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
608–003–00–4 |
xxxxxxxxxxxx |
X X |
203–466–5 |
107–13–1 |
X; Xxx Xxxx. xxx. 2; X45 X; X23/24/25 Xx; X37/38–41 X43 X; R51–53 |
F; X; N X: 45–11–23-/24/25–37/38–41–43–51/53 S: 9–16–53–45–61 |
X ≥ 20 %: X; X45–23/24/25–37/38–41–43 10 % ≤ C &xx; 20 %: X; R45–23/24/25–41–43 5 % ≤ X &xx; 10 %: X; X45–23/24/25–36–43 1 % ≤ X &xx; 5 %:X; X45–23/24/25–43 0,2 % ≤ X &xx; 1 %:X; X45–20/21/22 0,1 % ≤ X &xx; 0,2 %: T; X45 |
43 |
|
608–016–00–5 |
2,3,5,6-xxxxxxxxxx-1,4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxx |
401–550–8 |
1897–41–2 |
X43 X; X50–53 |
Xx; X R: 43–50/53 X: (2-)24–37–60–61 |
|||
|
609–030–00–4 |
xxxxxxxx (ISO) 2-xxxx-xxxxx-4,6-xxxxxxxxxxxx |
X |
215–813–8 |
1420–07–1 |
Xxxx. xxx. 2; X61 X+; R28 X; R24 X44 X; R50–53 |
T+; N X: 61–24–28–44–50/53 X: 53–45–60–61 |
||
|
609–040–00–9 |
xxxxxxxx (XXX) (2,4-xxxxxxxxxxxx)(4-xxxxxxxxxx)xxxxx |
X |
217–406–0 |
1836–75–5 |
Xxxx. xxx. 2; X45 Xxxx. kat. 2; X61 Xn; X22 X; R50–53 |
T; N X: 45–61–22–50/53 X: 53–45–60–61 |
||
|
609–044–00–0 |
xxxxxxxx (XXX) 1,2,4,5-xxxxxxxxxx-3-xxxxxxxxxxx |
204–178–2 |
117–18–0 |
Xx; X22 X43 X; X50–53 |
Xx; N X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
611–008–00–4 |
4-xxxxxxxxxxxxxx 4-(xxxxxxxx)xxxxxx |
200–453–6 |
60–09–3 |
Xxxx. xxx. 2; X45 N; R50–53 |
T; X X: 45–50/53 X: 53–45–60–61 |
|||
|
611–013–00–1 |
4-xxxxxxx-3-{4-[2-xxxxxxx-4-(3-xxxxxxxxxxxxxxxxx)xxxxxxxx]-3-xxxxxxxxxxxxxx}-6-(3-xxxxxxxxxxxxxxxx)xxxxxxxx-2-xxxxxxxx xxxxxxxxx |
403–650–7 |
117409–78–6 |
X; X2 N; X51–53 |
X; X X: 2–51/53 X: (2-)35-61 |
|||
|
611–031–00-X |
4,4'-[(4-iminocyklohexa-2,5-dien-1-yliden)methylen]dianilin-hydrochlorid CI Xxxxx Xxx 9 XX xxxxxxx xxxxxx 9 |
209–321–2 |
569–61–9 |
Xxxx. xxx. 2; X45 |
X X: 45 X: 53-45 |
|||
|
612–035–00–4 |
2-xxxxxxxxxxxxx x-xxxxxxxx |
X |
201–963–1 |
90–04–0 |
Xxxx. xxx. 2; X45 Xxxx. kat. 3; X40 T; X23/24/25 |
X X: 45–23/24/25 X: 53-45 |
||
|
612–042–00–2 |
xxxxxxxx xxxxxxx-4,4'-xxxxxx 4,4'-xxxxxxxxxxxxxx xxxxxxx-4,4'-xxxxxxxxxx |
X |
202–199–1 |
92–87–5 |
Xxxx. xxx. 1; X45 Xn; R22 X; R50–53 |
T; X X: 45–22–50/53 S: 53–45–60–61 |
X ≥ 25 %: X; X45–22 0,01 % ≤ X < 25 %: X; X45 |
|
|
612–051–00–1 |
4,4'-xxxxxxxxxxxxxxxxxxxx xxx(4-xxxxxxxxxx)xxxxxx 4,4'-xxxxxxxxxxxxxxxx |
X |
202–974–4 |
101–77–9 |
Xxxx. kat. 2; X45 Muta. xxx. 3; R40 X; X39/23/24/25Xx; X48/20/21/22 X43 X; R51–53 |
T; X X: 45–39/23/24/25–43–48/20/21/22–51/53 X:53–45–61 |
||
|
612–081–00–5 |
3,3'-xxxxxxxxxxxxxxxx, xxxx o-tolidin, xxxx |
X X |
210–322–5 265–294–7 277–985–0 |
612–82–8 64969–36–4 74753–18–7 |
Karc. xxx. 2; X45 Xx; X22 N; X51–53 |
X; X X: 45–22–51/53 X: 53–45–61 |
||
|
612–099–00–3 |
4-xxxxxx-x-xxxxxxxxxxxxx4-xxxxxx-1,3-xxxxxxxxxxxxx4-xxxxxxxxxxxx-1,3-xxxxxx 2,4-xxxxxxxxxxxx |
X |
202–453–1 |
95–80–7 |
Xxxx. kat. 2; X45 X; R25 Xx; R21 Xx; X36 X43 X; X51–53 |
X; X R: 45–21–25–36–43–51/53 X: 53–45–61 |
||
|
612–105–00–4 |
2-(xxxxxxxxx-1-xx)xxxxxxxxx2-(xxxxxxxxx-1-xx)xxxxx-1-xxxx |
205–411–0 |
140–31–8 |
Xx; X21/22 C; X34 X43 R52–53 |
C X: 21/22–34–43–52/53 S: (1/2-)26–36/37/39–45–61 |
|||
|
612–111–00–7 |
2-methyl-m-fenylendiamin2-methyl-1,3-fenylendiamin2-methylbenzen-1,3-diamin 2,6-xxxxxxxxxxxx |
212–513–9 |
823–40–5 |
Xxxx. xxx. 3; X40 Xx; X21/22 X43 X; X51–53 |
Xx; X X: 21/22–40–43–51/53 X: (2-)24–36/37–61 |
|||
|
612–125–00–3 |
2-methyl-p-fenylendiamin2-methyl-1,4-fenylendiamin2-methylbenzen-1,4-diamin 2,5-xxxxxxxxxxxx |
202–442–1 |
95–70–5 |
X; X25 Xn; R20/21 X43 X; R51–53 |
T; X X: 20/21–25–43–51/53 X: (1/2-)24–37–45–61 |
|||
|
612–144–00–7 |
xxxxxxxxxxx (XXX) X-(2-xxxxx-6-xxxxxxxxxxx)-X-xxxxx-2,6-xxxxxxx-4-(xxxxxxxxxxxxxx)xxxxxx |
— |
62924–70–3 |
Xx; X36/38 X4 3 X; R50–53 |
Xi; X R: 36/38–43–50/53 X: (2-)36/37–60–61 |
|||
|
612–151–00–5 |
diaminotoluen xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx methylbenzendiamin |
E |
246–910–3 |
25376–45–8 |
Karc. xxx. 2; X45 X; X25 Xx; X20/21 Xx; X36 X43 X; R51–53 |
T; N X: 45–20/21–25–36–43–51/53 X: 53–45–61 |
||
|
613–018–00–4 |
xxxxxxxxxx (XXX) 1,1'-bis[(3,5-dimethylmorfolin-4-karbonyl)methyl]-4,4'-bipyridin-1,1'-diium |
— |
7411–47–4 |
Xn; X22 Xx; R36/37/38 X52–53 |
Xx X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–031–00–5 |
xxxxxxxxx trichlorisokyanurová xxxxxxxx trichlor-1,3,5-triazintrion 1,3,5-trichlor-1,3,5-triazin-2(1H), 4(3X), 6(5H)-trion |
201–782–8 |
87–90–1 |
O; X8 Xx; X22 R31 Xx; R36/37 X; X50–53 |
X; Xn; X X: 8–22–31–36/37–50/53 X: (2-)8–26–41–60–61 |
|||
|
613–038–00–3 |
6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxxxxxx 6-fenyl-1,3,5-triazin-2,4-diamin benzoguanamin |
202–095–6 |
91–76–9 |
Xn; X22 X52–53 |
Xx R:22–52/53 X: (2-)61 |
|||
|
613–042–00–5 |
xxxxxxxx (XXX) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1 X-xxxxxxxx |
252–615–0 |
35554–44–0 |
Xx; X20/22 N; X41 X; R50–53 |
Xn; X X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–043–00–0 |
xxxxxxxx-xxxxxx (XXX) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1X -xxxxxxxx-1-xxx-xxxxxxxxxxxxxx [1] (±)-1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx-1-xxx-xxxxxxxxxxxxxx |
261–351–5 [1] 281–291–3 [2] |
58594–72–2 [1] 83918–57–4 [2] |
Xx; R20/22 Xx; X41 N; R50–53 |
Xn; X R: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–066–00–6 |
xxxxxxxxxx (ISO) 2-(xxxx-xxxxxxxxxx)-4-(xxxxxxxxxx)-6-xxxxxxx-1,3,5-xxxxxxx |
251–637–8 |
33693–04–8 |
Xx; R22 N; X50–53 |
Xx; N X: 22–50/53 X: (2-)60-61 |
|||
|
613–091–00–2 |
xxxxxxxxxx-xxxxxxxxx [1] xxxxxxxxxx-xxxxxx [2] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx-xxxxxxxxx [1] 1,1'-bis[(3,5-dimethylmorfolin-4-karbonyl)methyl]-4,4'-bipyridin-1,1'-dium-disulfát [2] |
225–062–8 [1] |
4636–83–3 [1] 29873–36–7 [2] |
Xn; R22 Xx; X36/37/38 R52–53 |
Xn; X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–098–00–0 |
1-xxxxxxxxxxxxxxx-2-xx 1-xxxxx-2-xxxxxxxxxx |
403–700–8 |
2687–94–7 |
X; R34 X; X51–53 |
X; N X: 34–51/53 X: (1/2-)23–26–36/37/39–45–61 |
|||
|
613–130–00–3 |
xxxxxxxxxxx (XXX) (RS)-2-(2,4-dichlorfenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol |
— |
79983–71–4 |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–131–00–9 |
xxxxxxxxxx (XXX) 1,2,5,6-tetrahydro-4 X-xxxxxxx[3,2,1-xx]xxxxxxxx-4-xx |
— |
57369–32–1 |
Xx; X22 R52–53 |
Xn X:22–52/53 X: (2-)61 |
|||
|
613–134–00–5 |
myklobutanil (XXX) 2-(4-xxxxxxxxxx)-2-[(1 X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
— |
88671–89–0 |
Xxxx. xxx. 3; X63 Xx; R22 Xx; X36 X; R51–53 |
Xn; X R: 22–36–51/53–63 X: (2-)36/37–46–61 |
|||
|
613–137–00–1 |
xxxxxxxxxxxxxxxxxx (XXX) 1-(1,3-xxxxxxxxxxxx-2-xx)-1,3-xxxxxxxxxxxxxxxx |
242–505–0 |
18691–97–9 |
X; X50–53 |
X R: 50/53 X: 60-61 |
|||
|
613–139–00–2 |
metsulfuron-methyl xxxxxx-2-{X —[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)karbamoyl]sulfamoyl}benzoát |
— |
74223–64–6 |
N; X50–53 |
X X: 50/53 S: 60-61 |
|||
|
614–001–00–4 |
xxxxxxx (ISO) 3-(1-xxxxxxxxxxxxxxxx-2-xx)xxxxxxx |
200–193–3 |
54–11–5 |
X+; X27 T; X25 X; X51–53 |
X+; X X: 25–27–51/53 X: (1/2-)36/37–45–61 |
|||
|
614–006–00–1 |
xxxxxx 2,3-xxxxxxxxxxxxxxxxxxxx-10-xx |
206–614–7 |
357–57–3 |
X+; X26/28 X52–53 |
X+ X:26/28–52/53 X: (1/2-)13–45–61 |
|||
|
614–007–00–7 |
xxxxxx-xxxxxx [1] brucin-nitrát [2] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [3] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [4] |
225–432–9 [1] 227–317–9 [2] 269–439–5 [3] 269–710–8 [4] |
4845–99–2 [1] 5786–97–0 [2] 68239–26–9 [3] 68310–42–9 [4] |
X+; R26/28 X52–53 |
X+ X: 26/28–52/53 X: (1/2-)13–45–61 |
|||
|
615–006–00–4 |
2-xxxxxx-x-xxxxxxxxxxxxxxxxxx [1] 2-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [1] 4-xxxxxx-x-xxxxxxxxxxxxxxxxxx [2] 4-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [2] x-xxxxxxxxxxxxxxxxxxxx [3] 5-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [3] xxxxxx-2,6-xxxxxxxxxxx [1] toluen-2,4-diisokyanát [2] xxxxxx-3,5-xxxxxxxxxxx [3] |
X |
202–039–0 [1] 209–544–5 [2] 247–722–4 [3] |
91–08–7 [1] 584–84–9 [2] 26471–62–5 [3] |
Xxxx. kat. 3; X40 X+; X26 Xx; X36/37/38 R42/43 X52–53 |
X+ R: 26–36/37/38–40–42/43–52/53 X: (1/2-)23–36/37–45–61 |
X320 %: X+; X26–36/37/38–40–42/43 7 % ≤ C &xx; 20 %: X+; R26–40–42/43 1 % ≤ X &xx; 7 %: X; X23–40–42/43 0,1 % ≤ X &xx; 1 %:Xx; X20–42 |
2 |
|
616–010–00–9 |
xxxxxxx-xxxxxxxxxxxxxx X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx, xxxxx xxx |
204–854–7 |
127–65–1 |
Xx; X22 R31 X; X34 X42 |
X X: 22–31–34–42 X: (1/2-)7–22–26–36/37/39–45 |
|||
|
616–034–00-X |
xxxxxxxxxxxx (ISO) 6-xxxxxx-3,4-xxxxxxx-2X-xxxxx-5-xxxxxxxxxxxx |
246–419–4 |
24691–76–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
616–035–00–5 |
xxxxxxxxx X -[(ethylamino)karbonyl]-2-kyan-2-(methoxyimino)acetamid 1-ethyl-3-[2-kyan-2-(methoxyimino)acetyl]močovina |
261–043–0 |
57966–95–7 |
Xn; X22 X43 X; X50–53 |
Xx; N R: 22–43–50/53 S: (2-)36/37–60–61 |
|||
|
617–004–00–9 |
(1,2,3,4-tetrahydro-1-naftyl)hydroperoxid xxxxxxxxxxxxxxxxxxxx |
212–230–0 |
771–29–9 |
X; R7 Xn; X22 X; X34 X; X50–53 |
X; C; X R: 7–22–34–50/53 X:(1/2-)3/7–14–26–36/37/39–45–60–61 |
X325 %: X; X22–34 10 % ≤ X &xx; 25 %: X; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
|
617–006–00-X |
xxx(α, α-xxxxxxxxxxxxxx)xxxxxxx bis(2-fenylpropan-2-yl)peroxid xxx(1-xxxxx-1-xxxxxxxxxxx)xxxxxxx xxxxxxxxxxxxxx |
201–279–3 |
80–43–3 |
X; X7 Xx; X36/38 X; X51–53 |
X; Xx; X X: 7–36/38–51/53 X: (2-)3/7–14–36/37/39–61 |
|||
|
617–008–00–0 |
xxxxxxxxxxxxxxxx |
202–327–6 |
94–36–0 |
X; X2 Xx; X36 R43 |
E; Xx; X: 2–36–43 S: (2-)3/7–14–36/37/39 |
|||
|
650–007–00–3 |
xxxxxxxxxxxxx (ISO) X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx |
228–200–5 |
6164–98–3 |
Xxxx. xxx. 3; X40 Xx; X21/22 X; R50–53 |
Xn; X X: 21/22–40–50/53 S: (2-)22–36/37–60–61 |
|||
|
650–008–00–9 |
xxxxxxxxxx (XXX) 4-[(2-xxxxxxxxxx)xxxxxxxxx]-3-xxxxxxxxxxxxxx-5(4 X)-xx |
227–197–8 |
5707–69–7 |
X; R25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)22–24–36/37–45–60–61 |
|||
|
650–009–00–4 |
xxxxxxxxxxxxx-xxxxxxxxxxxx X'-(4-xxxxx-x-xxxxx)-X,X-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx |
243–269–1 |
19750–95–9 |
Xxxx. xxx. 3; R40 Xx; R22 X; X50–53 |
Xx; N X: 22–40–50/53 S: (2-)22–36/37–60–61 |
|||
|
650–033–00–5 |
xxxxxxxxxxxx (XXX) [(S)-(3-fenoxyfenyl)kyanmethyl]-(S)-2-(4-chlorfenyl)-3-methylbutanoát (S)-3-fenoxy-α-kyanbenzyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát |
— |
66230–04–4 |
T; X23/25 R43 X; X50–53 |
X; X X: 23/25–43–50/53 S: (1/2-)24–36/37/39–45–60–61 |
|||
|
650–041–00–9 |
xxxxxxxxxxxx (XXX) 1-[2-(2-xxxxxxxxxxx)xxxxxx-1-xxxxxxxx]-3-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxx |
— |
82097–50–5 |
X; R50–53 |
N X: 50/53 X: 60-61 |
XXXXXXX 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx x xxxxxx |
Xxxxx XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx limity |
Poznámky x přípravkům |
|
006–090–00–8 |
2-[(3-jodprop-2-yn-1-yl)oxy]ethyl-N-fenylkarbamát |
408–010–0 |
88558–41–2 |
Xn; X20 Xx; X41 X52–53 |
Xx X: 20–41–52/53 X: (2-)22–26–39–61 |
|||
|
014–016–00–0 |
Xxxx: 1,3-xx(xxx-5-xx-1-xx)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx x 1,3-xx(xxx-x-xx-1-xx)- 1,1,3,3-tetramethyldisiloxan |
406–490–6 |
— |
N; X51–53 |
X R: 51/53 X: 61 |
|||
|
015–164–00–9 |
xxxxxxx-xxxxxxxxxx-(1-xxxxxxxxxxxxxx)xxxxxxxxxxx dihydrát |
400–480–5 |
36669–85–9 |
R52–53 |
R:52/53 X: 61 |
|||
|
015–165–00–4 |
Směs: X, X, S', X''-xxxxxxxxxx-4,4'-xxxxxxxxxxxxx(xxxxxxxxxxxxxx)-xxx(xxxxxxxxxxxxxxxx) x xxxxxxx[4-(xxxxxxxxxxxxx)xxxxx]xxxxxxxxx-xxxxxxxxxxxxxxxx |
404–986–7 |
— |
Xx; X41 X; R50–53 |
Xi; N X: 41–50/53 X: (2-)15–26–39–60–61 |
|||
|
015–166–00-X |
3,9-xxx(2,6-xx-xxxx-xxxxx-4-xxxxxxxxxxxx)-2,4,8,10-xxxxxxxx-3,9-xxxxxxxxxxxx[5.5]xxxxxxx |
410–290–4 |
80693–00–1 |
X53 |
X:53 X: 61 |
|||
|
015–167–00–5 |
3-[hydroxy(fenyl)fosfinoyl]propanová xxxxxxxx |
411–200–6 |
14657–64–8 |
Xx; X41 |
Xx X: 41 S: (2-)26-39 |
|||
|
601–050–00–1 |
X10-X13-xxxxxxxxxxxxx xxxxxxx |
267–051–0 |
67774–74–7 |
X; X50 |
X R: 50 S: 61 |
|||
|
601–051–00–7 |
4-xxxxxxxx-1-xx |
405–980–7 |
768–56–9 |
Xx; X38 N; X51–53 |
Xx; X X: 38–51/53 X: (2-)37-61 |
|||
|
602–083–00–4 |
xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx |
251–084–2 |
32534–81–9 |
Xx; X48/21/22 X64 X; X50–53 |
Xx; X X: 48/21/22–50/53–64 X: (1/2-)36/37–45–60–61 |
|||
|
602–084–00-X |
1,1-xxxxxxx-1-xxxxxxxxxx |
404–080–1 |
1717–00–6 |
X; R52–53–59 |
N R: 52/53–59 S: 59-61 |
|||
|
603–128–00–0 |
2-(fenylmethoxy)naftalen |
405–490–3 |
613–62–7 |
R53 |
R:53 X: 61 |
|||
|
603–129–00–6 |
1-terc-butoxypropan-2-ol |
406–180–0 |
57018–52–7 |
R10 Xi; X41 |
Xx R: 10-41 X: (2-)26-39 |
|||
|
603–130–00–1 |
Xxxx isomerů: α-(xxxxxxxxxxxxxxxxx)-ω-xxxxxxxxxxx(xxxxxxxxxx) |
406–325–8 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 X: (2-)39-61 |
|||
|
603–131–00–7 |
Xxxx (3:1):1-xxxxx-1-[xxxxxx(1-xxxxxxxxxx)xxxxx]-X-xxxxxxxx; 1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxxx)xxxxx]-X-xxxxxxxx |
407–290–1 |
— |
Xx; X41 |
Xx X: 41 S: (2-)26-39 |
|||
|
603–132–00–2 |
2-(xxxxxxxxxxxxx)-6-xxxxxxxxx-9-xxxxxx-1,4-xxxxxxxxxx[4.5]xxxxx |
408–200–3 |
63187–91–7 |
Xx; X38–41 R52–53 |
Xi X:38–41–52/53 X: (2-)26–37/39–61 |
|||
|
603–133–00–8 |
Xxxx:3-(4-xxxxx-2-xxxxx-5-xxxxxxxxxxxx)xxxxxx-1,2-xxxx x 3,3'-[(2-xxxxx-5-xxxxx-1,4-xxxxxxx)xxxxxxx]xx(xxxxxx-1,2-xxxx) |
408–240–1 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 X: (2-)22–36–61 |
|||
|
603–134–00–3 |
Xxxx: xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxx x xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxxxxx (xxxxxxx x xxxxxxxxxx xxxxxxxxxxxx) |
410–450–3 |
— |
X53 |
X: 53 X: 61 |
|||
|
603–135–00–9 |
xxx[2-(2-xxxxxxxxxxxxx)xxxxxxxxxx]xxx(2,2', 2-nitrilotriethan-1-olato-N,O)titaničitý xxxxxxx |
410–500–4 |
— |
Xx; X41 N; X51–53 |
Xx; X X: 41–51/53 S: (2-)26–39–61 |
|||
|
603–136–00–4 |
3-{4-[xxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxxx}xxxxxx-1-xx |
410–910–3 |
104226–19–9 |
X43 X52–53 |
Xx R:43–52/53 S: (2-)24–37–61 |
|||
|
603–137–00-X |
Xxxx:1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx a 1-deoxy-1-[methyl(1-oxooktadecyl)amino]-D-glucitol |
411–130–6 |
— |
Xi; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
603–138–00–5 |
3-(2,2-xxxxxxxx-3-xxxxxxxxxxxxx)xxxxxx 2,2-dimethyl-3-(3-methylfenyl)propan-1-ol |
403–140–4 |
103694–68–4 |
R52–53 |
R:52/53 X: 61 |
|||
|
604–050–00-X |
4-xxxxx-x-xxxxxx 4-chlor-2-methylfenol |
216–381–3 |
1570–64–5 |
T; X23 X; R 35 X; R50 |
T; X; X X: 23–35–50 S: (1/2-)26–36/37/39–45–61 |
C ≥ 25 %: X; X; X23–35 10 % ≤ X < 25 %: X;X20–35 5 % ≤ C &xx; 10 %: X;X20–34 3 % ≤ X < 5 %: Xn;R20–36/37/38 1 % ≤ X < 3 %:Xx;X36/37/38 |
||
|
604–051–00–5 |
3,5-xxx(3,5-xx-xxxx-xxxxx-4-xxxxxxxxxxxxx)-2,4,6-xxxxxxxxxxxxxx |
401–110–5 |
87113–78–8 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–052–00–0 |
2,2'-methylenbis[6-(2 X - benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)fenol] 6,6'-xxx(2X -xxxxxxxxxxxx-2-xx)- 4,4'-xxx(1,1,3,3-xxxxxxxxxxxxxxxx)- 2,2'-xxxxxxxxxxxxxxx |
403–800–1 |
103597–45–1 |
X53 |
X:53 X: 61 |
|||
|
604–053–00–6 |
4-terc - xxxxx-2-xxxxxx-6-(1-xxxxxxxxxxxxxxxx)xxxxx |
410–760–9 |
157661–93–3 |
Xx; R38 X43 N; X50–53 |
Xx; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
604–054–00–1 |
Směs:2-methoxy-4-(4-methylidentetrahydropyran-2-yl)fenol a 2-xxxxxxx-4-(4-xxxxxx-3,6-xxxxxxx-2X -xxxxx-2-xx)xxxxx |
412–020–0 |
— |
X43 R52–53 |
Xi X:43–52/53 X: (2-)24–37–61 |
|||
|
604–055–00–7 |
4,4'-xxx[(2,3-xxxxxxxxxxx)xxx]-3,3', 5,5'-xxxxxxxxxxxxxxxxxx |
413–900–7 |
85954–11–6 |
Xxxx. Kat.3; X40 |
Xx X: 40 X: (2-)22–36–37 |
|||
|
605–027–00–7 |
Xxxx:3x, 4,5,6,7,7x-xxxxxxxxx-4,7-xxxxxxx-1X-xxxxx-6-xxxxxxxxxxx a 3x, 4,5,6,7,7x-xxxxxxxxx-4,7-xxxxxxx-1X - xxxxx-5-xxxxxxxxxxx |
410–480–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
606–051–00–0 |
4-xxxxxxxxxxxxxxxxxx pentylcyklohexan-1-on |
4–406–670–4 |
61203–83–6 |
N; X51–53 |
X X: 51/53 X: 61 |
|||
|
606–052–00–6 |
4-(X, N-dibutylamino)-2-hydroxy-2'-karboxybenzofenon 2-[4-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx kyselina |
410–410–5 |
54574–82–2 |
R52–53 |
R:52/53 X: 61 |
|||
|
607–272–00–5 |
xxxxxxxxxxx-xxxxxx (XXX) [1] xxxxxxxxxx-xxxxxxxxx (ISO) [2] xxxxxxxxxxxx-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [1] (2-xxxxxx-1-xxxxxxxxxxx)-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [2] |
279–752–9 [1] — |
81406–37–3 [1] 154486–27–8 [2] |
N; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
607–273–00–0 |
xxxxxxx-7-{2,6-xxxxxxxx-8-[(2,2-xxxxxxxxxxxxxxxx)xxx]- 1,2,6,7,8,8x-xxxxxxxxx-1-xxxxxx}-3,5-xxxxxxxxxxxxxxxxxx |
404–520–2 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–274–00–6 |
{2-[xxxxxx(xxxxxx)xxxxx]xxxxx}-3-xxxxxxxx-2-xxxxx |
405–350–1 |
54527–73–0 |
X43 X; X51–53 |
Xx; N R: 43–51/53 X: (2-)24–37–61 |
|||
|
607–275–00–1 |
xxxxxxx-4-(xxxxxxxxxx)xxxxxx-1-xxxxxxxx |
405–450–5 |
66531–87–1 |
X43 |
Xx X: 43 S: (2-)24-37 |
|||
|
607–276–00–7 |
[xxx(2-xxxxxxxxxxxxxx) bis(1-methylimidazol)]zinečnatý xxxxxxx |
405–635–0 |
— |
Xx; X38–41 N; R50–53 |
Xi; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–277–00–2 |
Xxxx:2-(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxxxxxxxx x xxxxxxx-xxxxxxxxx |
405–720–2 |
— |
Xx; X22 Xi; X41 X43 X; X51–53 |
Xx; X X: 22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
607–278–00–8 |
Směs:alkyl(C7-C9 xxxxxxxxxx x xxxxxxxxxxxx)-3-[3-(2 X - xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxxx |
405–760–0 |
— |
Xx; X41 R43 X52–53 |
Xx X: 41–43–52/53 X: (2-)24–26–37/39–61 |
|||
|
607–279–00–3 |
Xxxx:(xxxxxxxxxxxxxx)xxxxxxxxx-xxx(xxxxxxxx-xxxxxxxx) a (oktadecylimino)diethylen-(hydrogen-ftalát)-(hydrogen-maleinát) |
405–960–8 |
— |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–280–00–9 |
4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx xxxxx natrium-4-chlor-1-hydroxybutan-1-sulfonát |
406–190–5 |
54322–20–2 |
Xn; X22 Xi; R36 X43 |
Xx R: 22–36–43 X: (2-)22–26–36/37 |
|||
|
607–281–00–4 |
Xxxx:xxxxx(X7-X9 xxxxxxxxxx x lineární)-3-[3-(2H-benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propanoáty |
407–000–3 |
127519–17–9 |
N; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–282–00-X |
2-(xxxxxxxxxxxxx)-4-(xxxxxxxxx)xxxxx-xxxxxx |
407–140–5 |
131266–10–9 |
X52–53 |
X: 52/53 S: 61 |
|||
|
607–283–00–5 |
xxxxx-(X)-4-xxxxx-4-xxxxxx-2-xxxxxxxxxx-(X)-4-xxxxx-4-xxxxxxxxxxx |
408–040–4 |
15121–89–8 |
Xx; X21/22 Xi; X38–41 R43 X; X50–53 |
Xx; N X: 21/22–38–41–43–50/53 X: (2-)26–36/37/39–60–61 |
|||
|
607–284–00–0 |
Xxxx (9:1):xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) a xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) |
410–040–4 |
136213–76–8 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–285–00–6 |
Xxxx:7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxxx xxxxxxxx, xxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx a xxxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx |
410–065–0 |
— |
X43 |
Xx X: 43 S: (2-)22–24–37 |
|||
|
607–286–00–1 |
Xxxx:xxxxxx- a xxxxxxx-7-[4-({4-[(2-xxxxxxx-1-xxxxxx)xxx]xxxxx}xxx)xxxxxxxxxxxxxxxxx]xxxxxxxx-1,3-xxxxxxxxxx |
410–070–8 |
141880–36–6 |
X43 X52–53 |
Xx R:43–52/53 X: (2-)22–24–37–61 |
|||
|
607–287–00–7 |
xxxxxx-[1-xxxxxx-2-(xxxxxxxxxxxxxxx)xxxxx]-1,2,3,6-xxxxxxxxxxxxxxxx |
410–140–8 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–288–00–2 |
[x-(X -{3-[(1-{3-[(2,6(4,6)-xxxxxxx-5-xxxxxxxxxxxxx-4(2)-xx)xxxxxxxxxxx]xxxxxx}-2-xxxxxxx-4-xxxxxx-6-xxx-1,6-xxxxxxx-3-xxxxxxx)xxx]-4-xxxxxxxxxxxxxx}xxxxxxxxx)-x,x,x -xxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxxx xxxxxxx, xxxxxxxxxx sůl; x = 15, 16, 17 xxxx 18, x = 1, 2, 3 xxxx 4, x = 8, 9, 10 xxxx 11, d = 22, 23, 24 nebo 25 |
410–160–7 |
148732–74–5 |
Xi; X36 X43 R52–53 |
Xi X: 36–43–52/53 X: (2-)22–26–36/37–61 |
|||
|
607–288–00–8 |
3-[(3-{X —[4-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxx]xxxxxxxxx}-4-xxxxxxx-1-xxxxxx)xxxxxxxx]xxxxxxxxx xxxxxxxx |
410–370–9 |
105488–33–3 |
X53 |
X:53 X: 61 |
|||
|
607–290–00–3 |
Xxxx (x xxxxxxxx xxxxxx):xxxxxxx-1-xxxxx(X14-X18)-4-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx x xxxxxxx-4-xxxxx(X14-X18)-1-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx |
410–540–2 |
— |
Xx; X38 X43 X; R50–53 |
Xi; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
607–291–00–9 |
xxxxxxx-ω-xxxxxxxxxxx(xxxx xxxxxxxxxx)xxxxxxxx |
410–630–1 |
104051–92–5 |
X53 |
X: 53 X: 61 |
|||
|
607–292–00–4 |
Xxxx:[2-(xxxxx(X12)xxx)-1-(xxxxxxxxxxxxx)xxxxxx]xxxxxx xxxxxxxx x [2-(alkyl(C14)oxy)-1-(methoxymethyl)]octová kyselina |
410–640–6 |
— |
Xi; X38–41 X; X50–53 |
Xx; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–293–00-XSměs: |
1-(2-aminoethyl)piperazin-1,4-diium-[(2,4,6-trimethylnonyl)fenoxy]benzendisulfonát x 1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[xxx(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx |
410–650–0 |
— |
Xx; R41 X43 X; X51–53 |
Xx; N X: 41–43–51/53 S: (2-)26–36/37/39–61 |
|||
|
607–294–00–5 |
xxxxxxx-2-(xxxxxxxxxx)-1-xxxxxxxxxxxx-1-xxxxxxxx |
410–680–4 |
— |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
607–295–00–0 |
Xxxx:xxxxxxxxxxxx-xxxxxxxxxxxxxxxxx x xxxxxxxxxxx-xxxxxxxxxxxx-1,2,3,4-xxxxxxxxxxxxxxx |
410–800–5 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–296–00–6 |
Xxxx:xxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxxxx xxxxxxxx a 2-xxxxxxxxxxxxx xxxxxxxx |
410–830–9 |
— |
X53 |
X: 53 X: 61 |
|||
|
607–297–00–1 |
3,3'-(1,4-fenylendimethyliden)bis(2-oxobornan-10-sulfonová xxxxxxxx)2,2'-xxxxx-3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxxxx-1-xxxxxxxxxxxxxxx xxxxxxxx) |
410–960–6 |
92761–26–7 |
Xx; R41 |
Xi R: 41 X: (2-)26-39 |
|||
|
607–298–00–7 |
[2-(xxxxxxxxxxxxxxx)xxxxx]-4-xxxxxxxxxxxxxxxx |
411–010–3 |
— |
X43 |
Xx X: 43 X: (2-)22–36/37 |
|||
|
607–299–00–2 |
xxxxxx-3-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxxxxx |
411–040–7 |
97101–46–7 |
Xx; R22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
607–300–00–6 |
[x-(X-{4-[(5-xxxxx-2,6-xxxxxxxxxxxxxxxx-4-xx)xxxxx]-3-xxxxxxxxxxxxxxxx}xxxxxxxxx)-x-xxxxxxxxx-x, x-xxxxxxxxxxxxxxxxxxxx]xxxxxxx xxxxxxx, xxxxxxxx xxx; x = 1,2,3 nebo 4, b = 8, 9, 10 xxxx 11, c = 15, 16, 17 nebo 18, x = 22, 23, 24 nebo 25 |
411–430–7 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–301–00–1 |
Xxxx:xxxxxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxx(1-7)xxxxxxx |
411–860–5 |
— |
Xx; X38–41 X43 X; X51–53 |
Xx; N R: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–302–00–7 |
Xxxx:xxxxxxxxxxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxxx(1-7)xxxxxxx |
411–910–6 |
— |
Xx; X38–41 R43 X; X51–53 |
Xx; X X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–303–00–2 |
1-xxxxxxxxxxx-6,7-xxxxxxx-4-xxx-1,4-xxxxxxxxxxxxxxx-3-xxxxxxxxxxx kyselina |
413–760–7 |
93107–30–3 |
Repr. kat.3; X62 X52–53 |
Xx R: 62–52/53 X: (2-)22–36/37–61 |
|||
|
608–023–00–3 |
4-(4-xxxxxxxxxx)-2-xxxxx-2-[(1X- 1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
406–140–2 |
114369–43–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
608–024–00–9 |
2-{4-[xxxxx(xxxxxxxx)xxxxx]xxxxx}xxxxx-1,1,2-xxxxxxxxxxxxxx |
407–650–8 |
97460–76–9 |
X53 |
X:53 X: 61 |
|||
|
608–025–00–4 |
[2-xxxxx-4,5-xxx(xxxxxxxxx)xxxxx]xxxxxxxxxxx |
410–970–0 |
117568–27–1 |
X53 |
X:53 X: 61 |
|||
|
609–053–00-X |
xxxxxxxxxxx-xxxxxxxxxxxxxxxx |
414–850–9 |
— |
X; X3 X; X8 Xxxx. kat. 2; X45 X; X23/25 X43 |
X; T X: 45–3–8–23/25–43 X: 53-45 |
|||
|
610–010–00–2 |
1-xxxx-2-(2-xxxxx)-1-xxxxxxxxxx |
406–110–9 |
35950–52–8 |
Xx; R22–48/22 C; X34 X43 X; X50–53 |
X; N X: 22–34–43–48/22–50/53 X: (1/2-)22–26–36/37/39–45–60–61 |
|||
|
611–043–00–5 |
Xxxx (2:1:1):[xxx(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx, [bis{6-[(2-amino-4-hydroxyfenyl)azo]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}]xxxxxxxxx xxxxxxxx x[{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-amino-6-hydroxyfenyl)azo]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx |
402–850–1 |
Xx X: 41–52/53 S: (2-)26–39–61 |
|||||
|
611–044–00–0 |
Xxxx:[xxx(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(4-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [(5-terc-butyl-3-nitrobenzen-1-azo-1'-naftalen-2,2'-diolato)(5-nitrobenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan xxxx-xxxxx(X12-X14)xxxxxx x[(4(5)-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx) (3-xxxxx-5-xxxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx |
403–720–7 |
117527–94–3 |
X; X51–53 |
Xx; R41 X52–53 |
|||
|
611–045–00–6 |
2-({4-[(4-xxxxxxxxxxxx)xxxxxxxxxx]-2-xxxxxxxxxxx}xxx)-3-xxxxxx-5-xxxxxxxxxxxx |
404–830–8 |
— |
X53 |
X:53 S: 61 |
X X: 51/53 S: 61 |
||
|
611–046–00–1 |
4,4'-xxxxxxx-2-xxxxxxxxxxxxxxx2-xxxxxxxxxxxxxxx-4,4'-xxxxxx |
407–590–2 |
43151–99–1 |
X; R25 Xx; X48/22 X43 X; X50–53 |
X; X X: 25–43–48/22–50/53 X: (1/2-)22–28–36/37–45–60–61 |
|||
|
611–047–00–7 |
Xxxx (1:1):2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–890–3 |
111381–11–4 |
X53 |
X: 53 X: 61 |
|||
|
611–048–00–2 |
Xxxx (1:1):2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx a 2-({4-[bis(2-acetoxyethyl)amino]fenyl}azo)-6,7-dichlorbenzothiazol |
407–900–6 |
111381–12–5 |
R53 |
R: 53 X: 61 |
|||
|
611–049–00–8 |
Směs (2:1:1)7-[(4-{[3-(xxxxxxxxxxxx)xxxxxx]xxxxx}-6-{[3-(xxxxxxxxxxxxx)xxxxxx]xxxxx}-1,3,5-xxxxxxx-2-xx)xxxxx]-3-{[4-(xxxxxxxx)xxxxx]xxx}-4-xxxxxxxxxxxxxxx-2-xxxxxxxx, xxxxxxxx xxxxxx x xxxxxx kyselina (2:1:1) |
408–000–6 |
118658–98–3 |
Xx; X48/22 X43 X52–53 |
Xx R: 43–48/22–52/53 X: (2-(22–36/37–61 |
|||
|
611–051–00–9 |
2-({4-[ethyl(2-hydroxyethyl)amino]-2-methylfenyl}azo)-6-methoxy-3-methylbenzothiazolium-chlorid |
411–110–7 |
136213–74–6 |
N; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
611–052–00–4 |
[xxxx{4-[(2-xxxxxxx-3,5-xxxxxxxxxxxx) xxx]-6-[(6-xxxxxxxxx-1-xxxxxx)xxx]xxxxxx-1,3-xxxxxxx}]xxxxxxxxx komplex, xxxxx sůl |
400–720–9 |
— |
R52–53 |
R: 52/53 X: 61 |
|||
|
612–156–00–2 |
Směs:trihexadecyl(methyl)amonium-chlorid x xxxxxxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx |
405–620–9 |
— |
Xx; X41 N; X50–53 |
Xx; X X: 41–50/53 S: (2-)26–39–60–61 |
|||
|
612–157–00–8 |
(X)-1-(1-xxxxxxxxxxxx-2-xx)xxxxx-1-xx-xxxx-xxxxxxxxxxxx |
410–780–8 |
— |
Xx; X22–48/22 Xx; R41 X43 N; R51–53 |
Xn; X X: 22–41–43–48/22–51/53 X: (2-)22–26–36/37/39–61 |
|||
|
612–158–00–3 |
Směs:[bis(5-alkyl(rozvětvený X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxx-2-xxxxxxxxxxxxxxxxxx[xxx(5-xxxxx(xxxxxxxxxx X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxxxxxxxxxxxxxxxx |
410–820–4 |
— |
X53 |
X: 53 X: 61 |
|||
|
612–159–00–9 |
xxxxxxx xxxxxxxx směsi 2,2,4-xxxxxxxxx- a 2,4,4-trimethylhexan-1,6-diaminu (x xxxxxxx XXXXXX), xxxxxxxx [(xxxxx(X10-X16)xxx)xxxxxx]xxxxxxx (Xxxxxx 8) a 4-xxxxxxxxxxxx-1-xxxxxxxxx xxxxxxxx |
410–880–1 |
— |
Xx; X22 C; X34 N; X50–53 |
X; X X: 22–34–50/53 X: (1/2-)23–26–36/37/39–45–60–61 |
|||
|
613–149–00–7 |
2-xxxx-xxxxx-5-[(4-xxxx-xxxxxxxxxxx)xxxxxxxx]-4-xxxxxxxxxxxxxx-3(2X)-xx |
405–700–3 |
96489–71–3 |
X; X23/25 X; X50–53 |
X; X X: 23/25–50/53 S: (1/2-)36/37–45–60–61 |
|||
|
613–150–00–2 |
2,2'-[xxxxxxxxx-1,4-xxxxxx(xxxxxx-1,3-xxxx)]xxx(xxxxxxxxxxx[2,1-x]xxxxx[xxx][3,8]xxxxxxxxxxxx-1,3,6-xxxxx) |
406–295–6 |
— |
X53 |
X:53 X: 61 |
|||
|
613–151–00–8 |
1-(2-xxxxx-3-X-xxxxx-5-X-xxxxxx-β-X-xxxxx-xxxxxxxxxxxxxx)-5-xxxxxxxxxxxxxxx-2(1X), 4(3 X)-xxxx |
406–360–9 |
104218–44–2 |
X53 |
X:53 S: 61 |
|||
|
613–152–00–3 |
xxxxx-X-(4,6-xxxxxxxxxxxxxxxxxx-2-xx)xxxxxxxx |
406–600–2 |
89392–03–0 |
X43 N; R51–53 |
Xi; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–153–00–9 |
2,3,5-xxxxxxxxxxxxxxx |
407–270–2 |
16063–70–0 |
X52–53 |
X:52/53 X: 61 |
|||
|
613–154–00–4 |
2-xxxxx-4-xxxxx-6-xxxxxxxxxxxxxxxx |
410–050–9 |
5734–64–5 |
Xx; X22 |
Xx R: 22 X: (2-)22 |
|||
|
613–155–00-X |
5-xxxxx-2,3-xxxxxxxxxxxxxx |
410–090–7 |
89402–43–7 |
X10 Xx; X22 R52–53 |
Xn X: 10–22–52/53 X: (2-)23–36–61 |
|||
|
613–156–00–5 |
2-xxxxx-4-xxxxx-5-xxxxxxxxxxxxxx 2-xxxxx-5-xxxxxxxxxxxxx-4-xxxxxxxxxxx |
410–260–0 |
83857–96–9 |
X43 X; X51–53 |
Xx; N X: 43–51/53 S: (2-)24–37–61 |
|||
|
613–157–00–0 |
2,4-diamino-5-(methoxymethyl)pyrimidin 5-(xxxxxxxxxxxxx)xxxxxxxxx-2,4-xxxxxx |
410–330–0 |
54236–98–5 |
Xx; X22–48/22 Xi; X36 |
Xx X: 22–36–48/22 X: (2-)22–26–36 |
|||
|
613–158–00–6 |
2,3-xxxxxxx-5-(xxxxxxxxxxxxxx)xxxxxxx |
410–340–5 |
69045–84–7 |
Xx; R20/22 Xx; R41 X43 X; X51–53 |
Xx; X X: 20/22–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
613–159–00–1 |
4-[2-(4-xxxx-xxxxxxxxxx)xxxxxx]xxxxxxxxxx |
410–580–0 |
120928–09–8 |
X; R25 Xx; X20 N; X50–53 |
X; X R: 20–25–50/53 X: (1/2-)37–45–60–61 |
|||
|
613–160–00–7 |
2-methyl-2,5-diazabicyklo[2.2.1]heptan-dihydrobromid |
411–000–9 |
125224–62–6 |
R43 |
Xi X: 43 X: (2-)24-37 |
|||
|
615–022–00–1 |
xxxxxx-3-(xxxxxxxxxxxxxxxxxx)xxxxxxx-2-xxxxxxxxxx |
410–550–7 |
79277–18–2 |
X; X2 R14 Xn; X48/22 X42/43 |
X; Xx X: 2–14–42/43–48/22 X: (2-)22–30–35–36/37 |
|||
|
615–023–00–7 |
xxxxxxxxxxx 2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxxx xxxxxxxxxxxxxx-2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxx |
410–900–9 |
83056–32–0 |
X10 X14 Xxxx. kat. 3; R40 Xx; X20–48/22 Xi; X41 X42 |
Xx R: 10–14–20–40–41–42–48/22 X: (2-)23–26–36/37/39 |
|||
|
616–044–00–4 |
X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)-2-(3-xxxxxxxxxxxxxxxx)xxxxxxxxx |
402–510–2 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
616–045–00-X |
2'-[(4-xxxxx-5-xxxxxx-3-xxxx-2-xxxxxxx)xxx]- 5'-(diethylamino)-2-methoxyacetanilid |
405–190–2 |
122371–93–1 |
R43 X53 |
Xx X: 43-53 X: (2-)22–24–37–61 |
|||
|
616–046–00–5 |
X -[2-(6-xxxxx-7-xxxxxxxxxxxxxx[1,5-x][1,2,4]xxxxxxx-4-xx)xxxxxx]-2-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxxxxxx |
406–390–2 |
— |
X; R50–53 |
N X: 50/53 X: 60-61 |
|||
|
616–047–00–0 |
Xxxx:X,X′,X″,X′′′ - tetraalkyl(C16)-2,2′, 2″, 2′′′ (ethylendinitrilo)tetraacetamid x X, X′,X″,X′′′ - tetraalkyl(C18)- 2,2′, 2′′, 2′′′-(xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx |
406–640–0 |
— |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
616–048–00–6 |
3'-(xxxxxxxxxxxxxx)xxxxxxxxxxxxxx |
406–740–4 |
1939–27–1 |
Xx; X48/22 N; R51–53 |
Xn; X X: 48/22–51/53 X: (2-)22–36–61 |
|||
|
616–049–00–1 |
2-(2,4-xx-xxxx-xxxxxxxxxxx)-X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxx |
408–150–2 |
99141–89–6 |
X53 |
X:53 S: 61 |
|||
|
616–050–00–7 |
1-[2,5-xxxxxxx-4-(1,1,2,3,3,3-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxx)xxxxxxxx |
410–690–9 |
103055–07–8 |
X43 X; R50–53 |
Xi; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
616–051–00–2 |
Směs:3,3'-bis(4-methylfenyl)- 1,1'-(4-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx x 3,3'-bis(4-methylfenyl)-1,1'-(2-methyl-1,3-fenylen)dimočovina Směs:2,4-bis[3-(4-methylfenyl)ureido]toluen x 2,6-xxx[(3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx |
411–070–0 |
— |
X53 |
X: 53 X: 61 |
|||
|
617–015–00–9 |
xxx(4-xxxxxxxxxxxxx)xxxxxxx |
407–950–9 |
895–85–2 |
X; X2 X; X7 N; X50–53 |
X; X R: 2–7–50/53 X: (2-)7–14–36/37/39–47–60–61 |
|||
|
650–032–00-X |
cyprokonazol (XXX) (2X, 3X)-, (2 X, 3 X)-, (2 X, 3 S)-, (2 X, 3 X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxx-1-(1X- 1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
94361–06–5 |
Xxxx. kat. 3; X63 Xn; X22 X; X50–53 |
Xx; N X: 22–50/53–63 X: (2-)36/37–60–61 |
XXXXXXX 2
POVAHA XXXXXXXXXXXX XXXXX XXXXXXXXX X XXXXXXXXXXXX XXXXXXX X XXXXXXXXX
Xxx směrnice Komise 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 3X
XXXXXXXXXX XXXXXX XXX BEZPEČNÉ ZACHÁZENÍ X NEBEZPEČNÝMI LÁTKAMI X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
PŘÍLOHA 3X
XXXXXXXXXX POKYNY XXX XXXXXXXX XXXXXXXXX X XXXXXXXXXXXX LÁTKAMI X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 4A
"B.10 XXXXXXXXXX — XXXXXXX XX XXXXXXXXXXXX XXXXXXX X XXXXX IN XXXXX
1. XXXXXX
Xxxx xxxxxx je xxxxxxxx metody OECD XX 473 — Xxxxxxx na xxxxxxxxxxxx xxxxxxx u xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx na xxxxxxxxxxxx xxxxxxx u xxxxx xx xxxxx má xxxxxxxxxxxxx xxxxxxxx, které xxxxxxxxx strukturní xxxxxxxxxxxx xxxxxxx x xxxxxxxxxxxxx xxxxxxx savců (1, 2, 3). Xxxxxxxxx xx xxx xxxx xxxxxxxxxxxx xxxxxxx: xxxxxxxxxxxx x xxxxxxxxxxxx. X xxxxxxx xxxxxxxxxx mutagenů xxxx indukované xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxx vyskytují. Xxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx indukovat xxxxxxxxx aberace. Xxxx xxxxxx však xxxx xxxxxx ke xxxxxxxxx xxxxxxxxxxx xxxxxxx x xxxx k xxxxxx xxxxx rutinně xxxxxxxxx. Xxxxxxxxxxxx xxxxxx x xxxxxxx jevy xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx u xxxxxxx x xxxxxxxx xxxxx xxxxxx x xxx, xx xxxxxxxxxxxx xxxxxx a s xxxx související xxxx xxxxxxxxxxx xxxxx x xxxxxxxxxx x v xxxxxx xxxxxxxxxxx buněk xxxxxxxxx xxxxxx, xxxx xxxxx na indukci xxxxxxxx x člověka x x xxxxxxxxx xxxxxx.
Xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxx xxxxx být xxxxxxx stabilizované xxxxxxx xxxxx, xxxxxxx xxxxx xxxx xxxxxxxx xxxxxxx xxxxxxx. Použité xxxxx xxxx xxxxxxx xx xxxxxxx schopnosti růstu x xxxxxxx, xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxxxx, xxxxxxxxxxxx chromozomů x xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
Xxxxxxx xxxxxxxxx xx xxxxx xxxxxx vyžadují xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx aktivace. Xxxxx xxxxxxxxxxx aktivační xxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxxx xx xxxx x savců. Xx xxxxx xx zcela xxxxxxxxx xxxxxxxx, xxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxx, jež xxxxxxxxxx vlastní mutagenitu x může k xxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx xxxxxxxx úrovní xxxxxxxxxxxx (4, 5).
Xxxx zkouška xx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxx x karcinogenů xxx xxxxx. Xxxxx xxxxxxxxx, xxx xxx xx xxxx xxxxxxx pozitivní, xxxx xxx savce xxxxxxxxxxx; mezi xxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxxx. Korelace xxxxxx xx xxxxxxxx xxxxx x přibývají důkazy x xxx, že xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx, xxxxx xxxxxx xxxxxx jinými mechanismy xxx xxxxxx xxxxxxxxxx XXX.
Xxx xxxx Obecný xxxx, část B.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : xxxxxxxxxx xxxxxxxxx chromozomu x xxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x opětného xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : strukturní poškození xxxxxxxxxx v xxxxxx xxxxx xxxx xxxxx x spojení xxxx xxxxxxxxx v xxxxxx xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx xxxxxx x xxxxx xx X-xxxx xxxxxxxxx XXX nedojde x xxxxxx, nýbrž xxxxxxxxx další X-xxxx. Xxxxxxxxx xxxx xxxxxxxxxx xx 4, 8, 16… chromatidami.
Gap : xxxxxxxxxxxx xxxx xxxxx xxx xxxxx jedné xxxxxxxxxx x s xxxxxxxxx odchylkou xxxxxxxxx.
Xxxxxxxxx xxxxx : xxxxx xxxxx, které xx xxxxxxxxx x xxxxxxxx, x xxxxxxxxx xxxxx xxxxx x populaci; xxxxx xxxxxx xxxxxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxx : odchylka počtu xxxxxxxxxx xx xxxxxxxxxx xxxxx obvyklého x xxxxxxxxx xxxx buněk.
Polyploidie : násobek haploidního xxxxx xxxxxxxxxxxxxx xxx (x), xxxx xxx xxxxxxxxx (tj. 3 x, 4 n xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx pozorovatelné xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx dělení ve xxxxxx xxxxxxxx; xxxx xx xxxx xxxxxx x fragmenty, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ METODY
Buněčné xxxxxxx jsou xxxxxxxxx xxxxxxxx xxxxx, x xx x xxxxxxxxxxxx xxxxxxxx x xxx xx. V xxxxxx xxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxx xxxxx xx xx buněčných xxxxxx xxxxx xxxxx zastavující xxxxxxxx (např. Xxxxxxxx® xxxx kolchicin), xxxxxxx xx sklidí, obarví x xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx xxxxx.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Buňky
Mohou xxx xxxxxxx různé buněčné xxxxx, xxxxx xxxx xxxxxxxx buněčné xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxx (např. fibroblasty xxxxxx xxxxxxxx, xxxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxx xxxxxx savců).
1.4.1.2 Xxxxx a xxxxxxxxxx xxxxxxxx
Xxx xxxxxxxxx xxxxxx xx xxxx být xxxxxxx vhodná xxxxxxxxxx xxxxx x inkubační xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx XX2, xxxxxxx x xxxxxxx). X xxxxxxxxxxxxxxx buněčných xxxxx x xxxxx xx xxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxxx modální xxxxxxx xxxxx xxxxxxxxxx x mělo xx xxx kontrolováno, xxx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxxx; x případě kontaminace xx xxxxxx xxx xxxxxxx. Pro xxxxxxx xxxxx a inkubační xxxxxxxx xx xxxx xxx známa normální xxxxx xxxxxxxxx cyklu.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxxxxxxxxx xxxxxxx xxxxx a xxxxx: xxxxx xx xxxxxxx x kmenových xxxxxx, xxxxxx xx xx xxxxxxxxxxxx média v xxxxxx xxxxxxx, aby xxxxxxxxx konfluence xxxx xxxxxxxxx, x xxxxxxxx xx xxx 37 °X.
Xxxxxxxxx: xxxx ošetřená xxxxxxxxxxxxxxx (xxxx. heparinem) xxxx xxxxxxxx lymfocyty xxxxxxxx xxxxxxxx se xxxxxxx do xxxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxxxxxxxxx) x xxxxxxxx xx xxx 37 °X.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxx, a xx x xxxxxxx metabolickou xxxxxxxx x xxx xx. Nejčastěji xxxxxxxxxx xxxxxxxx je kofaktorem xxxxxxxx postmitochondriální frakce (X9) xxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx enzymy, xxxx je Xxxxxxx 1254 (6, 7, 8 x 9), xxxx xxxx fenobarbitonu x β-naftoflavonu (10, 11 a 12).
Xxxxxxxxxxxxxxxxxxx xxxxxx xx v xxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxx x xxxxxxxxxxxxx 1 — 10 % xxx. Xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx může xxxxxxx xx xxxxx chemické xxxxx, xxxxx xx xxxxxxxx. X xxxxxxxxx xxxxxxxxx může být xxxxxx xxxxxx více xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx xxxxxxxx xxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx enzymy, xxxxxxxxx xxxxxxxx xxx endogenní xxxxxxxx. Volba použitých xxxxxxxxx linií xx xxxx být vědecky xxxxxxxxxx (např. xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx X450 xxx xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Xxxxxxxx xxxxx/xxxxxxxx
Xxxxx xxxxxxxx xxxxx by xxxx být před xxxxxxxx xx buňky xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx xxxxxxx přímo x testovacím systémům x/xxxx mohou xxx xxxx aplikací xxxxxxx. Xxxx by být xxxxxxx xxxxxxx připravené xxxxxxxx látky, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx xxxx xxx xxxx podezření, xx xxxxxxx se zkoušenou xxxxxx, x mělo xx xxx xxxxxxxxxx x xxxxxxxx buněk x x xxxxxxxxx X9. Jsou-li xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx zařazení xxxxxxxxx xxxxx o xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx zvážit xxxxxxx xxxxxxx rozpouštědel/vehikul. Xxx xxxxxxxx xxxxx xxxxxxxxx xx vodě by xxxx xxx xxxxxxx xxxxxxxxx rozpouštědla xxxxxxxxxxxx xxxx. Xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxx.
1.4.2.2 Expoziční koncentrace
Mezi xxxxxxxx, která xxxx xxx xxxxxxxxxx při xxxxxxxxx nejvyšší xxxxxxxxxxx, xxxxx xxxxxxxxxxxx, xxxxxxxxxxx x testovacím systému x xxxxx xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx xxx stanovena x xxxxxxxxxxxx xxxxxxxx x xxx xx x xxxxxxx experimentu xx xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx x xxxxx, xxxx xxxx xxxxxx xxxxxxxxxx, xxxxx xxxxxxxxxxxxxxx xxxxx xxxx mitotický xxxxx. Xxxx být xxxxxxx xxxxxxxx cytotoxicitu x xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx alespoň xxx xxxxxxxxxxxxxx koncentrace. V xxxxxxx xxxxxxxxxxxx xx xxxx xxxx koncentrace xxxxxxxx xxxxxxx dané xxxxxxxxx xx minimální xxxxxxxxx, případně xxxxxx xxxxxxxxx, xxx xxxxxxx xxxxxxx, že xx xx koncentrace neměly xxxxx xxxx xxxxx xxxxxxxx 2 xx Ö10. X okamžiku xxxxxxx by xxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxxx, xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxx (xxx x xxxx xxx 50 %). Xxxxxxxxx index xx xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxxxx xxxxxx x xxxxxx xx xxxx, která xxxxxxxx od xxxxxxxx. Xxxxxxxxx index xx xxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxx, u xxxxx xxxxx být xxxx metody stanovení xxxxxxxx obtížné x xxxxxxxxxxx. Xxxxxxxxx o xxxxxxxx xxxxxxxxx cyklu, xxxxxxxxx průměrná xxxxxxxxx xxxx (XXX), xxxxx xxx použity xxxx xxxxxxxxx xxxxxxxxx. V xxxxxxx XXX xxxx xxx x xxxxxxxx xxxxxxxxx xxxxxxx, x xxx xxxxx xxxxxxx xx xxxxxxxxx zpožděných xxxxxxxxxxx, x x xxxx xxxxxxxxx průměrné xxxxxxxxx xxxx xxxx xxx xx následek xxxxx podstatné oddálení xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
X xxxxxxx relativně xxxxxxxxxxxxxxx xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx koncentrace 5 μx/xx, 5 mg/ml xxxx 0,01 M, xxxxx xxxx, xxxxx x xxxx xx xxxxxxxx.
X xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxx, které xxxxxx xxxxxxx při xxxxxxxxxxxxx nižších, xxx xx jejich xxxxxxxxxxx, xx xxxx být xxxxxxx nejvyšší xxxxx x xxxxxxxxxxx, xxx xx xxx mezí xxxxxxxxxxxx v xxxxxxxx xxxxxxxxxxx xxxxx xx xxxxx doby aplikace. X určitých xxxxxxxxx (xxxx. xxxxxxx-xx se xxxxxxxx xxxxx při xxxxxxx xxxxxxxxxxxxx, xxx xx xxxxxxxxxxx) xx xxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxxx, xxx xxxxx xxxxxxx xx xxxxxxx. Xxxx být užitečné xxxxxxxx xxxxxxxxxxx na xxxxxxx x xx xxxxx expozice, xxxxx xxxxxxxxxxx x testovacím xxxxxxx se může x xxxxxxx xxxxxxxx xxxxx v důsledku xxxxxxxxxxx buněk, xxxx X9 xxx. Xxxxxxxxxxxxx xxx zjistit xxxxxxxx. Xxxxxxxxx xx xxxxxx xxxxx při xxxxxxxxxxx.
1.4.2.3 Xxxxxxxxx x pozitivní xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx měly xxx xxxxxxxxx x xxxxxxxxx xxxxxxxx (kontroly xxxxxxxxxxxx xxxx xxxxxxxx). Při xxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxx xxx xxx xxxxxxxxx kontrolu xxxxxxx xxxxxxxx látka, xxxxx x xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx.
X xxxxxxxxx xxxxxxxx xx xxx xxx použit xxxxx elastogen v xxxxxxxxxxx xxxxxxxxxxxxx, které xxxxxxxx poskytnou reprodukovatelný x detekovatelný xxxxxx xxx xxxxxx, xxxx xx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx.
Xxxxxxxxxxx xxxxxxxxxxx xxxxxxx by xxxx xxx xxxxxxx tak, xxx byl xxxxxx xxxxxxxx, ale xxx xxx xxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Příklady xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx:
|
Xxxx metabolické xxxxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
Xxx xxxxxx metabolické aktivace |
methyl-methansulfonát |
66–27–3 |
200–625–0 |
|
ethyl-methansulfonát |
62–50–0 |
200–536–7 |
|
|
1-ethyl-1-nitrosomočovina |
759–73–9 |
212–072–2 |
|
|
mitomycin X |
50–07–7 |
200–008–6 |
|
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
|
|
X xxxxxx xxxxxxxxxxxx xxxxxxxx |
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
Xxx pozitivní xxxxxxxx xxxxx být xxxxxxx x xxxx xxxxxx látky. Xxx xxxxxxxxx kontrolu xx xxxx xxx pokud xxxxx xxxxx x xxxxx xxxxxxx chemických xxxxx xx stejné xxxxxxxx xxxxx.
X xxxxxxxx xxxxxxxx xx xxxx xxx použity xxxxxxxxx xxxxxxxx xxxxxxxxxx xx xx xxxxxxxxx xxxxxxxxxxxx xxxx vehikula v xxxxxxxxxxx médiu x xxxxxxxxxx xxxxxxx xxxxxxxx xxxx kultury. Kromě xxxx by xxxx xxx xxxxxxxxxxxx kontroly xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx xxxxx xxxxxxxxx údaje xxxxxxxxxxx, xx zvolené xxxxxxxxxxxx xxxxxxxxxx xxxxx zhoubné xxxx xxxxxxxxx účinky.
1.4.3 Xxxxxx
1.4.3.1 Expozice zkoušené xxxxx
Xxxxxxxxxxxxx xxxxx se xxxxxxx xxxxxxxx xxxxx xxx za xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxx xxx něho. Xxxxxxxx lymfocytů by xxxx xxx xxxxxxxx xxx 48 xxxxx xx xxxxxxxxx stimulaci.
1.4.3.2 Xxx xxxxxx xxxxxxxxxxx xx xxxx být xxxxxxx xxxxxxx duplicitní xxxxxxx, x xxxxx xx xxxxxxx doporučuje x kultur xxx xxxxxxxxx xxxxxxxx nebo xxxxxxxx xxxxxxxxxxxx. Xxxxxxxx xxx xx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxx (13, 14), že xxxx duplicitními kulturami xx xxxxxxxxx xxxxxx, xxxx xxx xxxxxxxxx xxxxxxx xxxxxx xxxxxxx.
Xxxxxx xxxx těkavé látky xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx, xxxx. x xxxxx xxxxxxxxxx xxxxxxxxxxxx nádobách (15, 16).
1.4.3.3 Xxxx xxxxxxx kultur
V xxxxxx xxxxxxxxxxx xx xxxx xxx xxxxx xxxxxxxxx xxxxxxxx xxxxx, jak x metabolickou aktivací, xxx xxx xx, xx dobu 3 — 6 hodin, x xxxx xx xxx xxxxxxxx xx xxxxxx xxxx xx xxxxxxxx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx normální xxxxx xxxxxxxxx xxxxx (12). Xxxxxxxx xxxxx xxxxxx xxxx negativní xxxxxxxx xxx x xxxxxxxx, xxx xxx xxxxxxxx, xxx xx xxx xxxxxxxx dodatečný xxxxxxxxxx bez xxxxxxxx x xxxxxxxxxxxx xxxxxxxx xx do xxxxxx x době, xxxxx xxxxxxxx 1,5násobku xxxxxxxx xxxxx xxxxxxxxx cyklu. Xxxxxx xxxxxxxx xxxxx xxx xxxxx xxxxxxxxx xxx dobách xxxxxxxx xxxx xxxxxx xxxxxxx xxx 1,5xxxxxxx xxxxx xxxxx. Negativní xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxx xxx xxxxxxxxx xxxxxx xx případu. X případech, xxx xx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx za xxxxxxxx, xx mělo xxx podáno xxxxxxxxxx.
1.4.3.4 Xxxxxxxx xxxxxxxxx xxx xxxxxxx chromozomů
Do xxxxxxx xxxxxxx xx obvykle 1-3 hodiny před xxxxxxxxx přidá Colcemid® xxxx xxxxxxxxx. Pro xxxxxxxx preparátů pro xxxxxxx xxxxxxxxxx xx xxxxx xxxxxxx xxxxxxx xxxxxx x xxxxxxxxxx xxxxxx. Xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx, xxxxxx a xxxxxxxx xxxxx.
1.4.3.5 Xxxxxxx
Xxxxxxx preparáty, xxxxxx xxxxxxxxx xxxxxxxxxxx x negativních xxxxxxx, xx měly být xxxx xxxxxxxx xxx xxxxxxxxxxx nezávisle xxxxxxxx. Xxxxxxxx xxx fixaci xxxxx xxxxxxx ke xxxxx části xxxxx x xxxxxxxx x xx xxxxxx chromozomů, xxxx xx xxxxxxxxxxx xxxxx obsahovat centromery x xxxxx rovném xxxxxxx xxxxxxx ± 2 xxx všechny xxxx xxxxx. Xx xxxxxx koncentraci x xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxxx 200 dobře xxxxxxxxxxxxxx xxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxxxxxxxx mezi xxxxxxxxxx xxxxxxx. Xxxxx počet xxx snížit, xx-xx xxxxxxxxx xxxxx počet xxxxxxx.
Xxxxxx je xxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx, xx xxxxxxxx xxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxxxxxx, xxxx-xx xxxxxxxxxx.
2. ÚDAJE
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx x xxxx xx tedy xxx xxxxxxxxxxx množství buněk xx strukturní chromozomovou xxxxxxx (xxxxxxxxx) vyjádřené x procentech. Pro xxxxxxxxx a xxxxxxxxxxxxxx xxxxxxx xx měly xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx chromozomových xxxxxxx x jejich xxxxxx x četností. Xxxx xx zaznamenávají xxxxxxxx x uvádějí xx, xxx nezahrnují xx xx xxxxxxx xxxxxxxx xxxxxxx.
Xxxx xx xxx xxxx zaznamenána xxxxxxxx, xxxxx xxxx xxxxxxxxx xxx stanovení xxxxxxxxxxxx u xxxxx xxxxxxxxxxxx kultur a xxxxxxxxxxx xxxxxx v xxxxxxxx xxxxxxxxxxxxx s xxxxxxxxx.
Xxxx by xxx xxxxxxx xxxxx pro xxxxxxxxxx xxxxxxx. Xxxx xx xxxx být xxxxxxx xxxxx shrnuty xx xxxxx xxxxxxx.
Xxxxxxx xxxxx pozitivní xxxxxxxx xx xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx vyjasněny xxxxxx xxxxxxxxx, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxxx potvrdit xxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx x xxxx 1.4.3.3. Xxxxx xxxxxxxxx studie x xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx podmínek xx měla xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. X parametrům xxxxxx, které xx xxxxx xxx změněny, xxxxx xxxxxxx xxxxxxxxxxx x podmínky metabolické xxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx kritérií, xxxx. xxxxxx xxxxx buněk x chromozomovými aberacemi x xxxxxxxxxx na xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxxxx xxxxx. Xxxxxxxx by xxxx xxx uvážena biologická xxxxxxxxx výsledků. Při xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (3, 13). Xxxxxxxxxxx xxxxxxxxxx xx neměla xxx xxxxxxx určujícím xxxxxxxx xxx pozitivní xxxxxxx.
Xxxxxx xxxxx polyploidie xxxxx xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx mitotické xxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx aberace. Xxxxxx počtu buněk x xxxxxxxxxxxxxxxxxxx chromozomy xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx cyklu (17, 18).
Xxxxxxxx xxxxx, xxxxx xxxxxxxx nesplňují xxxx xxxxxxx xxxxxxxx, xx x xxxxx xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx experimentů poskytne xxxxx pozitivní xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx údajů xxxxxxxx xxxxxxx xxxxx x xxxxxxxx zkoušené látky. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxx znamenají, že xxxxxxxx látka xxxxxxxx x kultivovaných xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx aberace. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx látka xx xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx savců xxxxxxxxxx xxxxxxxxxxxx xxxxxxx.
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx o xxxxxxx musí xxxxxxxxx xxxx informace:
Rozpouštědlo/vehikulum:
- zdůvodnění xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x rozpouštědle/vehikulu, xx-xx xxxxx.
Xxxxx:
- xxx x xxxxx xxxxx,
- xxxxxxxxxx karyotypu x xxxxxxxx xxxxxxxxx xxxx xxxxx,
- xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx,
- xxxxxxxxx x xxxxx xxxxxxxxx xxxxx,
- xxxxxxx xxxxx xxxx, xxx xxxx použita xxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx,
- případně počet xxxxxx,
- případně metody xxxxxxxxx xxxxxxx xxxxxxx,
- xxxxxxx xxxxxxx počtu xxxxxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxxxxx xxxxx zastavující xxxxxxxx, xxxx xxxxxxxxxxx a xxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxx koncentrací x xxxxx xxxxxx, xxxxxx xxxx. xxxxx x cytotoxicitě a xxxxxx rozpustnosti, xxxx-xx x xxxxxxxxx,
- složení xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx xxxxxxxx x xxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxx xxxxxxx,
- xxxxxxxxx doba,
- xxxxx xxxxxxxx,
- případně xxxxxxx xxxxx při xxxxxxxx,
- xxx x xxxxxxx xxxxxxxxx metabolického xxxxxxxxxxx xxxxxxx, včetně xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx x xxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- kritéria xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxxxxxxxx metafází,
- xxxxxx xxxxxxxxx toxicity,
- kritéria xxxxxxxxxxx studie xx xxxxxxxxx, negativní xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity, xxxx. xxxxxx konfluence, xxxxx x xxxxxxxx xxxxx, xxxxx xxxxx, xxxxxxxxx xxxxx,
- známky xxxxxxx,
- xxxxx x xX a osmolalitě xxxxxxxxxxx média, xxxxx xxxx xxxxxxxxx,
- xxxxxxxx xxxxxxx, xxxxxx xxxx,
- xxxxx xxxxx x xxxxxxxxxxxxxx aberacemi x xxxx xxxxxxx xxxxxx xxx xxxxxx xxxxxxxxxxx x xxxxxxxxx kulturu,
- xxxxx xxxxxxx, xxxxx xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx závislost odpovědi xx xxxxx,
- případné xxxxxxxxxxx analýzy,
- xxxxx x xxxxxxxx negativní (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X. (1976), Xxxxxxxxxxx Xxxxxxx xxx Xxxxxxxxx Chemical Xxxxxxxx, in: Chemical Xxxxxxxx, Xxxxxxxxxx xxx Xxxxxxx xxx xxxxx Xxxxxxxxx, Xxx. 4, Xxxxxxxxxx, X. (xx) Xxxxxx Xxxxx, Xxx Xxxx xxx London, 1-29.
2) Ishidate, X. Xx., Sofumi, X. (1985), Xxx Xx xxxxx Xxxxxxxxxxx Aberration Xxxx Xxxxx Xxxxxxx Xxxxxxx Xxxx (XXX) Xxxxxxxxxx Cells xx Xxxxxxx, in: Xxxxxxxx xx Xxxxxxxxxx Research, Xxx. 5, Xxxxx, X. xx xx., (xxx) Elsevier Science Xxxxxxxxxx, Xxxxxxxxx-Xxx Xxxx-Xxxxxx, 427-432.
3) Xxxxxxxx, X. X., Xxxxxxxxx, X. X., Reuben, X., Xxxxxx, X., Xxxxx, X., Xxxxxx, X., Xxxxx, A. X., Xxxxxxxx, F., Ahmed, X., Duk, X., Xxxxx, X., Xxxxxxxx, X. X., Xxxxxxx, X. X., Xxxxxxxx, X., Zeiger X. (1978), Xxxxxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxxxxx xxxxxxxxx in Chinese xxxxxxx xxxxx xxxxx: Xxxxxxxxxx xx 108 xxxxxxxxx, Environ. Molec. Xxxxxxx. 10 (xxxxx. 10), 1-175.
4) Xxxxx, X., Xxxxxxxx, S. X., Xxxxxxxx, X. X., Ishidate, M. Xx., Brusick, X., Xxxxx, X., Xxxx, X. X. (1991), Xxxxxxxxxxxx xxxxx Extreme Xxxxxxx Conditions. A xxxxxx xxxx XXXXXX Xxxx Xxxxx 9, Xxxxxxxxxx Xxx., 257, 147-204.
5) Xxxxxx, T., Xxxxxx, X., Fukuda, X., Okumura, K., (1992), Xxxxxxxxxxxxxx of xxx xX xx Xxxxxxx Xxxxxxxx Xxxxxxxxx Xxxxx, Mutatation Xxx., 268, 297-305.
6) Ames, X. X., XxXxxx, X., Xxxxxxxx, E. (1975), Xxxxxxx for Xxxxxxxxx Xxxxxxxxxxx and Xxxxxxxx with xxx Xxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Mutation Xxx., 31, 347-364.
7) Maron, X. X., Xxxx, X. X. (1983), Xxxxxxx Xxxxxxx xxx xxx Salmonella Mutagenicity Xxxx, Mutatation Xxx., 113, 173-215.
8) Xxxxxxxxx, X. X., Xxxxx, X. X., xxx Xxxx, P. X. X., Xxxxxxx, M., xx Xxxxx, X. (1976), Cytogenetic Xxxxxxx xx Xxxxxxx/Xxxxxxxxxxx xxxxx Xxxxxxxxxx in x Xxxxxxxxxxx Xxxxxx Xx xxxxx, X. Xxxxxxxxx xx Xxxxxxxxxx Aberrations xxx Xxxxxx Xxxxxxxxx Xxxxxxxx xx Diethylnitrosamine (XXX) xxx Dimethylnitrosamine (XXX) xx XXX Xxxxx xx xxx Xxxxxxxx xx Xxx-Xxxxx Xxxxxxxxxx, Xxxxxxxxxx Xxx., 37, 83-90.
9) Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, X. Jr. (1979), Chromozomal Aberration Xxxxx on 29 Xxxxxxxxx Xxxxxxxx xxxx X9 Xxx In xxxxx, Xxxxxxxx Res., 66, 277-290.
10) Xxxxxx, X. M., Xxxxxx, X. X., Elcombe, X. X., Gatehouse, X. G., Xxxxxx, X. G., Xxxxxx, X. M., Xxxx, X. X. (1992), Xxxxxx xx UK Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx. Alternative xx Xxxxxxx 1254-xxxxxxx X9 in Xx xxxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 175-177.
11) Xxxxxxxxxx, X., Xxxxxxxx, X., Hara, X., Xxxxxxxx, X. (1976), X. Xxxx Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. an Xxxxxxx of Xxxxxxxxx Xxxxxxxxxx Systems, in: xx Xxxxxx, X. X., Xxxxx, J. X. Bend, J. X., Philpot, X. X. (eds), In xxxxx Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxx, Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
12) Xxxxxxxx, S. M., Xxxxxxx, X. X., Xxxxxxxx, X. Xx., Xxxxx, J. X., Xxxxxxxx, D. X., Xxxxxx, X., Mosesso, X., Xxxxxx, T. (1994), Xxxxxx xxxx Xxxxxxx Xxxxx xx Xx xxxxx Tests xxx Chromozomal Xxxxxxxxxxx, Xxxxxxxxxx Xxx., 312, 241-261.
13) Richardson, X., Xxxxxxxx, X. X., Xxxxx, X. X., Xxxxxxxx, X., Chanter, X. X., Xxxxxxxx, X. (1989), Xxxxxxxx xx Xxxx xxxx Xx xxxxx Cytogenetic Xxxxxx, in: Statistical Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Data, Xxxxxxxx, X. X., (ed) Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, 141-154.
14) Xxxxx, X. X., Xxxxxxxx, X. X. (1994), Xxxxxxxxx Flasks xxx xxx Xxxxxxxxx for Xx vitro Chromozome Xxxxxxxxxx Xxxxxx in XXX Xxxxx, Xxxxxxxxxx Xxx., 312, 139-149.
15) Xxxxx, X. X., Xxxxxx, F. C., XxXxxxx, X. X. (1982), XXX/XXXXX Xxxxxxxx Xxxxx: Evaluation xx Xxxxx xxx Xxxxxxxx Xxxxxxx, in: Xxxx, X. R., Xxxxx, X. X., Xxxxxxx, X. X. (eds), Xxxxxxxxx Xxxxxxx xx Xxxxxxxx Xxxxxx, New Xxxx, Plenum, 91-103.
16) Xxxxxx, P. O., Xxxxxx, X. X., Xx, A. P., Xxxxxx, X. L. (1983), Xxxxxxxxxx xx xx Exposure System Xxxxx Xxxxx Grown xx Collagen Xxxx xxx Detecting Highly Xxxxxxxx Mutagens xx xxx XXX/XXXXX Xxxxxxxx Xxxxx, Xxxxxxxxxxxxx Mutagen., 5, 795-801.
17) Locke-Huhle, X. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx hamster xxxxx xxxxxx xxxxx-xxxxxxxxx xxxxxxx G2 arrest, Xxxxxxxxxx Res., 119, 403-413.
18) Xxxxx, X., Xxxxxx, X., Xxxxxx, X. E. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication xx Xxxxxxx xxxxxxx xxxxx, Xxxxxx Res., 43, 1362-1364."
XXXXXXX 4X
"X.11 XXXXXXXXXX–XXXXXXX XX XXXXXXXXXXXX ABERACE X XXXXXXX XXXXXX XXXXX XXXXX XX XXXX
1. METODA
Tato xxxxxx xx xxxxxxxx xxxxxx XXXX TG 475 — Xxxxxxx na xxxxxxxxxxxx xxxxxxx x xxxxxxx xxxxxx xxxxx xxxxx (1997).
1.1 ÚVOD
Zkouška xx xxxxxxxxxxxx xxxxxxx x xxxxx in xxxx xx používána xxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx aberací indukovaných xxxxxxxxx látkou x xxxxxxx xxxxxx xxxxx xxxxx, xxxxxxx xxxxxxxx (1, 2, 3, 4). Rozlišují xx xxx xxxx xxxxxxxxxxxx xxxxxxx — xxxxxxxxxxxx x chromatidové. Xxxxxx xxxxxxxxxxx může znamenat, xx chemická látka xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxx. X xxxxxxx většiny chemických xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx typu, xxxxx xxxxxxxxxxxx aberace xx xxxxxx xxxxxxxxx. Xxxxxxxxxxxx xxxxxx a xxxxxxxxxxx jevy xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx a xxxxxxxx xxxxx důkazů o xxx, xx xxxxxxxxxxxx xxxxxx x související xxxx způsobující xxxxx x xxxxxxxxxx x x xxxxxx xxxxxxxxxxx xxxxx tlumících xxxxxx, xxxx xxxxx xx xxxxxxx xxxxxxxx x xxxxxxx x x xxxxxxxxxxxxxxxx xxxxxxxxx.
Xxx xxxx xxxxxxx xxxx rutinně xxxxxxxxx xxxxxxxx. Xxxxxxx xxxxx xx v xxxx xxxxxxx xxxxxx xxxx, poněvadž je xxxxxx xxxxxxxxxxxxxxxx tkání x obsahuje xxxxxxxx xxxxx s xxxxxxx xxxxxx, které se xxxxxx izolují x xxxxxxxxxxxx. Jiné xxxxx x xxxxxx tkáně xxxxxx xxxxxxxxx této xxxxxx.
Xxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxxxx určená x xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx umožňuje xxxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx, farmakokinetiku a xxxxxxx xxxxxxxx XXX, xxxxxxx xx mohou x xxxxxxx xxxxx x xxxxx xxxxx. Xxxxxxx in xxxx xx xxxxxx xxxxxxxx xxx další výzkum xxxxxxxxxxx účinků xxxxxxxxxx xxxxxxxx xx xxxxx.
Xxxxxxxx xxxxxxxx xxxxx o xxx, že xx xxxxxxxx látka xxxx xxxxxxxxx metabolity xxxxxxxxxx xx cílové tkáně, xxxx vhodné tuto xxxxxxx xxxxxx.
Xxx také Xxxxxx úvod, část X.
1.2 DEFINICE
Chromatidová aberace : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x xxxxxxxx spojení chromatid.
Chromozomová xxxxxxx : strukturní xxxxxxxxx xxxxxxxxxx v xxxxxx zlomu nebo xxxxx x xxxxxxx xxxx chromatid x xxxxxx místě.
Endoreduplikace : xxxxxx, xxx kterém x xxxxx xx X-xxxx replikace DNA xxxxxxx x xxxxxx, xxxxx následuje xxxxx X-xxxx. Xxxxxxxxx xxxx xxxxxxxxxx se 4, 8, 16,… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx xxxx xxxxx xxx xxxxx xxxxxxx xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxxx xxxxxxx xxxxxxx x xxxxxxxxx xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx chromozomových xxx (x), xxxx xxx xxxxxxxxx (tj. 3 x, 4 x xxx.).
Xxxxxxxxxx aberace : xxxxxxxxxxxxx pozorovatelné xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx xxxxxx xx xxxxxx xxxxxxxx; xxxx xx xxxx xxxxxx a xxxxxxxxx, xxxxxxxxxxxxxxxxxx nebo interchromozomální xxxxx.
1.3 PODSTATA XXXXXXXX XXXXXX
Xxxxxxx xxxx xxxxxxxxx xxxxxxxx látce xxxxxxx xxxxxxxx a xx xxxxxxx xxxxxxxx po xxxxxxxx xx xxxxxx. Xxxx xxxxxxxxx xx xxxxxxxx podá xxxxx xxxxxxxxxxx metafázi (xxxx. xxxxxxxxx nebo Xxxxxxxx®). X xxxxx kostní xxxxx xx xxxx xxxxxxxx xxxxxxxxx chromozomů, xxxxxx xx a xxxxxxxxx xx xxxxxxxxxxxx xxxxxxx xxxxx v xxxxxxxx.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Výběr xxxxx xxxxxxx
Xxxxx je xxxxxxxx potkan, xxx x xxxxxx čínský, xxxxxx xxx použít xxxxxxxx xxxxxx xxxxx xxxx. Xxxx xx xxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. V xxxxxxxx xxxxxxxx xxxxxx xx měla xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx a xxxxxx by x xxxx pohlaví překročit ± 20 % xxxxxxx hodnoty hmotnosti.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx mladá xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxxx skupinu x skupinu, xxxxx xx vystaví xxxxxxxx xxxxx. Klece xx xxxx xxx uspořádány xxx, xxx byl xxxx xxxxxx polohy xxxxxxxxxxxxx. Zvířata se xxxxxxxxxxx identifikují. Xxxxxxx xx x xxxxxxxxxxxxx xxxxxxxxxx alespoň xxx xxx aklimatizovat.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx látky xx xxxx být xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx látky mohou xxx xxxxxxxx xxxxx xxxx xxxxx xxx xxxx podáním xxxxxxx. Xxxx xx být xxxxxxx čerstvě připravené xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx při použitých xxxxxxxx dávek xxxxxxx xxxxxx a xxxx xx být xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx látkou. Xxxx-xx xxxxxxx jiná xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Doporučuje se xxxxx možno xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Kontroly
Součástí každého xxxxxxxxxxx xx měly xxx xxxxxxxxx x xxxxxxxxx (rozpouštědlo/vehikulum) xxxxxxxx xxx xxx pohlaví. X xxxxxxxx aplikace xxxxxxxx xxxxx by xxxx xxxxxxx kontrolní xxxxxxx xxxxxxxxxx identický xxxxxx jako xxxxxxx xx xxxxxxxxx, v xxxxx xxxxx x xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx in xxxx xxx expozičních xxxxxxxx, x nichž xx xxxxxxx, že xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxx xxxxxx. Dávky pozitivní xxxxxxxx xx xxxx xxx xxxxxxx tak, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx odečtu xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx byla xxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxxxxxxx xxx xxxxxxxx xxxxx a xxx xxx xxxxx x xxxxx xxxxxxx xxxxxxxx xxx xxxxxx. Xxx pozitivní xxxxxxxx xxxxx xxx xxxxxxx xxxxxxxx xxxxx ze xxxxxx xxxxxxxx xxxxx, xxxx-xx k xxxxxxxxx. Xxxxxxxx látek xxx xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx EINECS |
|
ethyl-methansulfonát |
62–50–0 |
200–536–7 |
|
1-ethyl-1-nitrosomočovina |
759–73–9 |
212–072–2 |
|
mitomycin X |
50–07–7 |
200–008–6 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx odběru by xxx být proveden xxxxx x xxxxxxxxxxx xxxxxxx, xxxx je xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx a xxx jinak podstupují xxxxxx proces xxxx xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxx údajů x xxxxxxxxx xxxxxxxxxx xxxxx x xxxxxxxxxxx xxxxxx x xxxxxxxx xxxxx x chromozomovými aberacemi. Xxxxxxx-xx se xxx xxxxxxxxx xxxxxxxx xxxxx xxxxx, xx nejvhodnějším xxxxxxxxx xxxx xxxxxxx xxxxxx. Xxxxx toho xx měly xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, neexistují-li xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, že xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5 POSTUP
1.5.1 Počet x xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x kontrolní xxxxxxx xx xxxxxx x xxxxxxx pěti xxxxxxxxxxxxxxxx xxxxxx xxx xxxxx pohlaví. Xxxxxxxx xxxx x xxxx xxxxxx x dispozici xxxxx ze studií xx xxxxxxx druhem x za xxxxxxx xxxxxxxx způsobu xxxxxxxx, xxx xxxxxxxxx, že xxxxxxxxxx mezi pohlavími xxxxxx x xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx. Xx-xx xxxxxxxx xxxxxxx specifická xxx xxxxxx pohlaví, xxxx xx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx xx xxx xxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx by xxxx xxx xxxxx xxxxx xxxxxxxx xxxxxxxxxxx. Xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxx xx xxxx dávkách, xxx. xxx xxxxx x xxx xxx x xxxxxxx xx xxxx než xxxxxxxx xxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx.
Xxxxxx by měly xxx odebrány xx xxxx různých xxxxxxxxxxx xx xxxxxxxx podané x xxxxxx xxx. X xxxxxxxx se xxxxx xxxxxxx po xxxxxx xxxx xx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx normální délky xxxxxxxxx cyklu (xxxx xxxx xxxxxxx 12 — 18 x). Xxxxxxxx doba xxxxxxxx xxx xxxxxx a xxxxxxxxxxxx xxxxxxxx xxxxx x rovněž xxx xxxxxx na kinetiku xxxxxxxxx cyklu xxxx xxx xxxx na xxxxxxxxx xxxxxxx xxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxx, xxxxxxxxxx se xxxxxxx xxxxx xxxxx xx 24 x xx xxxxxxx xxxxxx. Je-li xxxxxxxx rozložena do xxxx xxx xxxxxxx xxx, xxx xx xxx xxxxx proveden xx takové xxxx xx xxxxxxxx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx délky xxxxxxxxx xxxxx.
Xxxx usmrcením se xxxxxxxx xxxxxxxxxxxxxxxxx xxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® xxxx xxxxxxxxx). Xxxx se po xxxxxx době xxxxxxx x zvířat odběr. X xxxx xx xxxx xxxx xxxxxxxxx 3 — 5 x; u xxxxxx xxxxxxxx je xxxx xxxx přibližně 4 — 5 x. X xxxxxx xxxxx xx odeberou xxxxx x xxxxxxxxx se xx chromozomové xxxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx dostupných xxxxx xxxxxx xxx xxxxxxxx xxxxxxx xxxxx, xxxx by xxx xxxxxxxxx xx stejné xxxxxxxxxx, se stejným xxxxxx, kmenem, xxxxxxxx x xx xxxxxxxx xxxxxx xxxxxxxx, jež xx použijí v xxxxxx studii (5). X případě xxxxxxxx xx xxx xxxxx xxxxx xxxxxxx xxx xxxxxx xxxxx. Tyto xxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx xxxx použita xxxxx nejvyšší xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx jako xxxxx xxxxxxxxxxxx takové xxxxxx xxxxxxxx, že vyšší xxxxx xx vedly xxx xxxxxxx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx x letalitě. Látky xx specifickou xxxxxxxxxxx xxxxxxxxx xxx nízkých xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx kritériím stanovení xxxxx vyhovovat a xxxx xx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Nejvyšší xxxxx xxxx xxx xxxx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx x xxxxxx xxxxx xxxxxxx známky xxxxxxxx (např. xxxx xxx 50 % xxxxxxx mitotického xxxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x jednou xxxxxx xxxxxxx 2000 xx/xx xxxxxxx hmotnosti xxxxxxx xxxxxxxxxxx nebo xx xxxx dávkách x xxxxxx xxx nevykazuje xxxxx pozorovatelné xxxxxxx xxxxxx x xxxx-xx xx xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxxxxxxxx xx xxxxx studie xx xxxxx xxxxxxxx xxxxx za xxxxxxxxx. X xxxx trvajících xxxxxx xx xxxxxxx xxxxxx xxx 14xxxxx xxxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx/xxx x xxx xxxxx než 14xxxxx xxxxxxxx xx xxxxxxx xxxxxx 1000 xx/xx tělesné xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxx potřebu xxxxxx x limitní xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx se xxxxxxx xxxxxx xxxxxxxxxxxxxx, žaludeční xxxxxx xxxx vhodnou xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx injekcí. Jiné xxxxxxx xxxxxxxx xxxx x xxxxxxxxxxxx případech xxxxxxxxxx. Maximální xxxxx xxxxxxxx, xxxxx může xxx najednou podán xxxxxxxxxxxxxx nebo xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx hmotnosti. Použití xxxxxxx objemů, xxx xx xxxxxxx objem, xxxx xxx xxxxxxxxxx. Xx xx xxxxxxxx x xxxxxx látky, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx xxxx xxx variabilita xxxxxxxxxx objemu minimalizována xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx
Xxxxx xx xxxxxxxx xx xxxxxxx xxxxxx xxxx, xxxxxxxxxxxx xx x xxxxxx. Xxxxx xx nanesou xx podložní sklíčka x xxxxxx xx.
1.5.7 Xxxxxxx
Xxxx xxxxxxx cytotoxicity xx měl xxx x všech xxxxxxxxxxxx xxxxxx (včetně pozitivních xxxxxxx) a x xxxxxxxxxxxxxx xxxxxx xxx xxxxxxxxx kontrolu xxxxxxxx xxxxxxxxx xxxxx, x xx alespoň x 1000 xxxxx xx xxxxx zvíře.
U xxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxxx xxxxxxx 100 xxxxx. Xxxxx xxxxx xxx xxxxxx, xx-xx xxxxxxxxx velký xxxxx xxxxxxx. Všechny xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx kontrol xx xxxx xxx xxxx xxxxxxxxxxxxxx analýzou xxxxxxxxx xxxxxxxx. Xxxxxxx xxx xxxxxx často xxxxxxx xx xxxxxxxxxxxxxx zlomům xxxx xx xxxxxx xxxxxxxxxx x xxxxx xxxxx v xxxxxxxx, xxxx by vyšetřované xxxxx obsahovat centromery x xxxxx odpovídajícímu xxxxx 2 x ± 2.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx pro xxxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxx xx formě tabulky. Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx. Pro xxxxx xxxxx xx xxx xxx vyhodnocen xxxxx xxxxx, počet aberací xx buňku x xxxxx buněk x xxxxxxxxxxxxx xxxxxxx (xxxxxxxxxxxxxx xxxxxxxxx) vyjádřený x xxxxxxxxxx. Xxx xxxxxxxxxx x xxxxxxxxx skupiny xx xxxx xxx xxxxxxx xxxxx typy xxxxxxxxxxxx xxxxxxxxxxxxxx aberací x xxxxxx počtem x četností. Xxxx xx xxxxxxxxxxxxx xxxxxxxx x xxxxxxx xx, xxx xxxxxx xx xxxxxxxxxx xx celkové xxxxxxxx xxxxxxx. Xxxxxxxxxx-xx xxxxx o xxxxxxx x odpovědi mezi xxxxxxxxx, mohou xxx xxx xxxxxxxxxxxx xxxxxxx xxxxx xxx xxx xxxxxxx zkombinovány.
2.2 HODNOCENÍ X INTERPRETACE XXXXXXXX
Xxx xxxxxxxxx pozitivního xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx relativního xxxxx buněk s xxxxxxxxxxxxxx aberacemi v xxxxxxxxxx na xxxxx xxxx jasný nárůst xxxxx xxxxx s xxxxxxxxx pro skupinu x určitou xxxxxx x k xxxxxxxx xxxxxxxx odběru. Nejdříve xx měla xxx xxxxxxx xxxxxxxxxx relevance xxxxxxxx. Při hodnocení xxxxxxxx zkoušky xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (6). Statistická xxxxxxxxxx xx neměla xxx jediným xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx být xxxxxxxxx dalším xxxxxxxxx, xxxxxxx s xxxxxxxx xxxxxxxxxxxxxxxx podmínek.
Nárůst polyploidie xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Nárůst xxxxx xxxxx x xxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx, xx xxxxxxxx xxxxx má xxxxxxxxx xxxxxxxx progresi xxxxxxxxx xxxxx (7, 8).
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx výše xxxxxxx xxxxxxxx, xx považuje x xxxxx systému xx xxxxxxxxxxx.
Xxxxxx většina xxxxxxxxxxx poskytne xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx konečný xxxxx o xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx bez xxxxxx na xx, xxxxxxxx je xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx vivo znamenají, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxx xxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx znamenají, xx xxxxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx x kostní dřeni xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx xx xxx xxxxxxxxxxx pravděpodobnost, x xxxxx se zkoušená xxxxx xxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx, xxxx xxxxxxxxxx do xxxxxx xxxxx (xxxx. xxxxxxxxx xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx xxxxxxxxx tyto xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- použitý xxxx/xxxx,
- xxxxx, xxxxx x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- individuální xxxxxxxx xxxxxx na xxxxxxx zkoušky, xxxxxx xxxxxxx tělesné hmotnosti, xxxxxxx hodnoty a xxxxxxxxxx odchylky xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxx x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx xxxx provedena,
- xxxxxxxxxx xxxxxxxxx xxxxxx dávek,
- xxxxx x přípravě xxxxxxxx xxxxx,
- xxxxx x podávání xxxxxxxx xxxxx,
- xxxxxxxxxx způsobu xxxxxxxx,
- popřípadě xxxxxx xxxxxxx, xxx se xxxxxxxx látka dostala xx xxxxxxxx xxxxx xxxx xx cílové xxxxx,
- xxxxxxxx přepočet xxxx xxxxxxxxxxx zkoušené xxxxx x xxxxxx xxxx vodě (ppm) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx xxxxxx x xxxx,
- xxxxxxxx popis xxxxxxx xxxxxxxx x xxxxxx,
- metody xxxxxxxxx xxxxxxxx,
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, její xxxxxxxxxxx x délka xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxxxxxxxx xxxxx xx xxxxx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx na pozitivní, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity,
- xxxxxxxxx xxxxx,
- xxx a xxxxx aberací xxxxxxx xxxxxxxxxx xxx xxxxx xxxxx,
- xxxxxxx xxxxx xxxxxxx ve xxxxxxx xx xxxxxxxxx hodnotami x xxxxxxxxxxxx odchylkami,
- xxxxx buněk x xxxxxxxxx xx xxxxxxx xx xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx ploidie, pokud xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x negativní xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx x xxxxxxxx pozitivní kontrole.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X. (1984), Xxxxxxxxxxx Xxxxx in Xxxxxxx, xx: Xxxxxxxxxxxx Xxxxxxx: x Xxxxxxxxx Xxxxxxxx, X. Venitt, X. M. Parry (xxx), XXX Xxxxx, Xxxxxx, Xxxxxxxxxx D. X., 275-306.
2) Preston, X. X., Dean, X. J., Xxxxxxxx, X., Xxxxxx, X., XxXxx, X. F., Xxxxxx, X. (1987), Xxxxxxxxx Xx xxxx Xxxxxxxxxxx Assays: Xxxxxxxx xx Xxxxxxxxxx Xxxxxxxxxxx xx Xxxx Marrow Xxxxx, Xxxxxxxxxx Xxx., 189, 157-165.
3) Richold, X., Chandley, A., Xxxxx, J., Xxxxxxxxx, X. X., Xxxxxxx, X., Xxxxxxxxx, X. (1990), Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: X. X. Kirkland (xx.), Xxxxx Xxxxxxxxxxxx Xxxxx, XXXXX Recommended Xxxxxxxxxx. XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Xxxx X xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, New York, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
4) Xxxx, X. R., Xxxxxxx, X., XxxXxxxxxx, J. X., Anderson, X., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx-Xxxxxxx, X., Xxxxxx Xx., X. B., Xxxxxxxxxxxx, X., Preston, X. J., Xxxxxxx, X., Shimada, H., Xxxxx, X., Vannier, X. (1994), Report xxxx xxx Xxxxxxx Xxxxx on the xx xxxx Xxxxxxxxx Xxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 312, 305-312.
5) Xxxxxxx, X. X., Xxxxx, X. A., Xxxxxx, A. X., Xxxxxx, X. A., Xxx, J., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Hodson-Walker, X., Xxxxxx, X. X., Kirkland, X. X., Xxxxxxx, M. (1992), Xxxxxx xx Xxxxxxx Xxxxxxxxxx Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Society Xxxxxxx Xxxxx: Xxxx Xxxxxxx xx In xxxx Mutagenicity Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
6) Xxxxxx, D. P., Xxxxxxxx, D., Albanese, X., Xxxxxxxx, X. X., Xxxxx, X., Xxxxxxxx, R., Xxxxxxx, X., Xxxxxxxx, X. X., Xxxxxx, J. X. K. (1989), Xxxxxxxxxxx Analysis xx Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxxxx Xxxx XXX. Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Test Xxxx, X. X. Kirkland (xx.) Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, 184-232.
7) Xxxxx-Xxxxx, X. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx cells during xxxxx-xxxxxxxxx-xxxxxxx X2 arrest, Xxxxxxxxxx Res., 119, 403-413.
8) Huang, X., Xxxxxx, X., Trosko, X. X. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication in Xxxxxxx xxxxxxx xxxxx, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4C
"B.12 MUTAGENITA–TEST XXXXXXX ERYTROCYTÁRNÍCH XXXXXXXXXX XX XXXX
1. XXXXXX
Xxxx xxxxxx xx replikou xxxxxx XXXX TG 474 — Test xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx (1997).
1.1 XXXX
Xxxx savčích erytrocytárních xxxxxxxxxx xx xxxx xx xxxxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx, které xx xxxxxxxxxx xxxxxxxxx látkou, x xx xxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx x xxxxxx dřeně x/xxxx xxxxx xxxxxxxxx xxxx, xxxxxxx xxxxxxxx.
Xxxxxx xxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxxx xxxxx, xxxxx způsobují xxxxxxxxxxxxx poškození, xxxxx xxxxxxxxx xx tvorba xxxxxxxxxx obsahujících xxxxxxxxxxxxx xx (xxxxxxx) xxxxxxxxxxxx xxxxxxxxx xxxx xxxx xxxxxxxxxx.
Xxxx se xxxxxxxxxxx xxxxxx dřeně xxxx xx xxxxxxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxx je xxxxxxxx a mikrojádra, xxxxx xxx tom xxxxx xxxxxxxxx, xxxxxxxxx x xxxxxxxxxx, xxxxx xxxxx jádra xxxxxxxxxx. Xxxxxxxxxxxx mikrojader xx x xxxxxx buňkách xxxxxxxxx tím, že xxxxxxxxxx xxxxxx xxxxx. Xxxxxx xxxxxxx polychromatických xxxxxxxxxx s xxxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx xx xxxxxxx indukovaného xxxxxxxxxxxxxx xxxxxxxxx.
X xxxxx xxxxx xx xxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, poněvadž tato xxxx xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx nezralých (xxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxx xxxx xx xxxxxxxxxx xxxxxxxxxx u kteréhokoli xxxxx, x xxxxx xxxx prokázána neschopnost xxxxxxx xxxxxxxxxxx xxxxxxxxxx x mikrojádry, xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx, které xxxxxxxxx xxxxxxxxxx xxxx numerické xxxxxxxxxxxx aberace. Xxxxxxxxxx xxx rozlišit xxxxx xxxxxxxx. Ta xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx (kinetochorní) XXX v xxxxxxxxxx. Xxxxxxxxx xx xxxxxxx xxxxxxx nezralých (xxxxxxxxxxxxxxxxx) xxxxxxxxxx s xxxxxxxxxx. Xxxxx xxxxxxx (xxxxxxxxxxxxxxxxxx) xxxxxxxxxx v xxxxxxxxx xxxx, xxxxx obsahují xxxxxxxxxx, xxxxxxxxxxx na xxxxxx xxxxx xxxxxxx xxxxxxxxxx xxx rovněž xxxxxx xxxx xxxxxxx xxxxxxxx xxxxxxx, xxxxxxxx xxxx xxxxxxx exponována xxxxx týdny xxxx xxxx.
Xxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx in xxxx xx xxxxxxx xxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxx, neboť xxxxxxxx zohlednit xxxxxxx xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx a xxxxxxx xxxxxxxx XXX, třebaže xx mohou xxxxx x různých xxxxx x xxxxx, xxxxx x z xxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx je rovněž xxxxxxxx xxx další xxxxxx mutagenních xxxxxx xxxxxxxxxx x xxxxxxxxx xx xxxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, xx xx xxxxxxxx xxxxx nebo xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxx, není xxxxxx xxxx zkoušku xxxxxx.
Xxx také Xxxxxx xxxx, xxxx B.
1.2 XXXXXXXX
Xxxxxxxxxx (xxxxxxxxxx) : xxxxxx (xxxxxxx) xxxxxxxxxx, x níž (x xxxx) se během xxxxxx xxxxx připojí xxxxxx vřeténko umožňující xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x pólům xxxxxxxxx xxxxx.
Xxxxxxxxxx : xxxx xxxxx xxxxxxxxxx xxxxxxxx od xxxxxxxx xxxxx x xxxxx xxxx, xxxxxxxxx během xxxxxxxx mitosy (meiosy) xxxxxxxxxxxxxxx xx (lagging) xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxx xxxxxxxxxx.
Xxxxxxxxxxxxxxxx erytrocyt : xxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxx xxx xxxxxxxx xx xxxxxxxxx polychromatických xxxxxxxxxx xxxxxxxx xxxxxxxxxxx pro xxxxxxxx.
Xxxxxxxxxxxxxxx xxxxxxxxx : xxxxxxx erytrocyt ve xxxxxxxxx xxxxxxxxxx, který xxxxx xxxxxxxx xxxxxxxx, x může být xxxx xxxxxxxx od xxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxx xxxxxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xx vhodným xxxxxxxx vystaví xxxxxxxx xxxxx. Xxx xxxxxxx xxxxxx dřeně xx xxxxxxx ve xxxxxxx xxxxxxxx po xxxxxxxx xxxxxx, xxxxxxx xx xxxxxx xxxx, xxxxxxxx xx xxxxxxxxx a xxxxxx se (1, 2, 3, 4, 5, 6, 7). Xxx xxxxxxx xxxxxxxxx xxxx xx xxxx xx xxxxxxx xxxxxxxx xx expozici xxxxxxx, xxxxxxxxxx se xxxxxxxx xxxxxxxx a obarví xx (4, 8, 9, 10). Xxx xxxxxxxx x xxxxxxxxx xxxx by xxxx xxxx xxxxxxxx expozicí x xxxxxxxxx xxxxx xxxxxxxx xx xxxxxxxxx xxxx. Preparáty xxxx xxxxxxxxxxx xx xxxxxxxxxx xxxxxxxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxx použití xxxxxx dřeně se xxxx testovací zvíře xxxxxxxxxx myš xxxx xxxxxx, ačkoli xxx xxxxxx xxxxxxxx vhodný xxxxx druh. Při xxxxxxx xxxxxxxxx xxxx xx xxxxxxxxxx xxx. Xxx xxxx xxxxxx xxxxxxxx xxxxxx druh xxxxx za xxxxxxxxxxx, xx xxx x xxxx, u xxxxx xxxxxxx xxxxxxxxxxxx erytrocyty x xxxxxxxxxx, xxxx xxxx xxxxxxxxxx dostatečnou xxxxxxxxx xxxxxxxxx xxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Měly xx xxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxxx kmeny xxxxxxx xxxxxxxx pohlavně xxxxxxxxx xxxxxx. V xxxxxxxx xxxxxxxx studie xx xxxx xxx xxxxxxxx x hmotnosti xxxxxx minimální x xxxxxx by u xxxx xxxxxxx překročit ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx xxxxxx podmínky xxxxx xxxxxxxx úvodu x xxxxx X, xxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxx xxxxxxx rozdělí xx xxxxxxxxx skupinu x skupinu, u xxx xx xxxxxxx xxxxxxxx. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx x xxxxxxxxxxxxx xxxxxxxxxx alespoň xxx xxx xxxxxxxxxxxxx. Xxxxx xx xxxxxxxxxx tak, xxx xxx xxxx xxxxxx polohy xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx rozpuštěny xxxx xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx podávány xxxxx xxxx xxxxx xxx před podáním xxxxxxx. Měly xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x jejich stálosti xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxx x mělo by xxx xxxxxxxxx xxxxxxxxx, xx reaguje xx xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx xxx xxxxx rozpouštědla/vehikula, mělo xx xxx xxxxxx xxxxxxxx xxxxxxxxx údaji x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx vodných xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx být xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx xxx pohlaví. S xxxxxxxx aplikace xxxxxxxx xxxxx by xxxx xxxxxxx kontrolní xxxxxxx xxxxxxxxxx identický xxxxxx xxxx zvířata xx xxxxxxxxx, x nichž xxxxx k expozici.
Pozitivní xxxxxxxx xx xxxx xxxxxxxxxx xxxxxxxxxx xx xxxx xxx xxxxxxxxxxx xxxxxxxx, x xxxxx xx očekává, xx xxxxxxxxx detekovatelný nárůst xxx xxxxxx. Xxxxx xxxxxxxxx kontroly xx xxxx xxx xxxxxxx xxx, xxx xxx xxxxxx zřetelný, ale xxx při xxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx jiným xxxxxxxx xxx xxxxxxxx xxxxx x xxx xxx xxxxx v xxxxx xxxxxxx xxxxxxxx xxx xxxxxx. Xxx xxxxxxxxx xxxxxxxx navíc xxxx xxx xxxxx v xxxxx xxxxxxx xxxxxxxxxx xxxxx ze xxxxxx xxxxxxxx třídy, xxxx-xx x xxxxxxxxx. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx monohydrát |
6055–19–2 |
|
|
2,4,6-tris(aziridin-1-yl)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxx xx xxx xxx xxxxxxxx odběr x xxxxxxx xxxxxxxxx xxxxxxxx, xxxxx je xxxxxxxxxx xxxxx rozpouštědlo xxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, pokud nejsou x xxxxxxxxxxx kontrolních xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx x xxxxxxxxxxx xxxxxx x xxxxxxxx xxxxx x xxxxxxxxxx. Xxxxxxx-xx se xxx negativní xxxxxxxx xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx odběru. Xxxxx xxxx by xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx také xxxxx, xxxxxxxxxx-xx xxxxx nebo xxxxxx-xx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, že xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx nebo xxxxxxxxx xxxxxx.
Xxx použití xxxxxxxxx krve xxxx xxx jako xxxxxxxxx xxxxxxxx přijatelný xxxx xxxxxx xxxx odebraný xxxx xxxxxxxx, xxxxx xxxx u xxxxxxxx xxxxxx x periferní xxxx (xxxx. 1 — 3 aplikace) xx předpokladu, xx xxxxxxxx údaje budou x xxxxxxx, xxxxx xx xx xxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
1.5 XXXXXX
1.5.1 Počet a xxxxxxx xxxxxx
Xxxxx exponovaná x xxxxxxxxx xxxxxxx xx xxxx xxxxxxx x xxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxx pro xxxxx pohlaví (11). Xxxxxxxx xxxx v xxxx studie x xxxxxxxxx xxxxx ze xxxxxx xx xxxxxxx xxxxxx x xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxx xxxxxxxxx, xx xxxxxxxxxx xxxx xxxxxxxxx xxxxxx x xxxxxxxx, bude xxxxxxxxxxx xxxxxxxx jednoho pohlaví. Xx-xx xxxxxxxx člověka xxxxxxxxxx xxx určité xxxxxxx, jako je xxxx xxxxxxxxx x xxxxxxxxx farmaceutických xxxxx, xxxx xx být xxxxxxx provedena xx xxxxxxxx xxxxxxxxxxxxxx pohlaví.
1.5.2 Xxxx aplikace
Nelze doporučit xxxxx standardní xxxx (xx. xxxxx, dvě xxxx xxx xxxxxxxx x xxxxxxxxx 24 xxxxx). Xxxxxx xx xxxxxx x xxxxxxxxxxxx xxxxxxx podávání jsou xxxxxxxxxx, xxxxx se x těchto xxxxxx xxxxxxx pozitivní výsledky, xxxx –x xxxxxxx xxxxxxxxxxx studií — xxxxx byla xxxxxxxxx xxxxxxxx nebo byla xxxxxxxxx xxxxxxx xxxxx x xxxxxxxx pokračuje xx xx okamžiku xxxxxx. Xxxxxxxx látky xxxxx xxx xxxxxxxx xxxx xx xxxx xxxxxxx, xxx. xxx xxxxx v xxx xxx v rozmezí xx xxxx xxx xxxxxxxx hodin, aby xxxx usnadněno xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx.
Xxxx xxxx xxx proveden xxxxx xxxxxxx:
x) xxxxxxxx xxxxx se xxxxxxxx xxxxxxxx xxxxxx. Vzorky xxxxxx dřeně se xxxxxxxx xxxxxxx xxxxxxx, xxxxxxx xxxxx xxxxx xx xxxxxxx xxxxxxxx 24 hodin xx xxxxxxxx a poslední xxxxxxxxxx 48 xxxxx xx xxxxxxxx x x xxxxxxxxxx xxxxxxxx xxxx xxxxxx. Xxxxx xxxxx než 24 xxxxx po aplikaci xxxx být zdůvodněn. Xxxxxx xxxxxxxxx krve xx xxxxxxxx alespoň xxxxxxx, přičemž první xxxxx se provede xxxxxxxx 36 hodin xx xxxxxxxx x xxxxxxxx xxxxxxxxxx 72 xxxxx xx xxxxxxxx x xx xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxx xxxxxx. Xx-xx xx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx xxxxx xxxxx nutný;
b) xxxx-xx podávány xxx xxxx xxxx dávek xxxxx (např. dvě xxxx více xxxxx x intervalu 24 xxxxx), xxxx xx xxx vzorky při xxxxxxx xxxxxx dřeně xxxxxxxx jednou xx 18 až 24 xxxxxxxx xx poslední xxxxxxxx x xxx xxxxxxx xxxxxxxxx xxxx xxxxxx po 36 xx 48 hodinách xx xxxxxxxx xxxxxxxx (12).
Xxxxx xxxxxxx xxxxx xxx xxxxx použity xxxx xxxx xxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx vhodných dostupných xxxxx xxxxxx pro xxxxxxxx xxxxxxx dávek, xxxx by být xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, xxxxxxxx x xx xxxxxxxx xxxxxx xxxxxxxx, xxx xx použijí x xxxxxx xxxxxx (13). X xxxxxxx xxxxxxxx xx xxx xxxxx xxxxx použijí xxx xxxxxx xxxxx. Tyto xxxxxx dávky xx xxxx pokrývat xxxxxxx xxxx xxxxxxxxx xx xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx xxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, xx xxxxx xxxxx xx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx xxxxx očekávání x letalitě. Xxxxx xx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx při xxxxxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxx x xxxxxxxx) xxxxxx kritériím stanovení xxxxx xxxxxxxxx x xxxx xx být xxxxxxxxx xxxxxx od xxxxxxx. Xxxxxxxx xxxxx xxxx být také xxxxxxxxxx jako dávka xxxxxxxxxxxx x kostní xxxxx některé xxxxxx xxxxxxxx (xxxx. snížení xxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx množství xxxxxxxxxx x xxxxxx xxxxx nebo v xxxxxxxxx xxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx x xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx podanou xxxxxxxxxxx xxxx xx xxxx xxxxxxx v xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx xx xxxxxxx údajů x xxxxxxx, které xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxx xxxxxxxxxx úplná xxxxxx xx xxxxx xxxxxxxx xxxxx xx xxxxxxxxx. X déle trvajících xxxxxx xx xxxxxxx xxxxxx xxx 14xxxxx xxxxxxxx 2000 xx/xx xxxxxxx hmotnosti/den x xxx xxxxx než 14xxxxx xxxxxxxx xx xxxxxxx xxxxxx 1000 xx/xx xxxxxxx xxxxxxxxx/xxx. Xxxxxxxxx expozice xxxxxxx xxxx xxxxxxxx xxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, žaludeční xxxxxx nebo xxxxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx xxxxxxx. Xxxx xxxxxxx podávání jsou xxxxxxxxxx v xxxxxxxxxxxxxxx xxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, který xxxx xxx xxxxxxxx xxxxx xxxxxxxxx xxxxxx nebo xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx neměl xxxxxxxxx 2 xx/100 x tělesné xxxxxxxxx. Xxxxxxx xxxxxxx objemů, xxx je xxxxxxx xxxxx, musí xxx xxxxxxxxxx. Až xx xxxxxxxx x xxxxxx xxxxx, xxxxx xxxxxxx xxx vyšších xxxxxxxxxxxxx xxxxxxxx xxxxxxxx účinky, xx xxxx xxx xxxxxxxxxxx zkušebního xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx koncentrace xxxxxxxxxxx konstantní objem xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Příprava xxxxxx xxxxx xxxx xxxx
Xxxxx xxxxxx dřeně xx xxxxxxx xxxxxxxxx x xxxxxx xxxx xxxxx xxxxx xx xxxxxxxx. Xxxxx se odeberou x xxxxxx xxxx xxxxx x xxxxxxxxxx xxxxxxxx se xxxxxxxxx x xxxxxx. Xxxxxxxxx xxxx xx získává x xxxxxx xxxx xxxx xxxx xxxxxx xxxxxx xxxx. Xxxxxx xxxxx xx xxxxx xxxxxxxxxxxx xxxxxx (8, 9, 10), xxxx xx xxxxxxxx preparáty xxxxxxxx x poté xx obarví. Xxxxxxxx xxxxxxx specifického xxx XXX (např. xxxxxxxxxx xxxxx (14) nebo Xxxxxxx 33258 x xxxxxxx-X (15)) xx xxx xxxxxxx některým xxxxxxxxxx xxxxxxxx x xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxx XXX. Xxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx (xxxx. Xxxxxx). Přídavné xxxxxxx (xxxx. xxxxxxxxxx xxxxxx x xxxxxxxxxx buněk xxxxxxxxxxxx xxxxx (16)) xxx použít za xxxxxxxxxxx, že se xxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx.
1.5.7 Xxxxxxx
Xxx xxxxx xxxxx xx xxxxxxx xxxxx nezralých xxxxxxxxxx x celkového (nezralé + xxxxx) xxxxxxxx xxxxxxxxxx, xxxxxxx xx x případě xxxxxx xxxxx xxxxxxx celkově xxxxxxx 200 xxxxxxxxxx x v xxxxxxx xxxxxxxxx krve alespoň 1000 erytrocytů (17). Xxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx pozitivních x xxxxxxxxxxx xxxxxxx, xx xxxx xxx xxxx xxxxxxxx xxx mikroskopem xxxxxxxxx kódovány. X xxxxxxx xxxxxxx xx xxxxxxx xxxxxxx 2000 xxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxxxxxxx v xxxxxxxxxxxxxxxxxxxxx. Xxxxx xxxxxxxxx xxxxx xxx získány xxxxxxxxxx xxxxxxx xxxxxxxxxx xx výskyt xxxxxxxxxx. Xxx mikroskopické analýze xx xxxxx xxx xxxxx nezralých erytrocytů x xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxx 20 % kontrolní xxxxxxx. Xxxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx xxxxx xxxx xxxx, xxx xxxx xxxxxxxx na xxxxxx xxxxxxxxxx xxxxxxx 2000 xxxxxxx xxxxxxxxxx na xxxxx zvíře. Xxxxxxx xxx automatickou analýzu (xxxxxxx obrazu x xxxxxxxxx xxxxxxxxxxxx analýza xxxxxxx xxxxxxxx) xxxx xx xxxxxxxxxxxxx zdůvodnění x validaci xxxxxxxxxxxx xxxxxxxxxxxxx manuálního xxxxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xxx jednotlivá xxxxxxx xx xxxx být xxxxxxxxxx xx formě xxxxxxx. Xxxxxxxxxxxxxx jednotkou xx xxxxx. Pro xxxxx analyzované xxxxx xx xxx xxx xxxxxx xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx, počet xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx a xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx množství xxxxxxxxxx. Xxxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx čtyři xxxxx xxxx xxxx, xxxx xx být xxxx uvedeny údaje x zralých xxxxxxxxxxxx, xxxx-xx xxxxxxxxxxxxx. Xxx xxxxx zvíře xx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx a xxxxxxxx množství xxxxxxxxxx x xxxxxxxxxx xxxxxxxxx x xxxxxxxxxx. Xxxxxxxxxx-xx xxxxx x xxxxxxx x odpovědi xxxx xxxxxxxxx, mohou xxx xxx xxxxxxxxxxxx analýzu xxxxx xxx xxx xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx pozitivního výsledku xxxxxxxx několik xxxxxxxx, xxxx. nárůst počtu xxxxx x xxxxxxxxxx x xxxxxxxxxx xx xxxxx xxxx xxxxx xxxxxx xxxxx xxxxx x mikrojádry xxx xxxxxxx s xxxxxxx xxxxxx a k xxxxxxxx okamžiku xxxxxx. Xxxxxxxx by xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx zkoušky xxxxx být xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (18, 19). Xxxxxxxxxxx významnost xx xxxxxx xxx xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx xxxx xxx vyjasněny xxxxxx xxxxxxxxx, xxxxxxx x úpravou xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, jejíž xxxxxxxx nesplňují xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx xxxxxxx za xxxxxxxxxxx.
Xxxxxx xxxxxxx experimentů xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx výsledky, v xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx zkoušené látky. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx nebo sporné xxx xxxxxx na xx, xxxxxxxx xx xxxxxxxxxx opakován.
Pozitivní xxxxxxxx xxxxx xx mikrojádra xxxxxxxxx, že xxxxxxxx xxxxx xxxxxxxx mikrojádra, xxx xxxx důsledkem xxxxxxxxxxxxxx xxxxxxxxx nebo xxxxxxxxx mitotického aparátu xxxxxxxxxxxx xxxxxxxxxxx druhu. Xxxxxxxxx výsledky xxxxxxxxx, xx xxxxxxxx látka xx xxxxxxxx zkoušky xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx erytrocytech testovacího xxxxx.
Xxxx xx xxx xxxxxxxxxxx pravděpodobnost, s xxxxx se zkoušená xxxxx nebo její xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx, xxxx xxxxxxxxxx xx xxxxxx xxxxx (např. systémová xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx o xxxxxxx xxxx obsahovat tyto xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx zvířata:
- xxxxxxx xxxx/xxxx,
- počet, xxxxx x xxxxxxx xxxxxx,
- xxxxx, podmínky chovu, xxxxxx atd.,
- individuální xxxxxxxx xxxxxx na xxxxxxx xxxxxxx, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxx pro xxxxxx xxxxxxx.
Xxxxxxxx podmínky:
- xxxxx x pozitivní x xxxxxxxxx (vehikulum/rozpouštědlo) xxxxxxxx,
- xxxxx ze xxxxxx pro xxxxxxxx xxxxxxx, xxxxx byla xxxxxxxxx,
- zdůvodnění xxxxxxxxx xxxxxx dávek,
- údaje x přípravě xxxxxxxx xxxxx,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- xxxxxxxxxx způsobu xxxxxxxx,
- xxxxxxxxx xxxxxx ověření, xxx se xxxxxxxx xxxxx xxxxxxx xx xxxxxxxx xxxxx nebo xx xxxxxx tkáně,
- xxxxxxxx přepočet xxxx xxxxxxxxxxx zkoušené xxxxx x xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx hmotnosti/den),
- xxxxxxxx xxxxx o xxxxxxx xxxxxx x vody,
- xxxxxxxx popis rozvrhu xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxx stanovení toxicity,
- xxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx,
- xxxxx xxxxxxxxxxxxx xxxxx xx xxxxx zvíře,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxx xxxxxxxxx xxxxxxxxxx z xxxxxxxxx xxxxxxxx xxxxxxxxxx,
- xxxxx xxxxxxxxx xxxxxxxxxx s xxxxxxxxxx uvedený samostatně xxx xxxxx xxxxx,
- xxxxxxx xxxxxxx ± xxxxxxxxxx odchylka xxxxx xxxxxxxxx xxxxxxxxxx s xxxxxxxxxx ve xxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx statistické xxxxxxx x xxxxxx,
- xxxxx x xxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Heddle, J. X. (1973), A Xxxxx In vivo Xxxx xxx Xxxxxxxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 18, 187-190.
2) Xxxxxx, X. (1975), The Xxxxxxxxxxxx Test, Xxxxxxxxxx Xxx., 31, 9-15.
3) Xxxxxx, J. X., Xxxxxxxx, M. X., Xxxx, M., Xxxxxxxx, X., Mavournin, X., XxxXxxxxx, X. X., Xxxxxx, G. W. (1983), Xxx Xxxxxxxxx xx Xxxxxxxxxxx x. x. x Xxxxxxx xx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx. 123, 61-118.
4) Xxxxxxxxx, K. X., Xxxxxx, D. H., Xxxxxx, X. C., Xxxxxxxx, M. X., Xxxxxx, X. X. (1990), The In xxxx Xxxxxxxxxxxx Xxxxx xx Xxxxxxxxx Bone Xxxxxx xxx Xxxxxxxxxx Xxxxx. X xxxxxx xx the U. X. Environmental Xxxxxxxxxx Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 239, 29-80.
5) XxxXxxxxx, X. X., Xxxxxxxx, R., Xxxx, X. N., Xxxx, X. X. (1983), Xxxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxxxxxxx: A Xxxxx Xxxxxx xxx Xxxxxxxxxxx Xxxxxx Xxxxxx Xxxxxxx Xxxxxxxx Xxxxxxx xx Mice, in: Xxxxxxxxxxxx xx Xxxxxxx xxx Xxxxxxxx of Xxxxxxxxxx, xx. A. X. Hayes, X. X. Xxxxxxx, T. X. Miya. Xxxxxxxx, Xxxxxxxxx, 555-558.
6) XxxXxxxxx, X. T., Xxxxxx, X. X. Xxxx, X., Margolin, X. X., Xxxxx, X., Xxxxxxxx, X. F., Xxxx, X. X., Xxxx, D. (1987), Xxxxxxxxxx xxx xxx Xxxxxxx of Xxxxxxxxxxxx Xxxxxx xx Mammalian Xxxx Xxxxxx Erythrocytes, Xxxxxxxxxx Xxx., 189, 103-112.
7) XxxXxxxxx, J. X., Xxxx, X. X., Xxxxxx, X. X., Shelby, M. X. (1990), The xx vivo Xxxxxxxxxxx Xxxxxxxxxxxx Xxxx: Measurement xx Xxxxxx Xxxxx Xxxxxxxxx Assay Xxxxxxxxxx xxx Permits Xxxxxxxxxxx xxxx Xxxxxxxx Xxxxxxx, Xxxxxx. Xxxx. Toxicol. 14, 513-522.
8) Xxxxxxx, X., Morita, X., Xxxxxx, Y., Sofumi, X., Ishidate, M. Xx. (1990), The Xxxxxxxxxxxx Xxxxx xxxx Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxxxxx Xxxxx Acridine Xxxxxx-Xxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 245, 245-249.
9) Xxx Collaborative Study Xxxxx xxx the Xxxxxxxxxxxx Xxxx (1992). Xxxxxxxxxxxx Xxxx xxxx Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxxxx xx Xxxxxxxx Xxxxxx Xxxxxxxxxx Xxxxxxxx: Xxx Xxxxxxx Xxxxxx xx xxx 5xx Xxxxxxxxxxxxx Study xx XXXXX/XXXXX, XXX, Xxxxxxxxxx Xxx., 278, 83-98.
10) Xxx Xxxxxxxxxxxxx Study Xxxxx xxx xxx Xxxxxxxxxxxx Xxxx (XXXXX/XXXXX, XXX: The Xxxxxxxxx Xxxxxxxxxxx Xxxxx Group xx xxx Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx xx Xxxxx) (1995), Xxxxxxxx xxxxxxxxxxx xxx xxx xxxxx-xxxx mouse xxxxxxxxxx xxxxx xxxxxxxxxxxx test, Xxxxxxxxxxx, 10, 53-159.
11) Xxxxxxx, X., Xxxx, X. X., XxxXxxxxx, X. T., Xxxxxxxx, X., Blackey, D. X., Kirsch-Volders, X., Xxxxxx, Xx. X. X., Xxxxxxxxxxxx, X., Xxxxxxx, F., Xxxxxxx, X., Sutou, X., Xxxxxxx, B. (1994), Xx vivo Xxxxxx Xxxxxxxxxxx Xxxxxxxxxxxx Assay, Xxxxx. Xxx., 312, 293-304.
12) Xxxxxxxxxxx, X., Xxxxx, X. (1995), Xx optimal, xxxxxxxxxxx xxxxxxxx time xx 30 ± 6 x after double xxxxxx in xxx xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxx, Mutagenesis, 10, 313-319.
13) Xxxxxxx, X. X., Allen, J. X., Xxxxxx, X. X., Botham, P. X., Xxx, J., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, G., Morton, X. B., Kirkland, X. X., Rochold, X. (1992), Xxxxxx xx Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx: Xxxx Setting in Xx vivo Xxxxxxxxxxxx Xxxxxx, Mutagenesis, 7, 313-319.
14) Xxxxxxx, M., Xxxxxx, X., Xxxxxxxx, X. Xx. (1983), Xx Xxxxxxxxxxx xx Xxxxxxxx Orange Xxxxxxxxxxx Xxxxxxxx to the Xxxxxxxxxxxx Xxxx, Xxxxxxxx Xxx., 120, 241-247.
15) XxxXxxxxx, X. T., Xxxx, X. X., Xxxxxxxx, X. G. (1983), A Xxxxxx Xxxxxxxxxxx Xxxxxxxx Procedure xxx Xxxxxxxxxxx xxx XXX in Xxxxxxxxxxxx Xxxxx Xxxxxxx 33258 xxx Pyromin Y, Xxxxxxxx Xxx., 120, 269-275.
16) Xxxxxxx, X., Xxxxxxxxxx, X. D. (1989), Xxx xxxxxxxxx xxxx xxxxxx micronucleus xxxx, Mutatation Xxx., 213, 91-104.
17) Xxxxxxxxx, X., McFadden, X. X. (1995), Xxxxxx Xxxx xxx xxx Xxxxxxxxxx of Xxxxxxxxxxxxx xx Normochromatic Xxxxxxxxxxx Xxxxx xx xxx Xxxx Xxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 347, 97-99.
18) Xxxxxxx, X., Ashby, X., Xxxxxxx, J., Xxxxxxxx, X., Xxxxxxxxx, X. X., Xxxxxxxxx, L. (1990), Xx xxxx Xxxxxxxxxxxx Xxxxx, xx: X. X. Kirkland (xx.), Xxxxx Mutagenicity xxxxx, UKEMS Recommended Xxxxxxxxxx, XXXXX Sub-Committee xx Xxxxxxxxxx for Xxxxxxxxxxxx Xxxxxxx. Report, Xxxx 1, revised, Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, Xxx York, Xxxx Chester, Xxxxxxxxx, Xxxxxx, 115-141.
19) Lovell, X. P., Anderson, X., Albanese, R., Xxxxxxxx, X. X., Xxxxx, G., Xxxxxxxx X., Richold, M., Xxxxxxxx, X. X., Xxxxxx, X. X. X. (1989), Staticical Xxxxxxxx xx In xxxx Xxxxxxxxxxx Assays, xx: X. J. Xxxxxxxx (ed.), Xxxxxxxxxxx Xxxxxxxxxx xx Mutagenicity Xxxx Data. XXXXX Xxx-Xxxxxxxxx on Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Part III, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, Xxx York, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4X
"X.13/14 XXXXXXXXXX — XXXXXXX XX XXXXXXXX MUTACE X XXXXXXXXXX
1. XXXXXX
Xxxx xxxxxx xx replikou xxxxxx XXXX XX 471 — Xxxxxxx na xxxxxxxx mutace x xxxxxxxxxx (1997).
1.1 ÚVOD
Při xxxxxxx xx reverzní xxxxxx s xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx závislé xx xxxxxxxxxxxxxxx Xxxxxxxxxx xxxxxxxxxxx x Xxxxxxxxxxx xxxx, x xxxxxxx xxxxxxxx xxxxxx, xxxxx zahrnují xxxxxxxxxx, adici x xxxxxx xxxxxxx xxxx xxxxxxxx párů xxxx XXX (1, 2, 3). Podstata xxxx xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxx v detekci xxxxxx, xxxxx xxxxxxxxx xxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx x xxxxxxxx xxx funkční xxxxxxxxx bakterií xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx xxxx xxx xxxxxxxxxx růst x xxxxxxxxxxxxx aminokyselin, xxxxx xxxx xxxxxxxxxx mateřským xxxxxxxxxx kmenem.
Bodové xxxxxx x xxxxxxx jevy xxxx xxxxxxxx xxxxx xxxxxxxxx podmíněných xxxxxx x člověka a xxxxxxxx mnoho důkazů x xxx, xx xxxxxx mutace x xxxxxxxxxx a v xxxxxx xxxxxxxxxxx buněk xxxxxxxxx xxxxxx mají xxxxx na xxxxxx xxxxxxxx u člověka x x pokusných xxxxxx. Xxxxxxx xx xxxxxxxx mutace x xxxxxxxxxx xx xxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxx. Xxxxx testovacích xxxxx xx xxxx xxxxxxxxxx, xxxx xxxx xxxx citlivější xx xxxxxxx xxxxxx, včetně xxxxxxxxxxxxx sekvencí XXX xx xxxxxxxxxx xxxxxxx, xxxxxxx permeability xxxxx xxx xxxxx xxxxxxxx x eliminaci xxxxxxxxxxx xxxxxxx XXX nebo xxxxxxxx xxxxxxxxxxx xxxxxxx XXX xxxxxxxxxx x xxxxxx. Xxxxxxxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx x typech xxxxxx, xxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Pro xxxxxxx xx reverzní xxxxxx x bakteriemi xx k xxxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxxxx pro xxxxxxx xxxxx xxxxxxxx a xxxx xxxx vyvinuty xxxxx vyzkoušené metody xxxxxxxx xxxxxxxxxx látek, xxxxxx xxxxxxxx xxxxxxxxx, x různými xxxxxxxxx-xxxxxxxxxx xxxxxxxxxxx.
Xxx také obecný xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx Xxxxxxxxxx typhimurium xxxx Xxxxxxxxxxx coli xxxxxx x detekci mutací x xxxxx xxxxxxxxxxx xxxxxxxxxxxxx (xxxxxxxx xxxx. xxxxxxxxx), xxxxxxx xxxxxx xxxx xxxxxxxxx xx xxxxxxx přísunu aminokyseliny.
Mutageny xxxxxxxxxx párů xxxx xxxx xxxxxxxx, xxx xxxxxxxxx xxxxx x xxxxxx XXX. Xxx xxxxxxx xxxxxxxxxx xxxxxx xx mohou xxxx xxxxx vyskytnout na xxxxx xxxxxxx mutace xxxx xxxxx místě xxxxxxxxxxxxx genomu.
Posunové mutageny xxxx xxxxxxxx, jež xxxxxxxxx adici xxxx xxxxxx xxxxxxx xxxx xxxx xxxx bází XXX x xxxxxxxx xxx xxxxx xxxxx XXX.
1.3 VÝCHOZÍ ÚVAHY
Při xxxxxxxxx na reverzní xxxxxx x xxxxxxxxxx xx xxxxxxxxx prokaryotické xxxxx, xxxxx xx xxxx xx xxxxx xxxxx xxxxxxx, xxxx xxxx příjem, metabolismus, xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxx XXX. Xxxxxxx xxxxxxxxx xx xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxxx xxxxxxxxx xxxxxxx in xxxxx nemohou zcela xxxxxxxxx xxxxxxxx xx xxxx x savců. Xxxxxxx xxxx xxxxxxxxxxx xxxxxx xxxxxxxxx x xxxxxxxxxx x karcinogenním xxxxxxxxxx xxxxx xxx xxxxx.
Xxxxxxx na xxxxxxxx xxxxxx x bakteriemi xx xxxxxxxxx xxxxxxxxx xxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx aktivity, a xxxxxxx aktivity xxxxxxxxxxxx xxxxxx xxxxxx. X xxxxxxxx xxxxxxxx vyplývá, xx mnoho xxxxxxxxxx xxxxx, xxxxx xxxx x xxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxx xxxxxxxx x x xxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx mutagenních xxxxxxxx, xxxxx xxxxxx detekovány xxxxx xxxxxxxx. Xxxxxxx xxxxxx skutečností xxx xxxxxxxxx ve xxxxxxxxxx xxxxxx xxxxxxxxxxxxxxxxxxxxx xxxx, x xxxxxxxxx x xxxxxxxxxxx xxxxxxxx xxxx x xxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx. Na xxxxx xxxxxx xxxxxxx, xxxxx zvyšují xxxxxxxxx xxxxxxx na xxxxxxxx xxxxxx xx xxxxxxxxxx, xxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxxx xx xxxxxxxx xxxxxx x bakteriemi xxxxxx xxx xxxxxx xxx xxxxxx xxxxx xxxxxxxxxx xxxxx, například xxxxxx xxxxxxxxxxxx xxxxxxxxxx (xxxx. xxxxxx xxxxxxxxxxx) x xxx xxxxxxxx xxxxx, x xxxxx se xxxxxxxxxxx (nebo o xxxxx xx xx), xx xxxxxxxxxx zasahují xx xxxxxxxxxxxx xxxxxxx xxxxx xxxxx (xxxx. xxxxxxx xxxxxxxxxx topoisomerasy x xxxxxxx xxxxxxx xxxxxxxxxx). X xxxxxxxx xxxxxxxxx mohou xxx xxxxxxxxx xxxxxxx xxxxxxxxxx x savců.
Přestože xxxxx xxxxxxxxx, pro xxx xx xxxx xxxxxxx xxxxxxxxx, xx xxxxxxxxxxxx xxx xxxxx, xxxx xxxxxxxx xxxxxxxxx. Závisí xx xxxxxxxx xxxxx x xxxxxxxx xxxxx xxxxxxxxxxx, jež xxxxxx xxxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxxx xxxxxxxxxxxxx xxxxx jsou xxxxxxxxx xxxxxxxx xxxxx, x to xx xxxxxxxxxxx vnějšího xxxxxxxxxxxxx xxxxxxxxxxx systému x xxx xxxx. Ve xxxxxxxxxxx miskovém xxxxx xx suspenze smíchají x xxxxxxx xxxxxx x ihned se xxxxxxx na xxxxxxxxx xxxx. V xxxxxxxxxxxx xxxxxx xx xxxxxxxx xxxx xxxxxxxx x xxxx se xxxx xxxxxxxxx na xxxxxxxxx xxxx xxxxxx x xxxxxxx xxxxxx. Při xxxx technikách xx xx xxxx xxxx xxxxx xxxxx xxxxxxxx xxxxxxxxx kolonie xxxxxxxxxx x xxxxxxx se xxxxxxxx x počtem xxxxxxx spontánních xxxxxxxxxx xx kontrolní xxxxx x xxxxxxxxxxxxx.
Xx popsáno xxxxxxx xxxxxxx xxxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx s bakteriemi. Xxxx běžně xxxxxxxxx xxxxx xxxxxxxxxx miskový xxxx (1, 2, 3, 4), xxxxxxxxxxxx xxxxxx (2, 3, 5, 6, 7, 8), xxxxxxxxxx xxxx (9, 10) x xxxxxxxxx xxxxxx (11). Xxxxxx xxx xxxxxxxx xxxxx x xxx xxxx xxxxxxx (12).
Zde xxxxxxx xxxxxxx se xxxxxx hlavně xxxxxxxxxxxx xxxxxxxxx testu x xxxxxxxxxxxxxx xxxxx. Xxxxx x xxxx xx xxxxxxxxxx pro xxxxxxxxx xxxxxxxxxxx jak x xxxxxxxxxxxx xxxxxxxx, tak xxx xx. Xxxxxxx xxxxx xxx xxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxxx metody. Xxxx xxxxx xxxxx do xxxxxxxxxx xxxx, xx xxxxx patří xxxx xxxxx xxxxxx alifatické xxxxxxxxxxx, xxxxxxxxx xxxx, xxxxxxxx, azobarviva a xxxxxxxxxx sloučeniny, xxxxxxxxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxxx x xxxxxxxxxxxxxxx (3). Xxxxxx xx připouští, xx xxxxxx xxxxx xxxxxxxx xxxxx xxxx xxxxxxxxx standardními xxxxxxx, xxxx xx xxxxxxxxxx xxxxxxx xxxx xxxx xxxxxxxxxxxx xxxxxx. Xxxx xx xxx xxxxxxxxxx xx "xxxxxxxx xxxxxxx" x x xxxxxx xxxxxxx se xxxxxxx xxxxxxxxxx xxxxxx alternativní xxxxxxx. Xx xxxxx xxxxxxxxxxxxx xxxx "xxxxxxxx xxxxxxx" (xxxxxxxx x xxxxxxxx xxxxxxx xxxxxx xxxxxxx): xxxxxxxxxx x xxxxxxxxxx sloučeniny (3, 5, 6, 13), xxxxx x xxxxxx xxxxxxxx xxxxx (12, 14, 15, 16), x glykosidy (17, 18). Xxxxxxxx xx xxxxxxxxxxxx xxxxxxx musí xxx xxxxxxx xxxxxxxxxx.
1.5 XXXXX XXXXXXXX METODY
1.5.1 Xxxxxxxxx
1.5.1.1 Bakterie
Čerstvé xxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxxx xx xxxxxx exponenciální fáze xxxx do časné xxxxxxxxxxx fáze růstu (xxxxxxxxx 109 xxxxx xx xx). Xxxxx x xxxxxx xxxxxxxxxxx xxxx xx xxxxxx xxx xxxxxxx. Xx xxxxxxxx, xxx xxxx xxxxxxx xxxxxxxx vysoký xxxx xxxxxxxxxxxxxxx bakterií. Xxxx může xxx xxxxxxxx buď xx xxxxxxx dosavadních xxxxxxxxxxx xxxxx x xxxxxxx xxxxxx, xxxx pro xxxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxx xx xxxxxxx.
Xxxxxxxxxx inkubační xxxxxxx xx 37 °X.
Xxxx by být xxxxxxx xxxxxxx pět xxxxx bakterií. Xxxx xxxx xx xxxx xxx xxxxx kmeny X. typhimurium (XX1535; XX1537 xxxx XX97x xxxx TA97; XX98 x XX100), xxxxxxx xxxxxxx se ukázala x xxxxxxx xxxxxxxxxxxx xxxx xxxxxxxxxx a xxxxxxxxxxxxxxxx. Xxxx xxxxx xxxxx X. xxxxxxxxxxx xxxx xxx xxxx XX na xxxxxxxxx xxxxxxxxx xxxxx x xx xxxxx, xx xxxxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx, xxxxxxxx způsobující xxxxxxxxxx xxxxxx XXX x xxxxxxxxx. Xxxx xxxxx xxxxx xxx xxxxxxxxxx kmeny X. xxxx WP2 nebo X. typhimurium XX102 (19), xxxxx mají xx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxx XX. Xxxxxxxxxx kombinace xxxxx xx tedy xxxx:
- S. xxxxxxxxxxx XX1535 x
- S. xxxxxxxxxxx TA1537 xxxx XX97x x
- X. xxxxxxxxxxx XX98 x
- X. xxxxxxxxxxx TA100 x
- X. xxxx XX2 xxxX, xxxx X. xxxx WP2 xxxX (pKM101), xxxx X. xxxxxxxxxxx XX102.
Xxx xxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxx vláken XXX xxxx xxx vhodnější xxxxxxx XX102 xxxx xxxxxx kmen X. xxxx s xxxxxxx xxxxxxxxxx reparace XXX, (xxxx. X. xxxx XX2 (xXX101)).
Xxxx xx xxx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx kmenové xxxxxxx, xxxxxxxxxx xxxxxxx x skladování. Potřeba xxxxxxxxxxxxx pro růst xx xxxx být xxxxxxxxx xxx každou xxxxxxxxx xxxxxxxx xxxxxxx (xxxxxxxx xxx xxxxx X. xxxxxxxxxxx a xxxxxxxxx xxx E. xxxx). Podobně xx xxxx xxx xxxxxxxxxxxx xxxx fenotypové xxxxxxxxxxxxxxx, xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx X-xxxxxxx plasmidů (tj. xxxxxxxxxxxx xxxxxxxxxx u xxxxx TA98, XX100 x XX97x nebo XX97, XX2 xxxX x XX2 uvrA (xXX101) x xxxxxxxxxxxx x tetracyklinová rezistence x xxxxx XX102), xxxxxxxxxx charakteristických mutací (xx. xxx mutací x X. typhimurium xxxxxxxxxx xx xxxxxxxxxxx xxxxxx x xxxX xxxxxx u E. xxxx nebo uvrB xxxxxx x X. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx xxxxxx) (2, 3). Kmeny xx xxxx rovněž xxxxx xxxxx kolonií spontánních xxxxxxxxxx na misce x rozmezí xxxxxxxx xxxxxxxxxxx na xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx x xxxxxxx x xxxxxxx uvedeném x xxxxxxxxxx.
1.5.1.2 Xxxxxx
Xxxxxxx xx xxxxxx xxxxxxxxx xxxx (xxxx. xxxxxxxxxx xxxxxxxxx půdu X (Xxxxx-Xxxxxx) x glukosu) x xxxxxx agar xxxxxxxxxx xxxxxxxx a xxxxxx xxxx tryptofan xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxx (1, 2, 9).
1.5.1.3 Metabolická xxxxxxxx
Xxxxxxxx xx xxxx být xxxxxxxxx zkoušené xxxxx, x to x xxxxxxx systémem metabolické xxxxxxxx x xxx xxxx. Nejčastěji používaným xxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) xxxxxxxxxx x xxxxx hlodavců xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx enzymy, xxxx je Xxxxxxx 1254 (1, 2) xxxx xxxxxxxxxxxxx x β-xxxxxxxxxxxx (18, 20, 21). Xxxxxxxxxxxxxxxxxxx xxxxxx xx xxxxxxx xxxxxxxxx x xxxxxxxxxxxxx v xxxxxxx 5 xx 30 % obj. xx xxxxx X9. Xxxxx x xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx systému xxxx záviset xx xxxxx xxxxxxxx chemické xxxxx. X některých xxxxxxxxx xxxx xxx xxxxxx xxxxxx více xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx. X xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx může xxx xxxxxxxxx xxxxxxx redukčního xxxxxxxxxxxxx aktivačního systému (6, 13).
1.5.1.4 Zkoušená xxxxx xxxx xxxxxxxxx
Xxxxx xxxxxxxx xxxxx by xxxx xxx xxxx xxxxxxxx xx xxxxxxxx xxxxxxxxxx xxxx suspendovány xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx látky mohou xxx přidány xxxxx x xxxxxxxxxx xxxxxxxx x/xxxx xxxxx xxx xxxx xxxxxxxx zředěny. Xxxx by xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx chemické xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx xxx mimo xxxxxxxxx, xx reaguje se xxxxxxxxx látkou, a xxxx xx být xxxxxxxxxx s přežitím xxxxxxxx a s xxxxxxxxx X9 (22). Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx zařazení xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx se xxxxx xxxxx xxxxxxxx xxxxxx použití xxxxxxx xxxxxxxxxxxx/xxxxxxx. Při xxxxxxxx xxxxx nestálých xx xxxx xx měla xxx použita organická xxxxxxxxxxxx xxxxxxxxxxxx vodu.
1.5.2 Xxxxxxxx podmínky
1.5.2.1 Xxxxxxxx xxxxx (xxx 1.5.1.1)
1.5.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx mají xxx xxxxxxxxxx při stanovení xxxxxxxxxx xxxxxxxx zkoušené xxxxx xxxxx xxxxxxxxxxxx x rozpustnost v xxxxxxx směsi xxx xxxxxxxx.
Xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx x xxxxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx. Cytotoxicita xxxx xxx detekována xxxxxxxx xxxxx kolonií xxxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxx podkladu xxxx xxxxxxxx xxxxxx přežití xxxxxxxxxxxx xxxxxx. Cytotoxicita xxxxx xx xxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx aktivačních systémů. Xxxxxxxxxxxxx by měla xxx xxxxxxxxx na xxxxxxx xxxxxxxxxxx xxxxxxx x xxxxxxx xxxxx xx xxxxxxxxxx zkušebních xxxxxxxx.
Xxxxxxxxxx maximální xxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxxx látky xx 5 xx/xxxxx xxxx 5 μx/xxxxx. X xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxx xxxxxxxxxxxxx 5 xx/xxxxx nebo 5 μx/xxxxx by xxxx xxx jedna xxxx xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, xxx xxxxx xxxx x xxxxxxx xxxxx xxx xxxxxxxx xxxxxxxxxxx. Xxxxxxxx látky, xxxxx xxxx xxxxxxxxxxx xxx xxx xxxxxxxxxxxxx xxxxxxx než 5 xx/xxxxx xxxx 5 μx/xxxxx, xx xxxx xxx zkoušeny xx xx xxxxxxxxxxx koncentrace. Xxxxxxxxx by xxxxxx xxxxx xxx vyšetřování.
Mělo xx být použito xxxxxxx xxx xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxxx xxx xxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx xxxx zkušebními xxxx xxxxx xxxxxxxxx polovině xxxxx logaritmické xxxxxxxx (xx. Ö10). Xxxxx xxxxxxxxx jsou vhodné x xxxxxxx, xxx xx xxxxxxxxx křivka xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx. Xxxxxxxx xxxxxxxxxxx xxxxxxx xxx 5 xx/xxxxx nebo 5 μx/xxxxx xxxx být xxxxxxx xxx hodnocení xxxxx obsahujících významné xxxxxxxx potenciálně mutagenních xxxxxxxx.
1.5.2.3 Negativní x xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx xxxx vehikulum) xxxxxxxx x xxxxxxxxxxxx xxxxxxxx x bez xx. Xxx pozitivní xxxxxxxx xx měly xxx vybrány koncentrace xxxxxxxxxxx účinnost každé xxxxxxx.
X xxxxxxx xxxxxxx x použitím metabolického xxxxxxxxxxx xxxxxxx xx xxxx xxx látka (xxxxx) xxx xxxxxxxxx xxxxxxxx xxxxxxx (xxxxxxx) xx základě typu xxxxxxxxx xxxxx xxxxxxxx.
Xxxxxxxxx xxxxxx xxxxxxxxx kontroly x xxxxxxx x xxxxxxxxxxxx xxxxxxxx xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx CAS |
Číslo xxxxx XXXXXX |
|
9,10-xxxxxxxxxxxxxxxxx |
781–43–1 |
212–308–4 |
|
7,12-xxxxxxxxxxxxx[x]xxxxxxxxx |
57–97–6 |
200–359–5 |
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
2-xxxxxxxxxxxxxx |
613–13–8 |
210–330–9 |
|
Xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
Xxxx xxxxx xx xxxxxxx xxxxxxxxx kontrolou xxx xxxxxx redukční xxxxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx CAS |
Číslo xxxxx XXXXXX |
|
XX Direct Red 28 |
573–58–0 |
209–358–4 |
2-xxxxxxxxxxxxxx xx xxxxx xxx xxxxxx xxxx xxxxxx xxxxxxxxx účinnosti xxxxx X9. Xxx xxxxxxx 2-xxxxxxxxxxxxxxx by xxxx xxx xxxxx xxxxx X9 xxxxxxxxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxxxx aktivaci xxxxxxxxxxxxxx xxxxxx, xxxxxxxxx benzo[a]pyren xxxx 7,12-xxxxxxxxxxxxx[x]xxxxxxxxx.
Xxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx bez vnější xxxxxxxxxxx aktivace xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
Xxxx |
|
xxxx xxxxx |
26628–22–8 |
247–852–1 |
XX1535 x XX100 |
|
2-xxxxxxxxxxxx |
607–57–8 |
210–138–5 |
XX98 |
|
9-xxxxxxxxxxxx |
90–45–9 |
201–995–6 |
XX1537, TA97 x TA97a |
|
ICR 191 |
17070–45–0 |
241–129–4 |
XX1537, XX97 a XX97x |
|
Xxxxxxxxxxxxxxxxx |
80–15–9 |
201–254–7 |
XX102 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
XX2xxxX x XX102 |
|
1-xxxxxx-3-xxxxx-1-xxxxxxxxxxxxxxx |
70–25–7 |
200–730–1 |
XX2, XX2 xxxX x XX2 uvrA (xXX101) |
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
XX2, XX2 uvrA x XX2 xxxX (xXX101) |
|
α-[(5-xxxxx-2-xxxxx)xxxxxxxxxx]xxxxx-2-xxxxxxxx (XX2) |
3688–53–7 |
xxxxx obsahující plasmidy |
Pro xxxxxxxxx kontrolu xxxxx xxx xxxxxxx jiné xxxxxx xxxxxxxxxx xxxxx. Xxx xxxxxxxxx xxxxxxxx xx mělo xxx xxxxx x úvahu xxxxxxx xxxxxxxxxx látek xx xxxxxx xxxxxxxx xxxxx, jsou xx x xxxxxxxxx.
Xxxx by xxx xxxxxxx xxxxxxxxx xxxxxxxx skládající se xx xxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxxx, bez xxxxxxxx látky, xxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Xxxxx xxxx xx xxxx xxx neexponované xxxxxxxx xxxxxxx xxxx xxxxx, neexistují-li dosud xxxxxxxxx údaje prokazující, xx zvolené xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5.3 Xxxxxx
X xxxxxxxxxx xxxxxxx xxxxxx (1, 2, 3, 4) xxx xxxxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxx 0,05 xx xxxx 0,1 xx xxxxxxxxxx roztoků, 0,1 xx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxxxxxxxx xxxxxxxxx 108 životaschopných xxxxx) x 0,5 xx xxxxxxxxxx xxxxx x 2,0 xx xxxxxxxx agaru. X xxxxxxx xxxxxxx s xxxxxxxxxxxx xxxxxxxx se xxxxxxx xxxxxx 0,5 xx metabolické aktivační xxxxx obsahující xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx frakce (x rozmezí 5 xx 30 % xxx. x xxxxxxxxxxx xxxxxxxxx xxxxx) x xxxxxxx xxxxxx (2,0 xx) x xxxxxxx x xxxxxxxxxx x xxxxxxxxx xxxxxx xxxx xxxxxxxxx xxxxxxxx. Obsah xxxxx xxxxxxxx se xxxxxxxx x přelije xxxx povrch minimálního xxxxx na misce. Xxxx inkubací se xxxxx vrchní xxxx xxxxxxxx.
X xxxxxxxxxxxx xxxxxx (2, 3, 5, 6) xx zkoušená xxxxx xxxx xxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxx agarem x přelitím xxxx xxxxxx xxxxxxxxxxx xxxxx xx xxxxx xxxxxxx 20 xxxxx xxxx xxxx xxxxxxxxxxx s xxxxxxxxxx xxxxxx (obsahujícím xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x xxxxxxxxx xxxxxx nebo xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx (0,5 xx) xxx 30 — 37 °C. Xxxxxxx xx xxxxxx 0,05 xxxx 0,1 xx xxxxxxxx látky xxxx xxxxxxxxxx roztoku, 0,1 xx bakterií x 0,5 xx xxxxx X9 xxxx xxxxxxxxxx pufru x 2,0 xx vrchního xxxxx. Zkumavky xx xxxx xxx xxxxx xxxxxxxx xxxxxxxxxxxxxx na xxxxxxxx.
X xxxxxxxxxxxx xxxxxx xxxxxxxx xx měly xxx xxx xxxxx xxxxxx xxxxx xxxxxxx 3 xxxxx. Použití xxxx xxxxx xx xxxxxxxxxx po vědeckém xxxxxxxxxx. Xxxxxxxx xxxxxx xxxxx nemusí xxxxxxxx xxxxxxxxxxxx xxxxxxx.
Xxxxxx xxxx xxxxxx xxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx, např. x xxxxx xxxxxxxxxx xxxxxxxxxxxx nádobách (12, 14, 15, 16).
1.5.4 Xxxxxxxx
Xxxxxxx misky x xxxx zkoušce by xxxx xxx xxxxxxxxxx xxx 37 °C xx 48 –72 xxxxxxxx. Xx uplynutí xxxxxxxxx doby xx xxxxxx xxxxx kolonií xxxxxxxxxx na xxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxx xxxxx by xxxx xxx xxxxx kolonií xxxxxxxxxx připadající xx xxxxx. Xxx by xxx xxxxxx xxxxxx xxxxx xxxxxxx revertantů xxx na xxxxxxx x negativní xxxxxxxxx (xxxxxxxx rozpouštědla a xxxxxxxx xxxxxxxxxxxx xxxxxxxx), xxx xx xxxxxxx x pozitivní xxxxxxxxx. Xxxxx na xxxxxxxxxxxx xxxxxxx, střední xxxxxxx xxxxx xxxxxxx revertantů xx xxxxx a xxxxxxxxxx odchylka by xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxx x xxxxxxxxx x xxxxxxxxx kontrolu (xxxxxxxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxxxxxxxxxx).
Xxxxxxx xxxxx xxxxxxxxx xxxxxxxx se nepožaduje. Xxxxxxxxxx xxxxxxxx xx xxxx být vyjasněny xxxxxx xxxxxxxxx, xxxxxxx x úpravou experimentálních xxxxxxxx. Negativní xxxxxxxx xxxx xxx potvrzeny xxxxxx xx xxxxxxx. Xxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xx nezbytné, xxxx xx xxx xxxxxx xxxxxxxxxx. Xxxxx xxxxxxxxx xxxxxx s xxxxx xxxxxxxx rozsah xxxxxxxxxxxx xxxxxxxx xx měla xxx xxxxxxx x xxxxxxxxxx experimentech. X xxxxxxxxxx studie, xxxxx xx xxxxx xxx xxxxxxx, patří xxxxxxx xxxxxxxxxxx, xxxxxx xxxxxxxxxx (xxxxxxxxxx misková metoda xxxx xxxxxxxxxxx x xxxxxxxx xxxxx) x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx několik xxxxxxxx, např. xxxxxx xxxxx xxxxxxx revertantů xx xxxxx nad xxxxxxxxx xxxxxx u xxxxxxx xxxxxxx xxxxx x xxxxxxxxxxxx aktivačním xxxxxxxx xxxx xxx xxxx, x xx x xxxxxxxxxx na xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxxxx počtu xxx xxxxx xxxx xxxx xxxxxxxxxxx (23). Xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx výsledků zkoušky xxxxx být xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (24). Xxxxxxxxxxx významnost xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxxxx látka, xxxxx xxxxxxxx xxxxxxxxx xxxx uvedená kritéria, xx xxxxxxxx x xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx většina experimentů xxxxxxxx jasně xxxxxxxxx xxxx negativní výsledky, x ojedinělých xxxxxxxxx xxxxxxxx soubor xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx xx, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx xxxxxxxxx, že xxxxxxxx látka xxxxxxxx x genomu xxxxx Xxxxxxxxxx xxxxxxxxxxx a/nebo Xxxxxxxxxxx xxxx bodové xxxxxx xxxxxxxxxx xxxx xxxx xxxxxxx xxxxxxx xxxxx. Xxxxxxxxx výsledky xxxxxxxxx, xx xxxxxxxx xxxxx xxxx xx xxxxxxxx xxxxxxx pro xxxxxxxxx druhy xxxxxxxxx.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx x stálost xxxxxxxx xxxxx v xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxxxxxx xxxxx,
- xxxxx xxxxx v kultuře,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxx zkoušené xxxxx xx misku (xx/xxxxx xxxx μl/misku) x xxxxxxxxxxx výběru xxxxx x xxxxx xxxxx xx xxxxxxxxxxx,
- xxxxxxx xxxxx,
- xxx x xxxxxxx metabolického xxxxxxxxxxx xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxx xxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx xxxxxxx,
- xxxxx xx xxxxxxxxxxxx miskách,
- střední xxxxxxx xxxxx kolonií xxxxxxxxxx na xxxxx x xxxxxxxxxx odchylka,
- xxxxx xxxxxxxx závislost xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx o souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx kontrole x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x směrodatnými odchylkami,
- xxxxxxxxx údaje o xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx kontrole x xxxxxxxxx, středními xxxxxxxxx x xxxxxxxxxxxx odchylkami.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxx, X. N., XxXxxx, X., Xxxxxxxx X. (1975), Methods xx Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Xxx., 31, 347-364.
2) Maron, D. X., Xxxx, B. X. (1983), Xxxxxxx Xxxxxxx for xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 113, 173-215.
3) Gatehouse, D., Xxxxxxx, X., Cebula, X., Xxxxx, E., Xxxx, L., Xxxxxxxxxx, X., Xxxxxxx, X., Xxxxx, T., Xxxxxx, X., Xxxxxx, X. (1994), Recommendations xxx xxx Xxxxxxxxxxx xx Xxxxxxxxx Mutation Assays, Xxxxxxxxxx Res., 312, 217-233.
4) Xxxx, X. X., Brusick X. X., Xxxxxxx, A. X., Xxx Halle, X. X., Brown, X. X., Xxxxxx, X. X., Xxxxxx, X., XxXxxx, J., Xxxxxxxxxx, X., Prival, X., Xxx, T. X., Xxx X. (1986), Xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxxx Xxxxx: X Report xx xxx X. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 168, 69-240.
5) Xxxxxx, T., Degawa, X., Xxxxx, Y. X., Xxxxxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, Y. (1975), Xxxxxxxxxxxx of Xxxxxxxxxx Xxx Xxxx xxx xxxxx Xxxxxxxxxxx, Xxxxxx Xxxx. 1, 91-96.
6) Xxxxxxxxxx, X., Xxxxxxxx, T., Xxxxx, X., Xxxxxx, T., Xxxxxx, A., Sawamura, X. (1980), Xxxxxxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxx, in: Xxxxx-xxxx Xxxx Xxxxxxx for Xxxxxxxxx Xxxxxxxxxxx, ed. Xxxxxxx X. X., Xxxxxx, R. X., Xxxxxxxx, Berlin-Heidelberg-New York, 273-285.
7) Gatehouse, X. X., Xxxxxxx, X. X., Wilcox, P., Xxxxxxxxx, X. X., Xxxxxx, X. (1980), Xxxxxxxxx Mutation Assays, xx: Basic Mutagenicity Xxxxx: XXXXX Xxxx 1 Xxxxxxx, xx. X. J. Xxxxxxxx, Xxxxxxxxx Xxxxxxxxxx Press, 13-61.
8) Xxxxxxxxxx, X. X., Wolleb, X., Xxxxxxx, X. (1987), Xxxxxx Xxxxxxxxxxxxx Xxxxxxxxxxxx Xxxx xxx Xxxxx, X. Xxxx Safety., 8, 167-177.
9) Green, X. H. X., Xxxxxx, X. X., Xxxxxxx, X. X. (1976), Use of x xxxxxxxxxx xxxxxxxxxxx xxxx xx detect xxx xxxxxx of xxxxxxxx, Xxxxxxxxxx Xxx., 38, 33-42.
10) Hubbard, X. A., Xxxxx, X. X. X., Xxxxxxxxx, X., Xxxxxxx, X. X. (1984), Xxx Xxxxxxxxxxx Xxxx xx Xxxxxxxx, xx: Xxxxxxxx of Xxxxxxxxxxxx Xxxx Xxxxxxxxxx, 2. xxx., Kilbey, B. X., Xxxxxxx, X., Xxxxxxx, W., Xxxxx, X. (xxx.), Xxxxxxxx, Xxxxxxxxx-Xxx Xxxx-Xxxxxx, 141-161.
11) Xxxxxxxx, X. X., Xxxxxxx, P. J. (1981), Xx Xxxxxxxxxxx xx xxx Quantitative Xxxxxxxxxx Xxxxx xxx Xxxxxxxxxxx xxxx Xxxxxxx xx Xxxxxxxxxx xxxxxxxxxxx, Xxxxxxxxxxxxx Xxxxxxxxxxx, 3, 453-465.
12) Araki, X., Xxxxxxx, T., Xxxx, X., Xxxxxxxxxx, T. (1994), Xxxxxxxx Method xxx Mutagenicity Xxxxxxx xx Gaseous Xxxxxxxxx xx Using x Xxx Xxxxxxxx Xxx, Xxxxxxxxxx Res., 307, 335-344.
13) Prival, M. X., Xxxx, S. X., Xxxxxxxx, V. X., Xxxxxxx, X. X., Xxxxxxx, X. X. (1984), Xxxxxxxxxxxx xx Xxxxxxxxx xxx Xxxxxxxxx-Xxxxxxxx Xxxx and Xxxxxxxx Xxxxxxx Xxxx xx x Modified Xxxxxxxxxx Xxxxx, Mutatation Xxx., 136, 33-47.
14) Xxxxxx, E., Xxxxxxxx, X. X., Xxxxxxx, X., Xxxxxx, T., Xxxxxxxxxx, X. (1992), Xxxxxxxxxx Xxxxxxxxxxxx Xxxxx. X. Xxxxxxx xxxx xxx Xxxxxxx of 311 Chemicals, Xxxxxxx. Xxx. Mutagen., 19, 2-141.
15) Xxxxxx, X., Xxxxxxxx, K., Xxxxxxx, X. G. (1977), Xxxxxxxxx Xxxxxxxx xx Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxx Water, xx Xxxxxxxx xx Xxxxxxx Xxxxxxxxxx, X. Xxxxx, X. Bridges, X. Xxxxxx (xxx.) Xxxxxxxx, Xxxxxxxxx, 249-258.
16) Xxxxxx, X. X., Xxxxxxx, X. M., Xxxxxxxx, X. X., Xxxxxxx, X. X. (1987), Xxxxxxxxxxxx Technique to Xxxxxxx Xxxxxxxxx Xxxxxxxx xx Xxxxxxxx Xxxxxxx Xxxxxxxxx xx xxx Xxxx/Xxxxxxxxxx Xxxxx, Environmental Xxxxxxxxxxx, 9, 421-441.
17) Xxxxxxxxxx, X., Xxxxxxxxx, X., Xxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X. (1979), Mutagenicity xx xxx Naturally Xxxxxxxxx Xxxxxxxxxx Cycasin xxx Xxxxxxxxx Xxxxxxxxxxx Xxxxxxx Xxxxxxxxxx in Xxxxxxxxxx xxxxxxxxxxx, Xxxxxx Xxx., 39, 3780-3782.
18) Xxxxxx, X., Xxxx, X., Xxxxx-Xxxxx, A., Xxxx, X. N. (1980), Fecalase: A Xxxxx xxx Xxxxxxxxxx xx Xxxxxxx Glycosides xx Mutagens xx Xxxxxxxxxx Flora, Xxxx. Xxxx. Xxxx. Xxx. X. X. X, 77, 4961-4965.
19) Xxxxxx, X., Xxxxxx, A., Xxxx, X. X., Xxxxxxxxx, X. G. (1990), Xxxxxxxxxx xx Xxxxxxxxxx xxxxxxxxxxx XX 102 xxxx Xxxxxxxxxxx xxxx XX2 Xxxxxx xxxxxxx, Xxxxxxxxxxx, 5, 285-291.
20) Xxxxxxxxxx, T., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, X. (1976), X Safe Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. xx Xxxxxxx or Xxxxxxxxx Activation Xxxxxxx, xx: Xx xxxxx Xxxxxxxxx Xxxxxxxxxx in Xxxxxxxxxxx Xxxxxxx, xxx. X. X. xx Xxxxxx xx xx. Xxxxxxxx, North Holland, 85-88.
21) Elliot, X. X., Xxxxxx, X. X., Xxxxxxx, X. X., Gatehouse, X. X., Gibson, X. X., Xxxxxx, X. X., Xxxx, R. X. (1992), Xxxxxxxxxxxx xx Xxxxxxx 1254-xxxxxxx X9 xx xx xxxxx Genotoxicity Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
22) Xxxxx, D., Katzenellenbogen, X., Xxxx, B. X. (1981), Compatibility xx Organic Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx Xxxx, Mutatation Xxx., 88, 343-350.
23) Claxton, X. X., Xxxxx, X., Xxxxxxx, X., Xxxxxxxxxx, X., Xxxxxxxx, X., Xxxxxx, E. (1987), Guide xxx xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxx for Xxxxxxxxx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx., 189, 83-91.
24) Xxxxx, X. X. X., Xxxxx, M. X. X., Xxxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, X. D., Xxxxxx, D. X. (1989), Analysis of Xxxx xxxx Microbial Xxxxxx Xxxxxx, xx: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxx XX. Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, xx. Kirkland, X. X., Xxxxxxxxx Xxxxxxxxxx Xxxxx, 28-65."
XXXXXXX 4X
"X.17 MUTAGENITA — XXXXXXX XX XXXXXX XXXXXX X XXXXXXX XXXXX XX XXXXX
1. XXXXXX
Xxxx metoda xx xxxxxxxx xxxxxx XXXX XX 476 — Xxxxxxx xx xxxxxx xxxxxx x xxxxxxx savců xx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx xxxxxx mutace x xxxxxxx savců xx xxxxx xxx xxxxxx xxx detekci xxxxxxxx xxxxxx indukovaných xxxxxxxxxx látkami. Mezi xxxxxx xxxxxxx xxxxx xxxxx xxxxx lymfomu X5178X xxxx, buněčné xxxxx CHO, XXX-XX52 x X79 křečka xxxxxxxx x lymfoblastoidní xxxxx TK6 xxxxxxx (1). X xxxxxx xxxxxxxxx linií xxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxx xxx xxxxxxxxxxxxxx (XX) x xxxxxxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX) x xxxxxxxx xxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX). Xxxxxxx na xxxxxx XX, XXXX x XPRT xxxxxxxx xxxxx xxxxxxxx genetických xxxxxxxx. Xxxxxxxxxxx xxxxxx XX x XXXX xxxx xxxxxxx detekci xxxxxxxxxxx událostí (xxxx. xxxxxxxx xxxxxx), xxxxx xxxxx xxxxxxxxx x XXXX xxxxxx xx X chromozomech (2, 3, 4, 5, 6).
Xx xxxxxxx na xxxxxx xxxxxx x xxxxxxx xxxxx in xxxxx lze xxxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxx xxxx xxxxxxx xxxxx. Xxxxx xx xxxxxxxx xxxxx xxxxxxxxxx xxxxx x kultuře x xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
Xxxxxxx prováděné xx xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxx metabolické xxxxxxxx. Xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxx nemůže xxxxx xxxxxxxxx xxxxxxxx xx xxxx x xxxxx. Xx xxxxx se xxxxx xxxxxxxxx xxxxxxxx, xxxxx xx xxxxx x pozitivním xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx. X xxxxxxxxxx xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx, xxxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx xxxxxxxx xxxxxx xxxxxxxxxxxx (7).
Tato xxxxxxx xx xxxxxxx xx zjištění xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxx. Xxxxx xxxxxxxxx, xxx xxx xx xxxx xxxxxxx pozitivní, xxxx xxxxxxxxxxx xxxxx; xxxx xxxxx xxxxxxxx x karcinogenitou však xxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxxxxx na xxxxxxxx xxxxx a xxxxxxxxx xxxxxx o xxx, že xxxxxxxx xxxxxxxxxxx, xxxxx nejsou xxxxxxxx touto xxxxxxxx, xxxxx zřejmě působí xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx xxxxxxxxxx, které x xxxxxxxxxxxxx xxxxxxx xxxxxxxxxx (6).
Xxx také xxxxxx xxxx, část X.
1.2 XXXXXXXX
Xxxxx xxxxxx : xxxxxx xxxxxx xxxxxxxxx typu xxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxxx ztrátu xxxxxxxxxxx aktivity xxxxxxxxxx xxxxxxxx.
Xxxxxxxx substituce xxxx xxxx : látky, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxx xxxx xxxx x XXX.
Xxxxxxxx xxxxxxxx : xxxxx, xxxxx xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxx xxxx více xxxx xxxx x xxxxxxxx XXX.
Xxxx xxxxxxx xxxxxxxx : xxxx, xxxxx xxx vymizí x nově xxxxxxxxxx xxxxx xxxxxxxxx genové xxxxxxxx.
Xxxxxxx xxxxxxx : xxxxx pozorovaných xxxxxxxxxx xxxxx xxxxxx počtem xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxx xxxx : xxxxxx xxxxx xxxxx v xxxx ve xxxxxxxx x xxxxxxxxx xxxxxxxx xxxxx; xxxxxxx xx xxxx xxxxxx poměru xxxxxxxxx xxxxx x xxxxxxxx x x xxxxxxxxx xxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx x negativní xxxxxxxx.
Xxxxxxxxx xxxx x xxxxxxxx : xxxxxx xxxxx buněk x xxxxxxx xxxxxxx vzhledem x xxxxxxxxx kontrole.
Životaschopnost : xxxxxxxx xxxxxxxxx xxxxx x okamžiku xxxxxxxx na xxxxx xx xxxxxxxxxxxx xxxxxxxx xx xxxxxxx.
Xxxxxxx : xxxxxxxx klonování buněk xxx xxxxxxxx xx xxxxx xx xxxxx xxxxxx expozice; xxxxxxx xx obvykle xxxxxxxxx x poměru x xxxxxxx xxxxxxxxx populace xxxxx.
1.3 PODSTATA XXXXXXXX XXXXXX
Xxxxx, xxxxx x xxxxxxxx xxxxxx XX+/-® XX— /- xxxxxxxxxx xxxxxxxxxxxxxx (XX) jsou xxxxxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxx (XXX). Xxxxx xxxxxxxxxxx thymidinkinasu xxxx xxxxxxx xx XXX, xxx xxxxxxxxx xxxxxxxx xxxxxxxxx metabolismu x xxxxxxxxx xxxxx buněčné xxxxxx. Xxxxxxxx xxxxx xxxx tedy schopny xxxxxxxxxxx xx přítomnosti XXX, zatímco xxxxxxxx xxxxx, které xxxxxxxx xxxxxxxxxxxxxx tuto xxxxxxxxx xxxxxx. Xxxxxxx lze x xxxxx s xxxxxxxxxxxx XXXX xxxx XXXX xxxxxxx xxxxxxx xxxxxxxxxxxxxxx rezistence k 6-xxxxxxxxxxx (XX) xxxx 8-xxxxxxxxxx (XX). Xxxxxxxxxx xxxxxxxx látky by xxxx xxx pečlivě xxxxxxx, xxxxxxxx xx xx xxxxxxx xx xxxxxx xxxxxx x xxxxxxx xxxxx zkoušen xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx. Mělo by xxx například xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxxxxx xxxxxxxx zkoušené xxxxx pro xxxxxxxx xxxx xxxxxxxxxx xxxxx. Xxx zkoušení xxxxxxxxxx xxxxx, xxxxx mají xxxxxxxx xxxxxxxxx jako xxxxxxxx činidlo, xxxx xxxx být xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxx xxx xxxxxxx (8).
Xxxxx x xxxxxxxxx xxxx xxxxxxxxxxxxx kultuře xxxx xxxxxxx xxxx xxxxxxxxx zkoušené xxxxx xxx x xxxxxxxxxxxx xxxxxxxx, xxx bez xx, x xxxxxxxxxxxxxx xx xxxxxx xxxxxxxxx xxxxxxxxxxxx a za xxxxxx exprese xxxxxxxx xxxx xxxxxxx xxxxxxx (9, 10, 11, 12, 13). Xxxxxxxxxxxx xx obvykle zjistí xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxx relativního xxxxxxxxx xxxxx xxxxxx xx xxxxxxxx xxxx xxxxxxxx. Xxxxxxxxxx xxxxxxx se xxxxxxx v xxxxxxxx xxxxx xx vhodnou xxxx charakteristickou xxx xxxxx xxxxxxx lokus x xxx xxxxx, xxx xxxxxxx přibližně xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx mutací. Četnost xxxxxxx xx xxxxxxx xxx, xx xx xxxxxx xxxxx xxxxx xxxxx xx média xxxxxxxxxxxx xxxxxxxx činidlo xxx detekci xxxxxxxxxx xxxxx a do xxxxx xxx xxxxxxxxxx xxxxxxx, aby xxxx xxxxxxxxx účinnost xxxxxxxxx (xxxxxxxxxxxxxxx). Po vhodné xxxxxxxxx xxxx xx xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxx xx vypočte x počtu xxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxx a počtu xxxxxxx v médiu xxx xxxxxxxxxx xxxxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxx xxxxxxx x xxxx xxxxxxx xxxx x xxxxxxxxx xxxxx xxxx xxxxx, xxxxxx xxxxxxxx buněk X5171X, XXX, XXX-XX52, X79 xxxx XX6. Xxxx xxxxx v xxxx zkoušce xx xxxx vykazovat xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx frekvenci xxxxxxxxxxx xxxxxx. Xxxxx xx xxxx xxx xxxxxxxxxxxx, xxx xxxxxx xxxxxxxxxxxxx mykoplasmaty, a x případě xxxxxxxxxxx xx xxxxxx xxx xxxxxxx.
Xxxxxxx xx xxxx xxx xxxxxxxx tak, xxx měly xxxxxx xxxxxxxxxx xxxxxxxxx x xxxx. Počet xxxxxxxxx xxxxx, xxxxxx x xxxxxxxxxxx zkoušené látky xx xxx xxxx xxxxxxxxxx parametry xxxxxxx (14). Minimální xxxxx xxxxx, xxxxx xxxxxxx xxxxxxxx a které xxxxx použity x xxxxxx xxxxxx xxxxxxx, xx xxx xxx xxxxxxx na xxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxxx xx, aby xxx xxxxxx počet xxxxx, xxxxx xx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx. Xx však xxxxxxxxxx, xxx bylo xxxxxxx xxxxxxx 106 buněk. Xxxx xx být x xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx systému, xxx byla doložena xxxxxxxxxxxx výpovědní hodnota xxxxxxx.
1.4.1.2 Xxxxx a xxxxxxxxxx podmínky
Pro udržování xxxxxx xx xxxx xxx použita xxxxxx xxxxxxxxxx média x xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx XX2, xxxxxxx x xxxxxxx). Xxxxx xx xxxx xxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxx x xxxx buněk xxxxxxxxx xxx zkoušce. Je xxxxxxx xxxxxxxx, xxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxx tak, aby xxxx xxxxxxxxx optimální xxxx xxxxx během xxxxxx xxxxxxx x xxxxxxxxx jak xxxxxxxxxx, xxx xxxxxxxxxxxx xxxxx xxxxxx xxxxxxx.
1.4.1.3 Příprava xxxxxx
Xxxxx xx měly xxx získávány z xxxxxxxxx xxxxxx, xxxxxxxx xx kultivačního xxxxx x xxxxxxxxxx při 37 °X. Před xxxxxxxx v xxxx xxxxxxx může xxx xxxxxxxx xxxxxxxxx x xxxxxxx xxx přítomné xxxxxxxx buňky.
1.4.1.4 Metabolická xxxxxxxx
Xxxxx by xxxx xxx vystaveny xxxxxxxx xxxxx, x to x vhodným xxxxxxxx xxxxxxxxxxx aktivace a xxx xxxx. Nejčastěji xxxxxxxxxx systémem je xxxxxxxxxx dotovaná xxxxxxxxxxxxxxxxxxx xxxxxx (X9) xxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx, xxxx je Xxxxxxx 1254 (15, 16, 17 a 18), xxxx xxxx xxxxxxxxxxxxx a β-xxxxxxxxxxxx (19, 20).
Postmitochondriální frakce xx x konečném xxxxxxxxxx médiu obvykle xxxxxxxxx x xxxxxxxxxxxxx 1 — 10 % obj. Volba x xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxx na xxxxx xxxxxxxx xxxxx, xxxxx xx xxxxxxxx. V xxxxxxxxx xxxxxxxxx xxxx xxx vhodné xxxxxx xxxx xxx xxxxx xxxxxxxxxxx postmitochondriální xxxxxx.
Xxxx xxxxxxxx xxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxxx exprimujících xxxxxxxxxx aktivační xxxxxx, xxxxxxxxx možnosti pro xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxx buněčných linií xx xxxx xxx xxxxxxx xxxxxxxxxx (např. xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx X450 pro xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Xxxxxxxx xxxxxxxx látky
Pevné xxxxxxxx xxxxx xx xxxx xxx xxxx aplikací xx xxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx a popřípadě xxxxxxx. Kapalné zkoušené xxxxx xxxxx být xxxxxxx přímo x xxxxxxxxxx systémům a/nebo xxxxx xxx xxxx xxxxxxxx zředěny. Xxxx xx být použity xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx xxxxxxx skladování.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx být xxxx podezření, že xxxxxxx xx xxxxxxxxx xxxxxx, x xxxx xx být xxxxxxxxxx x xxxxxxxx xxxxx x s aktivitou X9. Xxxx-xx xxxxxxx xxxx než xxxxx xxxxxxxxxxxx/xxxxxxxx, mělo by xxx xxxxxx zařazení xxxxxxxxx údaji x xxxxxx xxxxxxxxxxxxx. Doporučuje xx pokud možno xxxxxxxx xxxxxx použití xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx xx vodě xx xxxx xxx xxxxxxx xxxxxxxxx rozpouštědla neobsahující xxxx. Xxxx lze xxxxxxxxx xxxxxxxx molekulového xxxx.
1.4.2.2 Xxxxxxxxx koncentrace
Mezi xxxxxxxx, xxxxx mají xxx xxxxxxxxxx xxx xxxxxxxxx nejvyšší xxxxxxxxxxx, xxxxx cytotoxicita, rozpustnost x xxxxxxxxxx systému x změny xX xxxx osmolality.
Cytotoxicita xx xxxx xxx stanovena x metabolickou xxxxxxxx x bez ní x hlavním xxxxxxxxxxx xx použití xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx x xxxxx, xxxx xxxx relativní účinnost xxxxxxxxx (přežití) xxxx xxxxxxxxx xxxxxxx xxxx. Xxxx xxx výhodné xxxxxxxx cytotoxicitu x xxxxxxxxxxx v xxxxxxxxxx xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxx koncentrace. X xxxxxxx xxxxxxxx by xxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx x minimální xxxxxxxxx, xxxxxxxx žádnou xxxxxxxxx, což bude xxxxxxx xxxxxxxx, že xx xx koncentrace xxxx xxxxx xxxxxxxx 2 xx Ö10. Xx-xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xx cytotoxicity, xxxx xx xxx xxxxxxxxx xxxxxxxxx 10 — 20 % (xxx xxxxxxx 10 %) xxxxxxx (relativní xxxxxxxx xxxxxxxxx) nebo xxxxxxxxx celkový xxxx. X xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx xxxxx by xxxx být xxxxxxxxx xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 xx/xx xxxx 0,01 M, xxxxx xxxx, xxxxx x xxxx xx xxxxxxxx.
Xxxxxxxxx nerozpustné látky xx xxxx xxx xxxxxxxx xx k xxxx rozpustnosti xx xxxxxxxxxxxx podmínek, xxxx xx xx xxxx xxx. Xxxx by xxx stanovena případná xxxxxxxxxxxxx x konečném xxxxx, xx kterému xxxx buňky xxxxxxxxxx. Xxxx xxx výhodné xxxxxxxx rozpustnost na xxxxxxx a xx xxxxx aplikace, xxxxx xxxxxxxxxxx xx může x průběhu xxxxxxxx x xxxxxxxxxx xxxxxxx xxxxx x důsledku xxxxxxxxxxx xxxxx, S9 xxxx, xxx. Nerozpustnost xxx zjistit vizuálně. Xxxxxxxxx by neměla xxxxx při xxxxxxxxxxx.
1.4.2.3 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx být xxxxxxxxx a negativní (xxxxxxxxxxxx xxxx vehikulum) xxxxxxxx xxx s xxxxxxxxxxxx xxxxxxxx, xxx xxx xx. Xxx xxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx, která x xxxxxxxxx xxxxxxxx vyžaduje xxxxxxxx.
Xxxxxxxxx xxxxxxxxx kontroly xxxxx xxx xxxx xxxxx:
|
Xxxx metabolické aktivace |
Lokus |
Látka |
Číslo XXX |
Xxxxx xxxxx Xxxxxx |
|
Xxx xxxxxx metabolické xxxxxxxx |
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
XX (xxxx x velké xxxxxxx) |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
|
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
X xxxxxx metabolickou xxxxxxxx |
XXXX |
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–4 |
|
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–549–8 |
||
|
7,12-xxxxxxxxxxxxxxxxxxxxxx |
57–97–6 |
200–359–5 |
||
|
XX (xxxx x xxxxx xxxxxxx) |
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|||
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
||
|
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–5 |
||
|
XXXX |
X-xxxxxxxxxxxxxxxxxxx (xxx xxxxxx xxxxxx X9) |
62–75–9 |
200–549–8 |
|
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
Xxxxx xxx použity xxxx jiné referenční xxxxx xxx xxxxxxxxx xxxxxxxx, xxxx. má-li xxxxxxxxx xxxxxxxx dosavadních xxxxx x 5-xxxx-2′-xxxxxxxxxxxx (XXX 59–14–3, XXXXXX 200–415–9), může xxx xxxx xxxxxxxxxx xxxxx xxxxxx xxxxxxx. Pro xxxxxxxxx xxxxxxxx xx xxxx být xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx pokud xxxxx ze xxxxxx xxxxxxxx xxxxx.
Xxxx by xxx xxxxxxx negativní xxxxxxxx xxxxxxx médiem xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxx xxxxx xxxxxxx xxxxxxxx jako xxxxxxxxxx xxxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx tehdy, xxxxxxxxxx-xx xxxxx kontrolní xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx nevyvolává žádné xxxxxxx nebo xxxxxxxxx xxxxxx.
1.4.3 Postup
1.4.3.1 Xxxxxxxx xxxxxxxx látce
Proliferující xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxx xxx za xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxx bez xxxx. Xxxxxxxx by xxxx xxxxx vhodnou xxxx (xxxxxxx je xxxxxx xxxx 3 až 6 xxxxx). Xxxxxxxxx xxxx xxxx být xxxxxxxxxxx xx jeden xxxx více xxxxxxxxx xxxxx.
Xxx xxxxxx zkušební xxxxxxxxxxx xxxxx být xxxxxxx duplicitní xxxxxxx xxxx xxxxx xxxxxxxxxx xxxxxxx. Xx-xx použita xxxxx xxxxxxx, xxx xx xxx xxxxx xxxxxxxxxxx xxxxxx tak, xxx xxx zajištěn xxxxxxxxxxxx počet xxxxxx xxx xxxxxxx (např. xxxxxxx osm xxxxxxxxxxxxxxxx xxxxxxxxxxx). Xxxx by xxx použity xxxxxxxxxx xxxxxxxxx xxxxxxxxx kultury (xxxxxxxx xxxxxxxxxxxx).
Xxxxxx nebo xxxxxx látky xx xxxx být xxxxxxxx xxxxxxxx xxxxxxxx, xxxx. x xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (21, 22).
1.4.3.2 Xxxxxxxxx přežití, xxxxxxxxxxxxxxxx a xxxxxxxx xxxxxx
Xx xxxxx expoziční xxxx se xxxxx xxxxxxx x kultivují xx xxxxxx stanovení xxxxxxx a za xxxxxx xxxxxxxx xxxxxxx xxxxxxxx mutantu. Xx xxxxxxxxxx cytotoxicity prostřednictvím xxxxxxxxx relativní účinnosti xxxxxxxxx (xxxxxxx) nebo xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxx xx xxxxxxx xxxxxxx xx xxxxxxxxx xxxx.
Xxxxx lokus xx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx, xxx umožnil xxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx nově xxxxxxxxxxxx xxxxxxx (HPRT x XXXX xxxxxxxx xxxxxxx 6 xx 8 xxx, TK alespoň xxx dny). Xxxxx xxxx xxxxxxxxxxx x xxxxx se selekčním xxxxxxxx (xxxxxxxxxx xxxxxxx) x bez xxxx (xxx xxxx) xx xxxxxx xxxxxxxxx počtu xxxxxxx a xxxxxxxxx xxxxxxxxx. Se stanovením xxxxxxxxxxxxxxxx (xxxxxxx xxx xxxxxxx četnosti xxxxxxx) xx započne xx xxxxx xxxx xxxxxxx xxxxxxxxx xx misku xxx xxxxxxxxxx činidla.
Je-li xxxxxxxx xxxxx pozitivní xx xxxxxxx X5178X XX+/-, xxxx xx xxx xxxxxxxxx xxxxxxx xx jedné xx xxxxxxxxxx kultur (x xxxxxxxx xxxxxxxxx xxxxxxxxxxx) x na negativních x xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx kultury podle xxxxxxxxx xxxxxxx. Xx-xx xxxxxxxx xxxxx xx xxxxxxx L5178Y XX+/- xxxxxxxxx, xxxx xx xxx rozdělení xxxxxxx xxxxx xxxxxxxxx xxxxxxx xxxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx. Xxx studiích za xxxxxxx XX6 XX+/- xxxx xxx také xxxxxxxxx xxxxxxxxx kultury xxxxx velikosti kolonií.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje xx měly zahrnovat xxxxxxxxx cytotoxicity x xxxxxxxxxxxxxxxx, xxxxx xxxxxxx x xxxxxxxx xxxxxxx xxx exponované x xxxxxxxxx kultury. X xxxxxxx xxxxxxxxx odpovědi xx zkoušku X5178X XX+/- xx xxxxxxx xxxxxxxxx xxxxxxx x xxxxx xxxxxxxxxxx xxxxxxxx xxxxx (xxxxxxxx xxxxxxxxx xxxxxxxxxxx) x x xxxxxxxxx x pozitivní xxxxxxxx xx xxxxxxx xxxxxxxx xxxx xxxxxxx — xxxxx xxxxxxx. Xxxxxxxxxxx x cytogenetická xxxxxx xxx xxxxxxx xxxxxxxxx velké kolonie, xxx xxxxxxx xxxxxxxxx xxxx kolonie byla xxxxxxxx xxxxxxxx (23, 24). Xx xxxxxxx XX+/- jsou xxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxxxx kolonie s xxxxxxxxx růstem (xxxxx) x kolonie x xxxxxxx xxxxxx (xxxx) (25). U xxxxxxxxxx xxxxx, které xxxxxxx xxxxxxxxxxxxxx genetické poškození, xx xxxxxxxxxxx doby xxxxxxxx, x tvoří xxxx malé xxxxxxx. Xxxxxxxxx má xxxxxxx xxxxxx xx ztrát xxxxxx xxxx až xx karyotypické viditelné xxxxxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxx xxxxxxxxx xxxx xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxxxxx, xxxxx indukují xxxxx xxxxxxxxxxxx xxxxxxx (26). Xxxx závažně postižené xxxxx mutantů rostou xxxxxxxx xxxxxx xxxx xxxxxxxx xxxxx a xxxxx xxxxx xxxxxxx.
Xxxx xx xxx udáno xxxxxxx (xxxxxxxxx xxxxxxxx xxxxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. Xxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxx xxxx xxxxx mutantů x xxxxx xxxxxxxxxx xxxxx.
Xxxx xx xxx uvedeny xxxxx xxx xxxxxxxxxx xxxxxxx. Dále xx xxxx být xxxxxxx xxxxx xxxxxxx xx xxxxx xxxxxxx.
Xxxxxxx xxxxx xxxxxxxxx odpovědi xx xxxxxxxxxx. Dvojznačné xxxxxxxx xx měly xxx xxxxxxxxx dalším zkoušením, xxxxxxx s xxxxxxx xxxxxxxxxxxxxxxx podmínek. Negativní xxxxxxxx xxxx být xxxxxxxxx xxxxxx xx xxxxxxx. Xxx, kde xxxx potvrzení xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxx, xx xxxxx xxxxx xxxxxxxxxx. Xxxxx xxxxxxxxx xxxxxx s xxxxx rozšířit xxxxxx xxxxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx x xxxxxxxxxx experimentech xxx pro dvojznačné xxxxxxxx, xxx pro xxxxxxxxx xxxxxxxx. K xxxxxxxxxx xxxxxx, xxxxx xx xxxxx xxx xxxxxxx, patří rozmezí xxxxxxxxxxx x podmínky xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX X INTERPRETACE XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx kritérií, xxxx. nárůst xxxxxxxx xxxxxxx v xxxxxxxxxx xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxx xxxxxxxx. Nejdříve xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxxxxxx významnost xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxx.
Xxxxxxxx látka, xxxxx výsledky xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx x xxxxx xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx experimentů xxxxxxxx jasně xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx údajů xxxxxxxx xxxxxxx xxxxx x aktivitě xxxxxxxx xxxxx. Výsledky xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx ohledu xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx na xxxxxx xxxxxx v xxxxxxx savců xx xxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxxxxx kultivovaných xxxxxxx savců xxxxxx xxxxxx. Reprodukovatelná pozitivní xxxxxxxxx xxxxxxxx na xxxxxxxxxxx xx xxxxx xxxxxxxx. Xxxxxxxxx výsledky xxxxxxxxx, xx xxxxxxxx xxxxx za podmínek xxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxxx buňkách xxxxx genové mutace.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx volby rozpouštědla/vehikula,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxx x xxxxx xxxxx,
- xxxxx xxxxxxxxx xxxxxx,
- případně xxxxx xxxxxx,
- xxxxxxxx xxxxxx xxxxxxxxx buněčné xxxxxxx,
- xxxxxxxxxxxx mykoplasmat.
Zkušební xxxxxxxx:
- xxxxxxxxxx výběru xxxxxxxxxxx x počtu xxxxxx, xxxxxx xxxx. xxxxx x xxxxxxxxxxxx x xxxxxx xxxxxxxxxxxx, jsou-li x xxxxxxxxx,
- xxxxxxx xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx xxxxxxxx x xxxxxxx xxxxxxxx xxxxx,
- inkubační teplota,
- xxxxxxxxx doba,
- délka xxxxxxxx,
- xxxxxxxx hustota xxxxx xxxxx xxxxxxxx,
- xxx a xxxxxxx xxxxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx x xxxxxxxxx kontroly,
- délka xxxx exprese (případně xxxxxx xxxxx xxxxxxxxxx xxxxx, xxxxxxxxx x xxxxxx xxxxx),
- xxxxxxxx xxxxxxx,
- kritéria klasifikace xxxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx,
- xxxxxx xxxxxxx k xxxxxxxx životaschopných a xxxxxxxxxx xxxxx,
- definice xxxxxxx podle xxxxxxxxx x xxxx (xxxxxxxx xxxxxx xxxxxxxx pro "xxxx" x "velké" xxxxxxx).
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx srážení,
- údaje x pH x xxxxxxxxxx během xxxxxxxx xxxxxxxx látce, xxxxx xxxx xxxxxxxxx,
- xxxxxxxx xxxxxxx, xxxx-xx xxxxxxxxxxx, xxxxxxx pro negativní x xxxxxxxxx kontroly,
- xxxxxxxxx předpoklady xxxxxxxxxx xxxxxxxxx xxxxxxx tvořící xxxx kolonie systémem X5178X XX+/-,
- podle xxxxxxxx závislost xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- údaje x xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx údaje x negativní (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxx mutantů.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X., XxXxxxxx, X. M., XxXxxxxx, X. J., Xxxxxx, X. R. (eds.) (1987), Banbury Report 28; Xxxxxxxxx Xxxx Xxxxxxxxxxx, Xxxx Xxxxxx Xxxxxx Xxxxxxxxxx, Xxx Xxxx.
2) Xxx, E. X. Y., Xxxxxxx X. X. (1968), Xxxxxxxxx Cell Genetics. XX. Xxxxxxxx Induction xx Xxxxxxxx Locus Xxxxxxxxx xx Chinese Xxxxxxx Xxxxx Xx xxxxx, Xxxx. Xxxx. Xxxx. Xxx. U. X. X, 61, 1306-1312.
3) Xxxxx, X. X., Thilly, X. X. (1982), Xxxxxxxx Xxxxx xx xxx Xxxxxxxxx Xxxxxx Locus xx Xxxxxxx Xxxxx Xxxxxxxxxxxx, Xxxxxxxx Res. 94, 467-485.
4) Moore, X. X., Xxxxxxxxx-Xxxxx, X., Xxxxx, X. X., Xxxxxxxxx, X. X. (1989), Differential Xxxxxx Xxxxxxxxxxxx at xxx Mouse Xxxxxxxx XX and XXX XXXXX Loci, Xxxxxxxxxxx, 4, 394-403.
5) Xxxxx, X. X., Stankowski, Xx. X. F., (1989), Xxxxxxxxxx xx xxx AS52/XPRT xxx xxx XXX/XXXX Xxxxxx: Xxxxxxxxxx xx Xxx Xxxx Candidates, Mutatation Xxx. 223, 121-128.
6) Xxxxx, X. S., Xxxxxxxxxx, X., Xxxxx, X. R., Xxxxx, X., Xxxxx, X., Xxxxxxxxxx, Xx. X. X., Theiss, X., Xxxxxxxx, X. (1994), Xxxxxxxxx Xxxx Gene Xxxxxxxx Assays Working Xxxxx Xxxxxx. Xxxxxx xx xxx Xxxxxxxxxxxxx Xxxxxxxx xx Standardisation xx Xxxxxxxxxxxx Xxxx Xxxxxxxxxx. Mutation Res. 312, 235-239.
7) Xxxxx, X., Xxxxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxxx, M., Xxxxxxx, D., Xxxxx, X., Xxxx, B. X. (1991), Xxxxxxxxxxxx Xxxxx Extreme Xxxxxxx Xxxxxxxxxx. X xxxxxx xxxx XXXXXX Xxxx Xxxxx 9, Mutation Xxx. 257, 147-204.
8) Xxxxx, X., XxXxxx, X., Xxxxxxx, J. X. X., Piper, X., Xxxxxxxxx, K. X. (1983), Xxxxxxxx Xxxx Xxxxxxxxx xx X5178X Xxxxx xx Xxxxxxx. X Xxxxxx xx xxx U. X. Environmental Protection Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 115, 225-251.
9) Li, A. X., Gupta, X. X., Xxxxxxx, X. X., Xxxxxx, X. X. (1988), X Xxxxxx and Xxxxxxxx xx the Xxxxxxx Xxxxxxx Ovary/Hypoxanthine Xxxxxxx Xxxxxxxxxxxxxx Transferase Xxxxxx xx Determine xxx Xxxxxxxxxxxx xx Chemical Xxxxxx: A Report xx Phase XXX xx xxx X. X. Xxxxxxxxxxxxx Protections Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 196, 17-36.
10) Xx, X. X., Xxxxxx, X. X., Choy, X. X., Hsie, X. X., Gupta, X. X., Xxxxxxx, X. X., X'Νxxxx, X. X., Riddle, X. X., Xxxxxxxxxx, L. X. Xx., Yang, X. X. (1987), X Xxxxx for xxx Xxxxxxxxxxx of xxx Xxxxxxx Hamster Xxxxx Xxxx/Xxxxxxxxxxxx-Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxx Mutation Xxxxx, Xxxxxxxxxx Xxx., 189, 135-141.
11) Xxxxx, X. X., Xxxxxxx, X. W., Xxxxxx, X. X. (1989), X Comparison xx Xxxxxxxx Xxxxxxxxx xx xxx XX xxx XXXX Xxxx xx Xxxxx Lymphoblastoid Xxxxx: Xxxxxxxxxxxx Xxxxxxxxxxx xxx Xxx xx xx Xxxxxxxxxx Class xx Xxxxxxxxx at xxx Xxxxxxxxx TK Locus, Xxxxxxxxxx Res., 216, 9-17.
12) Xxxxxxxxxx, X. X. Jr., Tindal, X. X., Xxxx, X. W. (1986), Xxxxxxxxxxxx xxx Xxxxxxxxx Xxxxxxxx xx Xxxxx Xxxxxxxxxxxxxxxxx and ICR 191-Xxxxxxx Xxxxxxxxx Analyses xx Xxxxx Xxxxxxxxxxxxxxxxx xxx XXX 191 Xxxxxxx Xxxxxxxx xx XX52 Xxxxx, Xxxxxxxxxx Xxx., 160, 133-147.
13) Xxxxxx, X. X., Xxxxxx, X. X., Xxxxx, D. (1984), Xxxxxxxxx xxx xxx X5178X/XX+/--XX+/- Xxxxx Lymphoma Xxxx Xxxxxxxxxxxx Xxxxx, xx: Xxxxxx, B. X. et xx (xxx.) Handbook of Xxxxxxxxxxxx Xxxx Procedures, Xxxxxxxx Xxxxxxx Xxxxxxxxxx, Xxx Xxxx, 239-268.
14) Xxxxxx, X. F., Xxxxx, X. X., Xxxxxx, G. M., Xxxxx, M. X. X., Xxxx, J., XxXxxxxx, X. B., Xxxxxxx X. X. (1989), Xxxxxxxxx Cell Xxxx Xxxxxxxx Xxxxxx Xxxxx xxxx Xxxxxx Xxxxxxxxx, xx: Statistical Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, Xxxxxxxx, X. J., xx., Xxxxxxxxx Xxxxxxxxxx Xxxxx, 66-101.
15) Xxxxxxxxxxxx, X., Xxxxxxx, S., Corti, X., Xxxxxx, X., Xxxxxxxx, X., Xxxxxxxxxx, X. (1977), Xxxxxxxxx xx 6-Xxxxxxxxxxx-Xxxxxxxxx Xxxxxxx xx X79 Xxxxxxx Xxxxxxx Xxxxx by Xxxxx-Xxxxx Xxxxxxxxx-Xxxxxxxxx Dimethylnitrosamine, Xxxxxxxxxx Xxx. 46, 365-373.
16) Xxxx, X. X., XxXxxx, X., Xxxxxxxx, X. (1975), Xxxxxxx xxx Xxxxxxxxx Xxxxxxxxxxx and Xxxxxxxx xxxx the Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Test, Xxxxxxxxxx Xxx. 31, 347-364.
17) Xxxxx, D., Johnson, X. X., Xxxxxxx, X. X. S., Xxxxxx X. X., Xxxxx X. X. X. (1979), Xxxxxxxxxx xxx Xxxxxxxxxxxxxxxx of xxx L5178Y/TK+/--Mouse Lymphoma Xxxxxxx Assay System, Xxxxx. Xxx. 59, 61-108.
18) Xxxxx, X. X., Xxxx, X. X. (1983), Xxxxxxx Xxxxxxx xxx the Xxxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Xxx. 113, 173-215.
19) Xxxxxxx, X. X., Combes, X. X., Xxxxxxx, X. X., Xxxxxxxxx, D. X., Xxxxxx, G. X., Mackay, X. X., Wolf, X. X. (1992), Alternatives xx Xxxxxxx 1254-Induced X9 xx: Xx xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx 7, 175-177.
20) Xxxxxxxxxx, X., Sawamura, X., Xxxx, X., Xxxxxxxx, T. (1976), X Safe Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. s. an Xxxxxxx xx Metabolic Xxxxxxxxxx Xxxxxxx, X: Xx xxxxx Xxxxxxxxx Xxxxxxxxxx in Mutagenesis Xxxxxxx, de Xxxxxx, X. J., Xxxxx, X. R., Bend, X. X., Philpot, X. X. (xxx), Xxxxxxxx, North-Holland, 85-88.
21) Xxxxx, X. X., Xxxxxx, X. X., XxXxxxx, X. T. (1982), XXX/XXXXX Xxxxxxxx Xxxxx: Xxxxxxxxxx xx Xxxxx xxx Xxxxxxxx Xxxxxxx, in: Ticc, X. R., Xxxxx, X. L., Xxxxxxx, X. X. (xxx), Xxxxxxxxx Xxxxxxx xx Xxxxxxxx Xxxxxx, Xxx Xxxx, Xxxxxx, 91-103.
22) Xxxxxx, P. O., Xxxxxx, J. X., Xx, A. X., Xxxxxx, X. X. (1983), Evaluation xx xx Xxxxxxxx Xxxxxx Xxxxx Xxxxx Xxxxx xx Xxxxxxxx Xxxx xxx Xxxxxxxxx Xxxxxx Xxxxxxxx Xxxxxxxx xx xxx XXX/XXXXX Xxxxxxxx Xxxxx, Xxxxxxx. Mutagenesis, 5, 795-801.
23) Applegate, X. X., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxxx, X., Xxxxxx, X. X. (1990), Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxx xx xxx Heterozygous Xxxxxxxxx Kinase Xxxxx xx Xxxxx Lymphoma Xxxxx, Xxxx. Xxxx. Xxxx. Xxx. U. X. X, 87, 51-55.
24) Xxxxx, X. X., Clive, D., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. G., Xxxxxx, N. T., Xxxxxx, X. (1985), Xxxxxxxx xx Xxxxxxxxxxxxxxxxxx, Xxxxxxxxx (XXX+) Mutants xx X5178X/XX+/--Xxxxx Xxxxxxxx Xxxxx, Xxxxxxxxxx Res. 151, 161-174.
25) Yandell, X. W., Xxxxx, X. X., Xxxxxx, X. X. (1990), Xxxxxxxxx Xxxxxxx Xxxxxxxx xx Xxxxxxxxx Xxxxxxxxx xx a Xxxxxxxxxxxx Xxxxxxxxx Xxxxx in Xxxxx Xxxxx, Mutatation Xxx. 229, 89-102.
26) Xxxxx, M. X., Xxxxx, C. L. (1990), Comparison xx Xxxxxxxxxx Xxxxxxxxxx Frequency xxx Xxxxx Xxxxxx XX-Xxxxxxxxx Xxxxxx Xxxxxxxxx xx X5178X/XX+/- 3.7.2X Xxxxx Xxxxxxxx Cells, Xxxxxxxxxxx, 5, 609-614."
XXXXXXX 4X
"X.23 XXXXXXX XX XXXXXXXXXXXX ABERACE XX XXXXXXXXXXXXXXX SAVCŮ
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx metody XXXX XX 483 — Xxxxxxx na chromozomové xxxxxxx xx xxxxxxxxxxxxxxx xxxxx (1997).
1.1 XXXX
Xxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx xx xxxx xx identifikovat xxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx savců (1, 2, 3, 4, 5). Rozlišují xx xxx typy xxxxxxxxxxxx aberací: chromozomové x chromatidové. X xxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx xxxxxxx se xxxxxx vyskytují. Xxxx xxxxxx xxxx xxxxxx xx stanovení numerických xxxxxxx x xxxx x tomuto xxxxx xxxxxxx xxxxxxxxx. Chromozomové xxxxxx a xxxxxxx xxxx xxxx xxxxxxxx xxxxx geneticky podmíněných xxxxxx u xxxxxxx.
Xxxxx xxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxx ve xxxxxxxxxxxxxxx x předpokládá xx tedy, xx xxxx xxxxxxx poskytne xxxxxxxxx xxxxxxx dědičných xxxxxx v germinálních xxxxxxx.
X této xxxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxxxx xx xxxx xx xxxxxxxx xxxxxxxxxxxx xxxxxxx při xxxxxx xxxxxxxxxxxxx. Xxxx xxxxxx xxxxx xxxxxx předmětem xxxx zkoušky.
Pro xxxxxxx xxxxxxx chromatidového xxxx xx spermatogoniích xx xxxx xxx — xxxxx než dojde xx xxxxxx léze — xxxxxxxxx xxxxx xxxxxxxxx xxxxxxx xxxxxx, xxxxx následuje xx xxxxxxxx. Xxxxx informace x xxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx x xxxxxxxxx-xxxxxxxx X, kdy se xxxxxxxxxx buňky xxxxxxx xxxxxxxxxxxx.
Xxxx xxxxxxx xx xxxx xx navržena xxx xxxxxxxxx, xxx xxxx xxxxxxxx somatických xxxxx xxxxxxx také x xxxxxxxxxxxx xxxxxxx. Xxxxx je tato xxxxxxx xx spermatogoniemi xxxxxxxx xxx posouzení xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxx faktory xxxxxxxxxxx xx xxxx, xxxxxxxxxxxxxxx x xxxxxxx xxxxxxxx XXX.
Xx varlatech xx přítomna řada xxxxxxxx spermatogonií x xxxxxx xxxxxxxxxx na xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxxxx aberace xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x xxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx. V závislosti xx xxx xxxxxx xx xxxxxxxxx, xxxxx xxxx xxxxxx být xxxxx generace xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx Xxxxxxxxx xxxxx x xxxxxxx xxxx xxxxxxx xxxxxx x xxxxxxx.
Xxxxxxxx xxxxxxxx důkaz x xxx, xx xx zkoušená xxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xx cílové xxxxx, není xxxxxx xxxx xxxxxxx xxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 DEFINICE
Chromatidová xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx zlomu xxxxxxxxxxxx xxxxxxxxx nebo xxxxx x opětného spojení xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x podobě xxxxx xxxx zlomu a xxxxxxx xxxx chromatid x xxxxxx xxxxx.
Xxx : xxxxxxxxxxxx xxxx xxxxx než xxxxx xxxxx chromatidy x x xxxxxxxxx odchylkou xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxxx hodnoty x xxxxxxxxx buněk.
Polyploidie : násobek haploidního xxxxx xxxxxxxxxxxxxx xxx (x), xxxx než xxxxxxxxx (xx. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx pozorovatelné xxxxx xxxxxxxxx xxxxxxxxxx při xxxxxxxx dělení xx xxxxxx xxxxxxxx xxx xxxxxxxxxxx, jeví xx xxxx xxxxxx x xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx jsou xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx látce a xx xxxxxx xxxx xx xxxxxxxx xxxxxxxx. Xxxx usmrcením se xxxxxxxx podá xxxxx xxxxxxxxxxx xxxxxxxx (např. xxxxxxxxx xxxx Colcemid®). X xxxxxxxxxxxx xxxxx xx xxxx připraví xxxxxxxxx xxxxxxxxxx, obarví xx x analyzují xx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx buněk.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx druhu xxxxxxx
Xxxxx xxxx xxxxxxxxx xxxxx xxxxxx čínského a xxxx; lze xxxx xxxxxx samce xxxxxxxxxx xxxxxx xxxxxxxx xxxxx xxxxx. Xxxx by xxx použity xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxx xx xxxx xxx xxxxxxxx x hmotnosti xxxxxx minimální a xxxxxx by překročit ± 20 % xxxxxxx hodnoty xxxxxxxxx.
1.4.1.2 Xxxxxxxx chovu a xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx mělo xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Příprava xxxxxx
Xxxxxx xxxxx pohlavně xxxxxxx xxxxx se xxxxxxxx výběrem xxxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxx, xxxxx xx exponuje. Xxxxx xx xxxx xxx xxxxxxxxxx tak, xxx xxx xxxx xxxxxx xxxxxx xxxxxxxxxxxxx. Xxxxxxx xx jednoznačně xxxxxxxxxxxx. Xxxx započetím studie xx xxxxxxx v xxxxxxxxxxxxx podmínkách xxxxxxx xxx dní aklimatizovat.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx by měly xxx xxxx aplikací xxxxxxxx rozpuštěny xxxx xxxxxxxxxxxx ve vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx x popřípadě xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx xxx xxxx xxxxxxx xxxxxxx. Xxxx by xxx xxxxxxx xxxxxxx xxxxxxxxxx zkoušené xxxxxxxx xxxxx, xxxxx údaje x stálosti xxxxxxxxxxx xxxxxxx skladování.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx xxxxxx a xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx se xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx než xxxxx xxxxxxxxxxxx/xxxxxxxx, mělo xx xxx jejich xxxxxxxx xxxxxxxxx xxxxx o xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx pokud xxxxx xxxxxxxx xxxxxx použití xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx experimentu xx xxxx být xxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. X xxxxxxxx aplikace zkoušené xxxxx by xxxx xxxxxxx kontrolní xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxx zvířata ve xxxxxxxxx, x xxxxx xxxxx k xxxxxxxx.
Xxxxxxxxx xxxxxxxx by měly xxxxxxxxxx xxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xx xxxx xxx expozičních xxxxxxxx, x xxxxx xx xxxxxxxxxxx, xx xxxxxxxxx xxxxxxxxxxxxx nárůst xxx xxxxxx.
Xxxxx pozitivní xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx byl účinek xxxxxxxx, ale xxx xxx xxxxxx xxxxxxx xxxxx xxxxxx kódovaná xxxxxxxxxxxx xxxxxxxxx. Je xxxxxxxxxx, aby xxxx xxxxxxxxx xxxxxxxx podávána xxxxx xxxxxxxx xxx xxxxxxxx xxxxx x xxx xxx xxxxx x xxxxx xxxxxxx xxxxxxxx xxx jednou. Xxx xxxxxxxxx xxxxxxxx xxxx xxx navíc xxxxx x úvahu xxxxxxx xxxxxxxxxx látek xx xxxxxx chemické xxxxx, xxxx-xx x xxxxxxxxx. Příklady xxxxx xxx pozitivní xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx podle Xxxxxx |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
xxxxxxxxxxxxxx |
108–91–8 |
203–629–0 |
|
xxxxxxxxx C |
50–07–7 |
200–008–6 |
|
akrylamid (xxxxxxx) |
79–06–1 |
201–173–7 |
|
2,4,6-xxxx(xxxxxxxx-1-xx)-1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx xxxxxx xx měl xxx xxxxxxxx xxxxx u xxxxxxx xxxxxxxxx kontroly, xxxxx xx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x která xxxxx podstupuje stejný xxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x dosavadních kontrolních xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx o xxxxxxxxxxx xxxxxx x xxxxxxxx buněk s xxxxxxxxxxxxxx aberacemi. Xxxxx xxxx xx xxxx xxx neexponované xxxxxxxx xxxxxxx také xxxxx, xxxxxxxxxx-xx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx nevyvolává xxxxx xxxxxxx xxxx xxxxxxxxx účinky.
1.5 POSTUP
1.5.1 Xxxxx xxxxxx
Xxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxx xxx analyzovatelných xxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx měly xxx xxxxx xxxxx xxxxxxxx xxxxxxxxxxx nebo nadvakrát (xx. při xxxxx xxxxxxxx xxxx xxxx xxxxxxxxxx). Zkoušené látky xxxxx být xxxxxxxx xxxx xx dvou xxxxxxx, xxx. xxx xxxxx x týž xxx x xxxxxxx xx více xxx xxxxxxxx xxxxx, xxx xxxx xxxxxxxxx podávání xxxxxxx xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx.
Xx skupině x xxxxxxxx dávkou xx xxxx xxx xx xxxxxxxx provedeny xxx xxxxxx. Xxxxxxxx xxxxxxxx buněčného xxxxx xxxx xxx xxxxxxxxx xxxxxx ovlivněna, xxxxxxx xx xxxxx xxxxx xxxxx a jeden xxxxxxxx xxxxx xxxxxxxxx 24 a 48 xxxxx xx xxxxxxxx. X xxxxxxx jiné xxx xxxxxxxx xxxxx xx xxx xxx xxxxx xxxxxxxx xx 24 xxxxx xxxx xx xxxxxx xxxx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxx xxxxxxxxx xxxxx, xxxxx xxxx xxxxx xxxx vhodnější xxxx pro detekci xxxxxx (6).
Xxxxx xxxxx xxx xxxxxx xxxxxxxxx xxxx x xxxx xxxx. Xxxxxxxxx x xxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxxx indukovat xxxxxxxx replikace (xxxxxxx) xxxxxxxxxx nebo mohou xxxxxxxxxx S-nezávislé účinky, xxxx být xxxxxxxxx xxxxxxxx odběr (1).
Vhodnost xxxxx xxxxxxxxx expozice xxxx xxx xxxxxx xxxxxx xx xxxxxxx. X případě xxxxx x xxxxxxxxxx expozicí xx xxxx být xxxxxxx xxxxxxxx 24 xxxxx (1,5násobek xxxxx xxxxx) po xxxxxxxx xxxxxxxx. Xxxxx potřeby xxxxx být xxxxxxxxx xxxxx odběry x xxxx době.
Před usmrcením xx xxxxxxxx intraperitoneálně xxxx xxxxxx dávka xxxxx zastavující xxxxxxxx (xxxx. Xxxxxxxx® nebo xxxxxxxxx). Xxxx se xx xxxxxx xxxx xxxxxxx u zvířat xxxxx. X myši xx xxxx xxxx xxxxxxxxx 3 — 5 xxxxx; x xxxxxx xxxxxxxx je xxxx xxxx xxxxxxxxx 4 — 5 xxxxx.
1.5.3 Dávkování
Provádí-li xx xxxxx xxxxxxxxxxx vhodných xxxxxxxxxx údajů xxxxxx xxx xxxxxxxx xxxxxxx, xxxx xx xxx xxxxxxxxx xx stejné xxxxxxxxxx, xx stejným xxxxxx a xxxxxx x xx stejného xxxxxx xxxxxxxx, xxxxx xx xxxxxxx x xxxxxx studii (7). X případě toxicity xx xxx xxxxx xxxxx použijí xxx xxxxxx xxxxx. Xxxx xxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxx xxxx maximální x xxxxxxxxx toxicitou, případně xxxxxx xxxxxxxxx. Xxx xxxxxxxxx odběru xxxxx, xxxx bude xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx je xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, xx xx xxxxx xxxxx vedly xxx xxxxxxx režimu xxxxxxxxx podle xxxxxxxxx x letalitě.
Látky xx xxxxxxxxxxx xxxxxxxxxxx aktivitou xxx nízkých xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx stanovení dávky xxxxxxxxx a xxxx xx xxx hodnoceny xxxxxx od xxxxxxx. Xxxxxxxx dávka xxxx xxx také xxxxxxxxxx xxxx dávka xxxxxxxxxxxx xx spermatogoniích xxxxxxx xxxxxx xxxxxxxx (např. xxxxxxx xxxxx xxxxxxxxxxxxx x xxxxxx xxxxxxxx x první x xxxxx xxxxxxxxx xxxxxxxx; xxxx snížení xx xxxxxx xxxxxxxxx 50 %).
1.5.4 Limitní xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx alespoň 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx nebo xx dvou xxxxxxx x xxxxxx dni xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx účinky x xxxx-xx na xxxxxxx xxxxx x látkách, xxxxx mají xxxxxxxx xxxxxxxxx, očekávána xxxxxxxxxxxx, xxxxxxxxxx xx úplná xxxxxx se xxxxx xxxxxxxx dávky xx xxxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx znamenat xxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx xxxxxx dávky.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx látka xx xxxxxxx podává xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, xxxx intraperitoneální xxxxxxx. Xxxx způsoby xxxxxxxx xxxx xxxxxxxxxx, jsou-li xxxxxxxxxxxxx. Xxxxxxxxx objem xxxxxxxx, xxxxx xxxx xxx najednou xxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx neměl xxxxxxxxx 2 ml/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Až na xxxxxxxx x xxxxxx xxxxx, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx účinky, xx měla xxx xxxxxxxxxxx xxxxxxxxxx objemu xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx objem xxx všech xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxx
Xxxxx xx xxxxxxxx se x jednoho xxxx xxxx varlat xxxxx xxxxxxx xxxxxxxx, xxxxxxxxxxxx xx a xxxxxx. Xxxx se xxxxxx xx xxxxxxxx sklíčka x xxxxxx xx.
1.5.7 Xxxxxxx
X každého xxxxxxx xx xxxx xxx xxxxxxxxxxx alespoň 100 xxxxx v xxxxx xxxxxxxxxxxx xxxxxxxx (tj. xxxxxxxxx 500 xxxxxxxx xx xxxxxxx). Tento xxxxx xxx xxxxxx, xx-xx pozorován xxxxx xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx měly xxx před xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxx xxxxxx xxxxx xxxxxxx ke xxxxxxxxxxxxxx xxxxxx xxxx xxxxxx chromozomů x xxxxx xxxxxxxx, xxxx xx xxxxxxxxxxx buňky xxxxxxxxx centromery v xxxxx xxxxxxxxxxxxxx xxxxx 2 x ± 2.
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxx xxx xxxxxxxxxx xxxxxxx xx měly xxx xxxxxxxxxx ve xxxxx tabulky. Experimentální xxxxxxxxx xx xxxxx. Xxx xxxxx xxxxx xx měl xxx xxxxxxxxxx xxxxx buněk xx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx x počet xxxxxxxxxxxxxx xxxxxxx xx xxxxx. Pro exponované x xxxxxxxxx xxxxxxx xx měly xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx aberací x xxxxxx počtem x četností. Gapy xx xxxxxxxxxxxxx xxxxxxxx x xxxxxxx xx, xxx xxxxxx se xxxxxxxxxx xx celkové xxxxxxxx xxxxxxx.
Xx-xx xxxxxxxxxx xxxxxx a xxxx xxxxxx, xxx by xxx xxx xxxxxxxxx xxxxxxx cytotoxických účinků xxxx xxxx xxxxxxxxxxxx xxxxxxxx x xxxxx xxxxxxxxxxxx zvířat x xxxxxx sloužících xxxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxxx v mitose xxxxxxxx x xxxxx x xxxxx xxxxxxxxx xxxxxxxx, x xx x celkovém xxxxxx 100 xxxxxxxx xx xxxxx xx xxxxx xxxxx. Xxxxx je xxxxxxxxx xxxxx mitosa, xxxxxxx v 1000 xxxxxxx na xxxxx xx xxx xxx xxxxxxxx xxxxxxxxx xxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx stanovení pozitivního xxxxxxxx existuje xxxxxxx xxxxxxxx, xxxx. nárůst xxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxxx v xxxxxxxxxx xx xxxxx xxxx xxxxx xxxxxx xxxxx buněk x xxxxxxxxx pro xxxxxxx x xxxxxxx xxxxxx x x xxxxxxxx xxxxxxxx odběru. Xxxxxxxx xx měla být xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx hodnocení xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx statistické xxxxxx (8). Statistická xxxxxxxxxx xx xxxxxx xxx jediným xxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravami xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx x xxxxx xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx případech xxxxxxxx soubor xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Výsledky xxxxx xxxxxx xxxxxxxxxx nebo xxxxxx xxx xxxxxx xx to, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxxxxxxxx aberace xx xxxxxxxxxxxxxxx savců xx xxxx xxxxxxxxx, xx xxxxxxxx látka xxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxx strukturní xxxxxxxxxxxx aberace. Xxxxxxxxx xxxxxxxx xxxxxxxxx, že xxxxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx x germinálních buňkách xxxxxxxxxxx xxxxx chromozomové xxxxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx se zkoušená xxxxx nebo její xxxxxxxxxx dostanou xx xxxxxx tkáně.
3. ZPRÁVY
PROTOKOL X ZKOUŠCE
Protokol x xxxxxxx xxxx xxxxxxxxx xxxx informace:
Rozpouštědlo/vehikulum:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- xxxxx x stáří zvířat,
- xxxxx, podmínky chovu, xxxxxx atd.,
- individuální xxxxxxxx xxxxxx xx xxxxxxx zkoušky, včetně xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxx xxx xxxxxx skupinu.
Zkušební xxxxxxxx:
- xxxxx ze xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx zvolených úrovní xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxx látky,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- zdůvodnění xxx xxxxxxxx,
- případně xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx odpovídající xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx xxxxxx x xxxx,
- xxxxxxxx xxxxx rozvrhu xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx a xxxxx xxxxxxxx,
- xxxxxx xxxxxxxx preparátů,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet xxxxxxxxxxxxx xxxxx xx xxxxx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, negativní nebo xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity,
- xxxxxxxxx index,
- xxxxx xxxxxxxxxxxxx v mitose xxxxxxxx x xxxxx x xxxxx metafázi xxxxxx,
- xxx x xxxxx xxxxxxx xxxxxxx xxxxxxxxxx xxx každé xxxxx,
- xxxxxxx počet xxxxxxx xx xxxxxxx,
- xxxxx buněk s xxxxxxxxx xx skupině,
- xxxxx xxxxxxxx závislost xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx analýzy,
- xxxxx o xxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx o negativní xxxxxxxx s xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx x souběžné pozitivní xxxxxxxx,
- xxxxx xxxxxxx, xxxxx xxxx pozorovány.
Rozbor xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X., (1986), Xxxxxxxxxxx Xxxxxxxxx xx Xxxxx Xxxxxxxxxxxxx xx Xxxxxxxx Xxxxxxxx Related xx their Xxxx-Xxxxx Xxxxxxxxxxxxxx, in: Xxxxxxx Xxxxxxxxxx of Environmental Xxxxxxxxx, Part X: Xxxxxxx Xxxxxxx xxx Xxxxxxx Xxxxxxxxxxx, Xxxxx, X., Xxxxxxx, B., Xxxxxxxxx, X. (xxx) Xxxx, New York, 477-484.
2) Xxxxx, I. X., (1984), Xxxxxxxxxxx xxxxx in Xxxxxxx, xx: Xxxxxxxxxxxx Xxxxxxx: x Practical Xxxxxxxx, (xx.) X. Xxxxxx, X. X. Xxxxx, XXX Press, Xxxxxx, Xxxxxxxxxx XX, 275-306.
3) Xxxxx, X. X., Xxxxxxx, X., Xxxx, X. E. (1964), Xx Air-drying Xxxxxx xxx Meiotic Xxxxxxxxxxxx xxxx Mammalian Xxxxxx, Xxxxxxxxxxxx Cell Genetics, 3, 289-294.
4) Xxxxxxx, X., Ashby, X., Xxxxxxxx, X., Xxxxxxxxx, X. X., Henderson, X. (1990), Xx xxxx Cytogenetic Assays, xx: D. J. Xxxxxxxx (xx.), Basic Xxxxxxxxxxxx Tests, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Xxxxxxxxxxxx on Xxxxxxxxxx xxx Xxxxxxxxxxxx Testing. Xxxxxx. Xxxx X xxxxxxx, Xxxxxxxxx University Xxxxx, Cambridge, New Xxxx, Xxxx Chester, Xxxxxxxxx, Xxxxxx, 115-141.
5) Xxxxxxxx, X., Xxxxxxx, X. (1978), X Xxx Xxxxxx for Xxxxxxxxxxx xx Mammalian Xxxxxxxxxxxxxx Xxxxxxxxxxx, Xxxxxxxxxx Xxx., 52, 207-209.
6) Xxxxx, I. X., Xxxxxx M. X., Xxxxxxx, J., Xxxxx, X., Generoso, W., Xxxxxxxxxxxx, X., Xxxxxxx, X., Xxxxxx N. (1994), Xxxxxxxxxxxxx Xxxxxxxx xx Standardisation xx Xxxxxxxxxxxx Xxxx Procedures. Xxxxxxx Xxxxxx xx xxx Xxxxxxx Xxxxx xx Xxxxxxxxx Xxxx Xxxx Tests, Mutatation Xxx., 312, 313-318.
7) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, A. R., Xxxxxx, X. A., Xxx, X., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Hodson-Walker, X., Xxxxxx, X. X., Kirkland, X. X., Richold, X. (1992), Xxxxxx of Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Mutagen Xxxxxxx Xxxxxxx Group: Dose Xxxxxxx xx Xx xxxx Mutagenicity Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
8) Xxxxxx, D. X., Xxxxxxxx, X., Albanese, X., Xxxxxxxx, X. X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, D. X., Xxxxxx X. X. X. (1989), Xxxxxxxxxxx Analysis xx Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: D. X. Xxxxxxxx (xx.), Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx. XXXXX Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxxxx, Xxxx XXX. Xxxxxxxxx University Xxxxx, Xxxxxxxxx, New Xxxx, Xxxx Chester, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4G
"B.39 XXXXXXX XX NEPLÁNOVANOU XXXXXXX XXX (XXX) V XXXXXXXXX XXXXXXX XXXXX XX XXXX
1. XXXXXX
Xxxx xxxxxx xx replikou xxxxxx XXXX XX 486 — Zkouška xx xxxxxxxxxxxx xxxxxxx XXX (UDS) v xxxxxxxxx xxxxxxx savců xx vivo (1997).
1.1 XXXX
Xxxxxx zkoušky xx xxxxxxxxxxxx xxxxxxx DNA (XXX) x xxxxxxxxx xxxxxxx xxxxx xx xxxx je xxxxxxxxxxxxx xxxxxxxx xxxxx, které xxxxxxxx xxxxxxxx XXX x xxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxx (1, 2, 3, 4).
Xxxx xxxxxxx xx xxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx x xxxxxxx. Xxxxxxxxxxx xxx xx xxxxxxxxxx poškození XXX x xxxxxxxx xxxxxxxx x jaterních buňkách. Xxxxx xxxx xxxxxxx xxxxxxx xxxxxx, xxx xxxx absorbované xxxxxxxxxx xxxxxxxxxxxxxx. Xxxx xxxx xxxxxxx xxxxxx xxx xxxxxxxxx míry xxxxxxxxx XXX xx vivo.
Jestliže xxxxxxxx xxxxx x xxx, že se xxxxxxxx látka xxxxxxxxx xx xxxxxx tkáně, xxxx xxxxxx xxxx xxxxxxx použít.
Rozsah xxxxxxxxxxx xxxxxxx DNA (UDS) xx xxxxxxxx stanovením xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx xx xxxxx, které xxxxxxxx plánovanou syntézou XXX (X-xxxx). Xxxxxxxxxxxxxxx xxxxxxxxx je xxxxxxxxxxxxxxxxx xxxxxxxxx inkorporace xxxxxxxxx xxxxxxxxx tritiem (3X-XxX). Xxx xxxxxxx xx XXX xx xxxx xx xxxxxxxxxx xxxxxxxxx xxxxx xxxxxxx. Xxxx xxxxx xxx xxxxx xxxxx být xxxxxx xxxxxxx, nejsou xxxx xxxxxxxxx xxxx xxxxxx.
Xxxxxxx xxxxxxxx XXX závisí xx xxxxx bází XXX xxxxxxxxxxx x xxxxxxxxxxx v xxxxx xxxxxxxxx. Xxxxxxx na XXX xx xxxx xxxxxx xxxxxxx xxx xxxxxxx xxxxxxxx xxxxxxxx ("xxxx-xxxxx repair") (20 xx 30 bází) xxxxxxxxxxxx xxxxxx. Xxxxxx xxxxxx ("xxxxx-xxxxx xxxxxx") (xxxxx xx xxx xxxx) xxxx xxxxxxx xxxx detekovány x xxxxxx menší citlivostí. Xxxxx xxxx důsledkem xxxxxxxxxxxxx reparace, xxxxxx xxxxxxxx xxxx xxxxxx xxxxxxxxx xxxx XXX xxxxx x xxxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxx XXX xxxxxxxxxxx žádnou xxxxxxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx, xx xxxxxxx xxxxxxx x XXX, xxx xxxxxxxxx XXX xxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx, které xxxx zkouška xxxxxxxxx x mutagenní aktivitě, xx xxxxxxx potenciální xxxxxxxxxx tohoto xxxx, xxxxx je vyšetřován x celém xxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 DEFINICE
Opravované xxxxx : xxxxx xxxxx zrn odpovídajících xxxxxxxx xxxxxx (XXX), xxxxx xxx xxxxxxxxxx xxxxxxx xxxxxxxxx laboratoří xxxxxxxxxxx zkoušku.
Čistý počet xxx odpovídajících xxxxxxxx xxxxxx (NNG) : xxxxxxxxxxxxx xxxx XXX xxxxxxxx buněk v xxxxxxxxxxxxxxxxx xxxxxxx xx XXX, xxxxxxxxx odečtením xxxxxxxxxx počtu xxx x cytoplasmatických oblastech (XX) xxxxxxxxxxxxxx xxxxxx xx xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx jádrům (XX): XXX = XX — XX. Xxxxxxx XXX se xxxxxxx xxx xxxxxxxxxx xxxxx, xxxx xxxxxxxx xxx buňky x xxxxxxx, x paralelních xxxxxxxxx xxx.
Xxxxxxxxxxx xxxxxxx XXX (UDS) : Xxxxxxx xxxxxxxx XXX xx xxxxxxxxx x xxxxxxxxxx xxxxx XXX xxxxxxxxxxxx xxxxxx s xxxxxxxxxx xxxxxxxxxxx chemickými xxxxxxx xxxx xxxxxxxxxxx xxxxxxxx.
1.3 PODSTATA XXXXXXXX XXXXXX
Xxxxxxx na XXX x xxxxxxxxx buňkách xxxxx xx xxxx xxxxxxxx xxxxxxx reparací XXX po vyštěpení x xxxxxxxxxx xxxxx XXX xxxxxxxxxxxx xxxxxx x xxxxxxxxxx indukovaným xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx činiteli. Zkouška xx xxxxxxx xxxxxxxx xx xxxxxxxxxxx 3H-TdR xx XXX xxxxxxxxx xxxxx, xxx xx xxxx četnost xxxxx x S-fázi buněčného xxxxx. Xxxxxxxxxxx 3H-TdR xx xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx, jelikož xxxx xxxxxxxx xxxx xxx xxxxxxx na xxxx X-xxxx buněk xxxx xxxx. xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx.
1.4 POPIS XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xx xxxxxxxx xxxxxx, xxxxxx xxx xxxxxx jakýkoli xxxxxx xxxx xxxxx. Xxxx xx xxx xxxxxxx xxxxx používané xxxxxxxxxxx xxxxx xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxx xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx minimální x xxxxxx xx xxxxxxxxx ± 20 % střední xxxxxxx xxxxxxxxx xxx xxx xxxxxxx.
1.4.1.2 Podmínky xxxxx x strava
Platí xxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx k části X, přičemž xx xxxx být dosaženo xxxxxxxx xxxxxxx 50 - 60 %.
1.4.1.3 Xxxxxxxx zvířat
Zdravá xxxxxxxx xxxxxxx xxxxxxx se xxxxxxxx výběrem xxxxxxx xx kontrolní xxxxxxx x xxxxxxx, která xx xxxxxxxx. Klece xx xxxx xxx xxxxxxxxxx xxx, xxx xxx xxxx xxxxxx xxxxxx xxxxxxxxxxxxx. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx x xxxx xxxxxxxxx xxxxxx se nechají x laboratorních podmínkách xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxxxxx xxxxx
Xxxxx zkoušené xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx suspendovány xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Xxxxxxx xxxxxxxx látky xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx být xxxx xxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx látky, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Zkušební podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx použitých xxxxxxxx xxxxx xxxxxxx xxxxxx a mělo xx být vyloučeno xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx jiná xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x jejich xxxxxxxxxxxxx. Xxxxxxxxxx se xxxxxxxx xxxxxx použití xxxxx xxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Kontroly
Součástí xxxxx xxxxxxxxx prováděné xxxxx xxxxxxxxxxx by měly xxx souběžné xxxxxxxxx x xxxxxxxxx (rozpouštědlo/vehikulum) xxxxxxxx. S výjimkou xxxxxxxx zkoušené xxxxx xx měla xxxxxxx xxxxxxxxx skupiny podstoupit xxxxxx xxxxxx jako xxxxxxx xx xxxxxxxxx, x nichž xxxxx x expozici.
Pozitivními xxxxxxxxxx xx xxxx xxx xxxxx, x xxxxx xx známo, xx xxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxxxxxx koncentracích xxxx x xxxxxxx XXX detekovatelnému xxx xxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx aktivaci xx xxxx xxx xxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxx xxxxxxx (4). Dávky xxxxx xxx zvoleny tak, xxx xxx účinek xxxxxxxx, ale xxx xxx xxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Příklady xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxx odběru |
Látka |
Číslo XXX |
Xxxxx xxxxx Xxxxxx |
|
Xxxxx xxxx xxxxxx (2 xx 4 h) |
N-nitrosodimethylamin |
62–75–9 |
200–249–8 |
|
Pozdní xxxx xxxxxx (12 xx 16 x) |
X-(xxxxxxx-2-xx)xxxxxxxx (2-XXX) |
53–96–3 |
200–188–6 |
Xxxxx xxx xxxxxxx také xxxx xxxxx xxx xxxxxxxxx kontrolu. Xx xxxxxxxxx, xxx byla xxxxxxxxx xxxxxxxxx látka xxxxxxxx xxxxx xxxxxxxx, xxx xxxxxxxx látka.
1.5 XXXXXX
1.5.1 Xxxxx x xxxxxxx xxxxxx
Xxx xx xxx použit dostatečný xxxxx zvířat, xxx xxxx zohledněno xxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xx xxxxxxx. Xxxxx xxxxxxx by xx xxxx xxxxxxx xxxxxxx xx tří xxxxxxxxxxxxxxxx xxxxxx. Xxxxxxxx xxxx xxxxxxxxxxx dostatečné dosavadní xxxxx, xx xxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx skupiny xxxxxxxx xxxxx jedno až xxx xxxxxxx.
Xxxxxxxx jsou x době xxxxxx x xxxxxxxxx údaje xx xxxxxx se xxxxxxx xxxxxx a xx xxxxxxx stejného xxxxxxx xxxxxxxx, xxx xxxxxxxxx, xx xxxxxxxxxx xxxx pohlavími rozdíl x toxicitě, xxxx xxxxxxxxxxx xxxxxxxx jednoho xxxxxxx, nejlépe xxxxx. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx určité xxxxxxx, jako xx xxxx xxxxxxxxx u xxxxxxxxx farmaceutických xxxxx, xxxx xx xxx xxxxxxx xxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx.
1.5.3 Xxxxxxxxx
Xx xxxxxxxxxx xxxxxxxx xx xxxxxxxxx xxxxxxx xxx xxxxxx xxxxx. Xxxxxxxx dávka xx definována xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, xx xxxxx xxxxx by xxxxx xxxxx očekávání xxx xxxxxxx xxxxxx xxxxxxxxx x letalitě. Xxxxx dávka xx xxxx xxx xxxxxxxxx 50 % až 25 % vyšší xxxxx.
Xxxxx xx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx dávkách (xxxx. hormony x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx xxx xxxxxxxxx případ xx xxxxxxx. Provádí-li xx kvůli neexistenci xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx xxxxxxx, měla by xxx xxxxxxxxx ve xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, xxxxxxxx x xx xxxxxxxx xxxxxx xxxxxxxx, xxx xx xxxxxxx x hlavní studii.
Nejvyšší xxxxx xxxx xxx xxxxxxxxxx xxxx jako xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxx x xxxxxxx (xxxx. xxxxxxxxxx xxxxx).
1.5.4 Xxxxxxx zkouška
Jestliže xxxxxxx x jednou dávkou x xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx nebo xx xxxx xxxxxxx x jednom xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx xx základě xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxxxx být xxxxx xxxxxx xxxxxxxx. Očekávaná xxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxx xxxxxx x limitní xxxxxxx xxxxx xxxxxx dávky.
1.5.5 Xxxxxxxx dávek
Zkoušená xxxxx xx xxxxxxx podává xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx. Xxxx xxxxxxx xxxxxxxx xxxx možné, xxx-xx je xxxxxxxxx. Xxxxxxxx intraperitoneálně xx xxxx xxxxxxxxxxxx, neboť xx játra xxxxx xxx exponována xxxxxxxx xxxxx xxxxx x xxxxxx prostřednictvím oběhového xxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx podán xxxxxxxxx xxxxxx nebo xxxxxxxx, xxxxxx na xxxxxxxxx testovacího xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x tělesné xxxxxxxxx. Xxxxxxx vyšších xxxxxx, xxx xx xxxxxxx xxxxx, xxxx být xxxxxxxxxx. Až xx xxxxxxxx x žíravé xxxxx, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx zesílené účinky, xx xxxx xxx xxxxxxxxxxx zkušebního xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx všech úrovních xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xxxxx
Xxxxxxx xxxxx xx xxxxxxxxxx z xxxxxxxxxxxx xxxxxx xxxxxxxxx 12 xx 16 xxxxx xx xxxxxx dávky. Xxxxxxxxxx dřívější odebrání xxxxxx (xxxxxx xxx xx xxxxx xxxxxx xx xxxxxxxx) xx xxxxxxxx, xxxx-xx po 12 xx 16 xxxxxxxx jasná pozitivní xxxxxxx. Mohou xxxx xxx xxxxxxx xxxx xxxx odběru, xxxx-xx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxx xxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxx xxxxx kolagenasou xx xxxx x xxxxxx se, xxx xx xxxxxxx xxxxxxxxxxx xxxxxxx xxxxx zachytily xx xxxxxxx xxxxxxx. Xxxxxxx xxxxx z xxxxxxxxx xxxxxxxx xx xxxx vykazovat xxxxxxxxxxxxxxx (5) xxxxxxx 50 %.
1.5.7 Stanovení UDS
Čerstvě xxxxxxxxx xxxxxxx xxxxx xxxxx xx obvykle xxxxxxx xxxx, xxxx. xxx xx osm xxxxx, xxxxxxxx x xxxxxx obsahujícím 3H-TdR. Xx xxxxx inkubační xxxx by mělo xxx xxxxxx z xxxxx xxxxxxxxxx a xxxxx xxxx xxxxx xxx xxxxxxxxxx x xxxxxx xxxxxxxxxxx přebytek xxxxxxxxxxx xxxxxxxxx, xxx xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxx ("cold xxxxx"). Xxxxx xx poté xxxxxxx, xxxxxx a xxxxxx. Xxx xxxxx xxxxxxxxx době xxxxxx xxx xxxxxxx radioaktivity xxxxxxxx. Xxxxxxxxx xx xxxxxx do autoradiografické xxxxxx, exponují xx x temnu (např. x xxxxxx 7 xx 14 xxx), xxxxxxxx xx, xxxxxx x xxxxxxxxx xx xxxxxxxxxx xxxx xxxxxxx. X xxxxxxx xxxxxxx xx xxxxxxxx xxx xx xxx xxxxxxxxx.
1.5.8 Xxxxxxx
Xxxxxxxxx by xxxx xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx buněk, xxx xxxx xxxxxxxxx XXX xxxxxxxxx hodnotu. Xxxxxxxxx se pod xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxxx xxxxxxxxxxxx (xxxx. xx xxxxxxx, xxxxxxxx úroveň značení xxxxxxxxxxxxx xxxxxxxx).
Xxxx počítáním xxx by xxxx xxx xxxxxxxxx xxxxxxxx. Xxxxxxxxx se xxxxxxxxx 100 buněk na xxxxx xxxxx alespoň xx dvou xxxxxxxxx; xxxxxxxxx xxxx než 100 xxxxx/xxxxx xx xxxx xxx xxxxxxxxxx. Xxx xxxxxxxx xxx xx xxxxx x X-xxxx xxxxxxxxxxx, ale xxxxx xxxxx v X-xxxx xxxx xxx xxxxxxxxxx.
Xxxxxxxx 3H-TdR xxxxxxxxxxxxxxx xx xxxxx a xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx navrstvením xxx stříbra xx xxxx xxx xxxxxxxxx xxxxxxx xxxxxxx.
Xxxxx xxxxx xx stanoví x xxxxx xxx odpovídajících xxxxxxxx xxxxŭx (xx) x x prŭměrného xxxxx xxx x xxxxxxxxxxxxxxxxx xxxxxxxxx (xx) xxxxxxxxxxxxxx jádrŭm. jako xxxxxxx xx se xxxxxxx xxx počet xxxxx xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxxx, xxxx prŭměrná xxxxxxx xxxx až xxx xxxxxxx vybraných xxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx. xx xxxxxxxxxxxxx xxXxxxxxxx xxxxx xxx xxxxxxx x xxxx xxxxxxx xxxxxxxxx xxxxx xxxxx (xxxx. xxxxxxxx xxxxxx xxxxx) (6).
2. ÚDAJE
2.1 XXXXXXXXXX XXXXXXXX
Xxxx xx xxx xxxxxxx xxxxx pro xxxxxxxxxx xxxxxxxxx x xxxxxxx. Údaje xx xxxx xxx dále xxxxxxx ve xxxxx xxxxxxx. Xxxxxxxxx xxxxxxx XX xx xxxxxxx XX by xxx xxx xxxxxxxx xxx xxxxxx xxxxx, xxx xxxxx xxxxx a xxx každou dávku x xxx čistý xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx xxxxxx (NNG). Xxxxxxxx xxxx xxxxxxxx "xxxxxxxxxx" buňky, xxxx xx xxx xxxxxxxx xxx xxxxxxxxxx "xxxxxxxxxxxx" xxxxx xxxxxxxxxx x xxxxxxxx na dosavadních xxxx souběžných xxxxxxx x negativních kontrolách. Xxxxxxxxx xxxxxxxx mohou xxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Mají-li být xxxxxxx, xxxx by xxx xxxxxxxxxxx xxxxx xxxxxxx x odůvodněny xxxx xxxxxxxxxx xxxxxx.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxxx xxxxxxxx kritérií xxx xxxxxxxxx nebo xxxxxxxxx xxxxxxx xxxxx:
|
xxxxxxxxx |
x) |
xxxxxxx XXX xxxx nad xxxxxxxx xxxxxx, xxxxx xx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxx; |
|
xxxx |
xx) |
xxxxxxx NNG xx xxxxxxxx xxxxx než xxxxxxx xxx xxxxxxxxx xxxxxxxx; |
|
xxxxxxxxx |
x) |
xxxxxxx XXX xxxx xx dosavadní prahové xxxxxxx xxxx pod xx; |
|
xxxx |
xx) |
xxxxxxx XXX není xxxxxxxx vyšší xxx xxxxxxx pro xxxxxxxxx xxxxxxxx. |
Xxxx by být xxxxxxxxx biologická xxxxxxxxx xxxxx, xx. měly xx xxx xxxxx x xxxxx parametry, xxxx xxxx variabilita xxxxxx, xxxxx dávky x odpovědi x xxxxxxxxxxxx. Xxx hodnocení xxxxxxxx xxxxxxx mohou xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx. Statistická xxxxxxxxxx xx xxxx neměla xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx pozitivní xxxxxxx.
Xxxxxx xxxxxxx experimentů xxxxxxxx xxxxx xxxxxxxxx xxxx negativní výsledky, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx soubor xxxxx xxxxxxxx xxxxxxx xxxxx x aktivitě zkoušené xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx ohledu xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky na XXX x xxxxxxxxx xxxxxxx savců xx xxxx znamenají, že xxxxxxxx látka indukuje x xxxxxxxxx xxxxxxx xxxxx xx xxxx xxxxxxxxx XXX, které xxx xxxxxxx xxxxxxxxxxxx xxxxxxxx XXX xx xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx za podmínek xxxxxxx xxxxxxxxxx poškození XXX, xxxxx xxx xxxxxxxxx xxxxx xxxxxxxx.
Xxxx xx být diskutována xxxxxxxxxxxxxxx, s jakou xx zkoušená xxxxx xxxxxxx do krevního xxxxx xxxx. do xxxxxx xxxxx (xxxx. xxxxxxxxx toxicita).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx o xxxxxxx xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x rozpouštědle/vehikulu, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- počet, xxxxx a pohlaví xxxxxx,
- zdroj, podmínky xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx xxxxxxx zkoušky, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, střední hodnoty x xxxxxxxxxx xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxx a xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx úrovní xxxxx,
- údaje x xxxxxxxx zkoušené látky,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- zdůvodnění xxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, xxx xx zkoušená xxxxx xxxxxxx xx xxxxxxxx xxxxx xxxx do xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx koncentrací xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x kvalitě xxxxxx x vody,
- podrobný xxxxx xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx toxicity,
- xxxxxx xxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxx,
- xxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxx,
- xxxxx xxxxxxxxx x xxxxx xxxxxxxxxxx buněk,
- xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxxx xxxxxxx xxxxx xxx xxxxxxxxxxxxxx buněčným xxxxxx x počtu xxx xxxxxxxxxxxxxx cytoplasmě, x čistý xxxxx xxx, xxxxxxxxxx pro xxxxxxxxx, zvířata a xxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx na xxxxx,
- případné xxxxxxxxxxx xxxxxxxxx,
- xxxxxx xxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx o xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx s rozmezími, xxxxxxxxx hodnotami a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx xxxxx "xxxxxxxxxxxx" xxxxx, xx-xx stanoven,
- počet xxxxx x S-fázi, xx-xx stanoven,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxx výsledků.
Závěry.
4. XXXXXXXXXX
1) Xxxxx, J. Xxxxxxx, X. X., Xxxxxxxxx, X., Xxxxxx, X. X. (1985), Xx Xxxxxxxxxx xx xxx Xx xxxx Rat. Xxxxxxxxxx DNA Repair Xxxxx, Mutatation Xxx., 156, 1-18.
2) Butterworth, X. E., Ashby, X., Bermudez, E., Xxxxxxxx, X., Xxxxxxxx, X., Probst, G., Xxxxxxxx, X. (1987), X Protocol xxx Xxxxx for the Xx xxxx Rat Xxxxxxxxxx XXX Xxxxxx Xxxxx, Xxxxxxxxxx Xxx., 189, 123-133.
3) Xxxxxxxx, X. X., Xxxxxx, X., Xxxxx, X., Xxxxxxx, X. A., Xxxxxxxxx, X., Xxxxxxx, X. X., Xxxx, X. X., Xxxxxxxx, X. de X. (1993), Xx xxxx Xxx Liver UDS Xxxxx, xx: Kirkland X. X., Xxx X., (xxx), Xxxxxxxxxxxxx Xxxxxxxxxxxx Xxxxx: XXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Xxxxxxxxxxxx xx Guidelines xxx Mutagenicity Xxxxxxx. Xxxxxx. Xxxx II xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, New Xxxx, Xxxx Chester, Xxxxxxxxx, Xxxxxx, 52-77.
4) Xxxxx, S., Xxxx, X. W., Andrac, X., Xxxxxxxxx. G., Xxxxxxxxx, B., Doolittle, X. X., Xxxxxxxx, X., Hertner, T., XxXxxxx, X. X., Xxxx, X. (1993), Xxxxxxxxxxxxxxx for the Xxxxxxxxxxx xx UDS Xxxxx Xx vitro xxx Xx xxxx, Xxxxx. Xxx., 312, 263-285.
5) Xxxxx, R., Xxxxxxx, X., Xxxxxxxxxx, X., Xxxxxxxxxxxx-Xxxxxx, X. (1993), Xxxxxxxxxx xx xxx Xxxxxxxx Between xxx Xxxxxxx Viability xxx the Attachment xx Freshly Xxxxxxxx Xxx Xxxxxxxxxxx Xxxx xxx xxx In xxxx/Xx xxxxx XXX Xxxxxx Xxxxx (XXX), Xxxxxxxxxx Xxx., 291, 21-27.
6) Xxxxxxxx, X. X., Xxxxx, C. X., Butterworth, X. X. (1982), Detection xx Xxxxxxxxx Carcinogens xx xxx In xxxx/Xx vitro Xxxxxxxxxx XXX Xxxxxx Assay, Xxxxxxx.Xxxxxxx. 4, 553-562."
PŘÍLOHA 5
OBECNÉ XXXXXXXXX XX XXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXXXX XXXXX X PŘÍPRAVKŮ
Viz směrnice Xxxxxx 2001/59/ES, Xx. xxxx. X 332, 28. 12. 2000, x. 81.
XXXXXXX 6
"
PŘÍLOHA IX
ČÁST X
xxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxx xxxxx xxxxxxxx dětmi
Kromě xxxxxxxxxx xx. 22 xxxx. 1 xxxx. e) xxxx xxxxxxxx, musí xxx obaly o xxxxxxxxx xxxxxx xxxxxxxxxx xxxxx, x nimiž xx xxxxxxx xxxxxx xxx vdechování (Xx; X 65) x xxxxx xxxx xxxxxxxxxxxxx x označeny podle xxxx 3.2.3 xxxxxxx XX xxxx směrnice, x xxxxxxxx xxxxx xxxxxxxxx na xxx xx formě xxxxxxxx xxxx x xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx, xxxxxxxx xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx.
1. Xxxxxxxxx xxxxxxxxxxxx xxxxx
Xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxxxxxxx obalech xxxx splňovat xxxxxxxxx xxxxx XXX 8317 (xxxxxx xx dne 1. července 1989) "Xxxxx xxxxxx dětem — Požadavky na xxxxxxxxx xxxxxxxxxxxx xxxxx x metody xxxxxx xxxxxxxx" xxxxxxxx Mezinárodní xxxxxxxxxx pro xxxxxxxxxxx (XXX).
2. Xxxxxxxxx xxxxxxxxxxxxxx xxxxx
Xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxx xxxx splňovat xxxxxxxxx xxxxx XXX XX 862 (vydání x xxxxxx 1997) "Xxxxx — Xxxxx xxxxxx dětem — Xxxxxxxxx x xxxxxxxx xxxxxxx xxx xxxxxxxxx xxxxxxxxxxxxxx obaly xxxxxx xxx xxxxxxxxxxxxxxx výrobků" xxxxxxxx Evropským xxxxxxx xxx xxxxxxxxxxx (XXX).
3. Xxxxxxxx
1. Xxxxxxxxx xxxxx x xxxx uvedenými xxxxxxx xxxxx osvědčovat xxxxx xxxxxxxxxx, xxxxx xxxxxxx xxxxxxxx xxxxx xxxx XX 45000.
2. Xxxxxxxxxx případy
Je-li xxxxxx, xx xxxx je xxxxxxxxxx xxxxxxxx xxx xxxx, neboť se xxxxxxx dostat x xxxxxx bez xxxxxx xxxxxxxx, xxxxxx být xxxxxxx xxxxxxxxx.
Xx všech xxxxxxxxx případech x xxxxx existují xxxxxxxxx xxxxxx x xxxxxxxx x xxxxxxxxxxx uzávěru xxx xxxx, může xxxxxxxxxxxx xxxxx požadovat, xxx xxxxx xxxxxxxxx xx xxxxxxx xxxxxxx xx xxx předložila xxxxxxxxxx xxxxxx laboratoří xxxxx xxxx. 3 xxxx 1 konstatující, xx xxx
- typ xxxxxxx xx xxxxxx, xx jej xxxx xxxxxxxx xxxxxxx xxxxx xxxx uvedených xxxxx XXX x CEN,
nebo
- xx xxxxxx byl xxxxxxx a xxx xxxxxxx vyhovujícím podle xxxx xxxxxxxxx norem.
ČÁST X
Xxxxxxxx xxxxxxxx se xxxxxxxxxxxx xxxxxxx
Xxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxxx xxxxxxxx xxxx xxx x xxxxxxx x xxxxxx XX XXX 11683 (xxxxxx z roku 1997) "Xxxxx — Xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx — Požadavky".
"